



Centre for Heart Lung Innovation UBC and St. Paul's Hospital

Basic, clinical, and translational research for heart, lung, and blood vessel diseases



2018 Annual Report

AT A GLANCE

Established in **1977** by **Drs. James Hogg and Peter Paré**

Director	Dr. Don Sin
Associate Director	Dr. Jordan Guenette
Principal Investigators	37
Early Career Investigators	3
Investigators	17
Research Associates	7
Technicians	25
Visiting Scientists	7
Post-Doctoral Fellows	32
Graduate Students	47
Other Students	64
Core/Operations Staff	37
TOTAL	276
Named Research Chairs*	19
Funding in FY 2018-19**	\$13.3 Million
Space	over 50,000 square feet
Hosted Biotech / Spin-off companies	5

CORE Facilities:

Cardiovascular Registry
Lung Tissue Registry
Cellular Imaging and Biophysics
Imaging Services
Histology
Molecular Phenotyping
Preclinical Services
Clinical Research
Information Technology

Department Affiliations

Anesthesiology, Pharmacology, and Therapeutics
Computer Sciences
Health Sciences
Medical Genetics
Medicine
 Cardiology
 Critical Care Medicine
 Endocrinology
 Infectious Diseases
 Respiratory Medicine
Pathology and Laboratory Medicine
Physical Therapy
Radiology
Surgery


*Details in [PI Profiles](#).

**April 2018 to March 2019. Details in [Appendix A](#).

TABLE OF CONTENTS

4	MESSAGE FROM THE DIRECTOR
5	About the Centre for Heart Lung Innovation
6	RESEARCH SPOTLIGHT
12	HLI INVESTIGATORS
14	New Investigators
15	Principal and Early Career Investigator Profiles
25	Recognizing Research Excellence
27	Peer Reviewed Publications
29	High Impact Papers by HLI Investigators in 2018
38	KNOWLEDGE TRANSLATION
43	Spin-off Companies
44	TRAINING THE NEXT GENERATION OF SCIENTISTS
46	HLI Summer Student Research Program
46	Summer Student Research Day
47	Heart + Lung FEST
47	HLI Trainee Research Day
48	HLI Career Day
48	High School Science Week
49	HLI Weekly Seminars
49	Trainee Association
50	Trainee Awards
52	Trainee Career Paths
53	HLI OPERATIONS
54	Centre Operational Highlights
56	Events at the HLI
60	PARTNERSHIPS AND ACKNOWLEDGEMENTS
61	Supporting our Fight against Heart and Lung Diseases
62	APPENDICES
63	Appendix A: HLI Grants, Contracts, Clinical Trials and Agreements
76	Appendix B: Publications by HLI PIs in 2018
99	Appendix C: HLI 2018 Friday Seminar Series
101	Appendix D: HLI 2018 Research in Progress Seminars

MESSAGE FROM THE DIRECTOR



Dear Colleagues,

2018 was a banner year for investigators, trainees, and all the staff at the Centre for Heart Lung Innovation (HLI). We remained at the forefront of exceptional research in heart and lung diseases, made significant contributions to these areas, and impacted on patient care. Our research has revolutionized management of cardiac valvular diseases, advanced our understanding of COPD by identifying new genetic and pathologic markers of disease, enabled discovery of new blood biomarkers of sepsis, and identified novel sources for atherosclerotic plaque genesis and progression. These are but a few of the many notable achievements by HLI investigators and their teams over the past year.

2018 was also a year of unprecedented success in procuring research funding and awards, totaling over \$13 million for the fiscal year of 2018/2019 and publication output, totaling more than 305 publications, including a landmark report on early COPD from HLI Principal Investigator, Dr. Tillie Hackett, in LANCET Respiratory Medicine.

The Centre added a new Principal Investigator, Dr. Kelly McNagny, PhD, a UBC Professor of Medical Genetics. With the new appointment of Education Director Dr. Scott Tebbutt in 2018, the Centre launched the inaugural HLI Trainee Association, a student-led program to enrich the trainee experience. The Centre is committed to training a world-class group of next generation researchers and scientists in heart and lung research.

The Centre's successes are dependent on the critical, continued support of our funding partners and donors. HLI scientists, trainees, and staff express our sincere gratitude to: the Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Canada Foundation for Innovation, BC Knowledge Development Fund, Providence Health Care, University of British Columbia, Heart and Stroke Foundation of Canada, Canadian Lung Association, BC Lung Association, St. Paul's Foundation, the National Institutes of Health, Simon Fraser University, vendors, industry collaborators, donors, and most importantly to our patients, who are our partners in research and our inspiration in all that we do.

Regrettably, heart and lung diseases remain the leading causes of morbidity and mortality in BC and throughout Canada. We at HLI are committed in finding new solutions to address this enormous burden through innovation, translation, training and partnerships. With Redevelopment of St. Paul's Hospital and its research infrastructure, this process will be accelerated.

Sincerely,

Don D. Sin, MD

Director and De Lazzari Family Chair, Centre for Heart Lung Innovation

Professor, UBC Department of Medicine

About the Centre for Heart Lung Innovation

The Centre for Heart Lung Innovation (HLI, previously known as the iCapture and James Hogg Research Centre) is a University of British Columbia (UBC) Senate-approved Centre of Cardiovascular, Pulmonary, and Critical Care expertise, housed within Providence Health Care at St Paul's Hospital. The HLI's reporting and management structure is shown in Figure 1.




Figure 1. Governance and management structure of the Centre for Heart Lung Innovation in 2018.

RESEARCH SPOTLIGHT

Dr. Tillie Hackett and HLI team make first discovery of the early damage in the small airways of COPD patients

Chronic obstructive pulmonary disease (COPD) is a group of chronic lung diseases characterized by limitations in airflow, and is the leading cause of death and hospital admissions in BC and Canada. Previously, it was believed that only very severe COPD patients exhibited tissue damage within the small airways in the lungs.

“These patients often have little to no symptoms, so it was believed their lungs were relatively undamaged.”



In this landmark study, Dr. Tillie Hackett (above right) and her team of researchers discovered that significant tissue damage can be detected in the smallest airways within the lung in patients with mild and moderate COPD. The researchers were able to image airways <0.5 mm in diameter using an innovative, ultra high-resolution, micro computed tomography (CT) imaging instrument at HLI, with specialized software developed by the team. This equipment was purchased through funding from CFI, BCKDF, and St. Paul's Foundation.

This CIHR-funded study underscores the importance of studying the small airways in early stages of COPD to improve our understanding of the disease and to develop targeted therapies. Currently, COPD patients are not given any medications until more advanced disease develops, and the medications available are only symptom-relieving. This research suggests that COPD patients should be treated at the earliest stages when the disease may be more responsive to therapy. This finding will also revolutionize the way clinical trials for new COPD drugs are conducted. Evaluating new drugs on patients with early disease may yield more successes and accelerate the development of effective COPD therapies.

“Now that we know the severity of the damage, we need to look at earlier intervention to ensure the best outcomes for COPD patients.”

Co-first authors Dr. Hyun-Kyoung Koo, Dr. Dragoş Vasilescu, and Steve Booth are all HLI trainees.

This study was also featured in [UBC News](#), [BC Medical Journal](#), and the [Vancouver Sun](#), and was selected as a UBC Faculty of Medicine Top 10 Highlight of 2018.

Koo HK, Vasilescu DM, Booth S, Hsieh A, Katsamenis OL, **Fishbane N, Elliott WM, Kirby M**, Lackie P, Sinclair I, Warner JA, Cooper JD, **Coxson HO, Paré PD, Hogg JC, Hackett TL**. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. *Lancet Respir Med*. 2018 Aug;6(8):591-602. doi: 10.1016/S2213-2600(18)30196-6. Epub 2018 Jul 4. PubMed PMID: 30072106.

HLI personnel are bolded in the Research Spotlight citations.

Dr. Liam Brunham and HLI investigators uncover links between lipoproteins and sepsis



Sepsis is described as the body's overactive response to infection that results in injury of its own tissues and organs, which can lead to septic shock, organ failure, and death. Sepsis leads to 6 million deaths globally each year. It is known that levels of a molecule called high-density lipoprotein cholesterol (HDL-C) are lowered during sepsis, and this decrease is associated with worse survival.

In this study involving 200 patients, Dr. Liam Brunham (left) and his team discovered that the cholesteryl ester transfer protein (CETP) gene plays a key role in the drop in HDL-C levels in sepsis. Excitingly, there are already drugs designed against CETP for treating cardiovascular disease. Although these drugs did not have significant benefits for cardiovascular disease, further research will show if these drugs can be repurposed to improve survival rates for sepsis patients.

First author Mark Trinder is a HLI MD/PhD student and a Vanier Canada Graduate Scholar.

Trinder M, Genga KR, Kong HJ, Blauw LL, Lo C, Li X, Cirstea M, Wang Y, Rensen PCN, Russell JA, Walley KR, Boyd JH, Brunham LR. Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. *Am J Respir Crit Care Med.* 2019 Apr 1;199(7):854-862. doi: 10.1164/rccm.201806-1157OC. PubMed PMID: 30321485.

Dr. Scott Tebbutt develops a new blood test to identify patients at risk of an allergic asthma response



Allergic asthma is the most common type of asthma. Some allergic asthma patients experience an allergen-induced late-phase asthmatic response (LAR), which is characterized by airway contraction, airway inflammation, mucus hypersecretion, airway remodeling, and more severe symptoms than the initial reaction. It is a challenge for physicians to correctly identify which patients will develop these late phase responses to provide proper management and treatment.

Using the CFI, BCKDF, and St. Paul's Hospital Foundation funded new Nanostring Elements platform, a state-of-the-art instrument that simultaneously measures a panel of DNA and RNA molecules, Dr. Tebbutt (left) and his team have developed and validated a blood test that can accurately predict whether a patient will undergo a LAR. The Trinity biomarker panel simultaneously measures 14 RNA transcripts found in the blood to discriminate between responses from different allergic asthma patients.

The Trinity biomarker panel resulting from this study will help stratify heterogeneous patient groups, select therapies, reduce overtreatment, identify new drug targets, improve the efficacy of clinical trials, and accelerate the availability of novel medications for allergic asthma patients.


First author Amrit Singh is a former HLI graduate student and a recipient of the Canadian Institutes of Health Research Doctoral Award–Frederick Banting and Charles Best Canada Graduate Scholarship.

Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, Gauvreau GM, FitzGerald JM, Boulet LP, O'Byrne PM, Tebbutt SJ. Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response. *Am J Respir Crit Care Med.* 2018 Feb 15;197(4):450-462. doi: 10.1164/rccm.201701-0110OC. PubMed PMID: 29087730.

Dr. Don Sin and HLI researchers find correlations between the sputum microbiome and mortality rates in COPD patients

Chronic obstructive pulmonary disease is a group of chronic lung diseases characterized by poor airflow with prognoses that vary dramatically from mild symptoms to death. A challenge for effective COPD management is for clinicians to accurately stratify patients according to risk of disease progression.

The microbiome refers to the collection of microorganisms (such as bacteria, virus, fungus, etc) in an ecosystem. In this study funded by Genome Canada, Genome BC, and St. Paul's Hospital Foundation, sputum, which consists of saliva and mucus, was collected from 102 COPD patients, and the researchers discovered a correlation between the composition of the patient sputum microbiome and 1-year mortality in COPD patients who were hospitalized due to an acute event. Dr. Sin (above) and his team found that patients who did not survive one year after discharge had less diverse sputum bacterial populations. The researchers also discovered that the patients had worse survival if they had the bacteria *Staphylococcus* or did not have *Veillonella* bacteria in their sputum.



This work suggests that COPD patient sputum may be used to identify specific at-risk patients for closer monitoring following discharge from the hospital.

First author Fernando Sergio Leitao Filho is a HLI postdoctoral fellow and a recipient of the Canadian Institutes of Health Research ICS Travel Award and American Thoracic Society Abstract Scholarship.

Leitao Filho FS, Alotaibi NM, Ngan D, Tam S, Yang J, Hollander Z, Chen V, FitzGerald JM, Nislow C, Leung JM, Man SFP, Sin DD. Sputum Microbiome is Associated with 1-Year Mortality Following COPD Hospitalizations. *Am J Respir Crit Care Med.* 2018 Oct 30; doi: 10.1164/rccm.201806-1135OC. [Epub ahead of print] PubMed PMID: 30376356.

Dr. Chris Carlsten analyzes protein changes in the lungs after allergen and diesel exhaust co-exposures



Diesel exhaust is a significant, global health problem, but how human health is affected by diesel exhaust is poorly understood. Dr. Carlsten (left) and his team were interested in examining how exposures to diesel exhaust, an allergen, or both would affect the health of the lungs. Specifically, they studied the proteins produced by the lungs of human volunteers using a mass spectrometer, an instrument that can accurately identify specific proteins.

The research team found that there were 79 proteins that changed by more than 4-fold when the volunteers were exposed to diesel exhaust and an allergen, compared to allergen exposure alone. Further proteomic analyses of these 79 proteins suggest that diesel exhaust and allergen co-exposure increased the inflammatory and oxidative stress responses in the lungs.

This study elucidates new biological mechanisms in the lungs that result from the presence of two common air pollutants that are relevant worldwide.

Mookherjee N, Piyadasa H, **Ryu MH, Rider CF, Ezzati P, Spicer V, Carlsten C.** Inhaled diesel exhaust alters the allergen-induced bronchial secretome in humans. *Eur Respir J.* 2018 Jan;51(1). doi: 10.1183/13993003.01385-2017. Print 2018 Jan. PubMed PMID: 29371381.

Dr. Jordan Guenette pioneers the use of supplemental oxygen for pulmonary rehabilitation patients



Interstitial lung disease causes irreversible scarring of the lungs that eventually affects breathing function and oxygen intake. Dyspnoea, or shortness of breath, is a debilitating symptom affecting patients with chronic lung disease, including interstitial lung disease. For idiopathic pulmonary fibrosis, the most common interstitial lung disease, the average survival from time of diagnosis is only 2 to 3 years.

Dr. Jordan Guenette (left) and his team of researchers recently published significant findings investigating the mechanisms that cause shortness of breath and strategies to relieve this symptom. They discovered that breathing in higher levels of oxygen dramatically improved the shortness of breath of lung disease patients. One patient was able to exercise on an exercise bicycle for 7 minutes breathing room air (21% oxygen) but this increased to 43 minutes when breathing in 60% oxygen.

“We were able to take those results and secure over \$2.1 million to take this intervention across the country.”

In the same study, the team also uncovered new details regarding how the nervous system contributes to shortness of breath in lung disease. This work has launched a new clinical trial at 8 centres across Canada. By improving the capacity of lung disease patients to stay active, this research will positively impact patient quality of life.

First author Michele Schaeffer is a HLI postdoctoral fellow and a recipient of UBC's 4-Year Doctoral Fellowship and the BC Lung Association Respiratory Rehabilitation Fellowship.

Schaeffer MR, Ryerson CJ, Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, Mitchell RA, Sheel AW, Khalil N, Camp PG, Guenette JA. Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. *Eur Respir J.* 2018 Jan;51(1). doi: 10.1183/13993003.01726-2017. Print 2018 Jan. PubMed PMID: 29348183.

This study was also highlighted in a feature [video](#) produced by the BC Lung Association and an [article](#) in the Providence Health Care's The Daily Scan.

Dr. Honglin Luo examines the mechanisms of viral heart infections



Coxsackievirus B3 is a major etiological factor for myocarditis (infection of the heart) and virus-induced heart failure, for which effective therapy is lacking. There is increasing evidence that aberrant accumulation of protein aggregates and damaged organelles contribute to heart failure; however, the underlying molecular mechanism remains poorly characterized.

Dr. Luo (left) and her team studied how coxsackievirus B3 disrupts a cellular degradation pathway (called autophagy), leading to impaired protein homeostasis. They discovered that coxsackievirus B3 directly targets sequestosome 1 and CALCOCO2, two autophagy adaptor proteins that normally act to eliminate protein aggregates and damaged organelles. These two proteins differentially regulate viral replication before succumbing to degradation by viral proteases. This study provides novel mechanistic insights between virus infections and impaired protein homeostasis as a consequence of disrupted autophagy.

By improving our understanding of viral infection mechanisms, Dr. Luo and her group of researchers can strategize future therapeutic targets for treating coxsackievirus B3 infections.

First author Yasir Mohamud is an HLI PhD student and a recipient of the UBC 4-Year PhD Fellowship and ALS-Canada/Brain-Canada Doctoral Fellowship

Mohamud Y, Qu J, Xue YC, Liu H, Deng H, Luo H. CALCOCO2/NDP52 and SQSTM1/p62 differentially regulate coxsackievirus B3 propagation. *Cell Death Differ.* 2018 Aug 28; doi: 10.1038/s41418-018-0185-5. [Epub ahead of print] PubMed PMID: 30154446.

Dr. Del Dorscheid elucidates a pathway integral to airway repair in asthma

Asthma is a chronic airway inflammatory disease characterized by attacks of breathlessness and wheezing which occur with varied severity and frequency. The epithelium is the outer layer of cells in the breathing tubes that is exposed to various agents in the environment, and needs to constantly maintain and repair itself in response to stimuli and insults. Asthma patients generally have defective mechanisms in airway epithelium repair.



One research focus of Dr. Del Dorscheid (right) and his team is to understand how a molecule called IL13 repairs and maintains the airway epithelium “wall” against the environment. In this work, Dr. Dorscheid’s team discovered that a protein receptor, IL13R α 2, which responds to the IL13 molecule, is a key player in resolving injuries to the airway epithelium. Importantly, they also discovered that asthmatic lung airways have dramatically less IL13R α 2.


Together, this study points to the IL13/IL13R α 2 pathway as an important node to consider for the design of asthma therapies.

First author Jasmine Yang is a HLI PhD student.

This study was featured in [Science and the City](#).

Yang SJ, Allahverdian S, Saunders ADR, Liu E, Dorscheid DR. IL-13 signaling through IL-13 receptor α 2 mediates airway epithelial wound repair. *FASEB J.* 2019 Mar;33(3):3746-3757. doi: 10.1096/fj.201801285R. Epub 2018 Nov 27. PubMed PMID: 30481486.

Dr. Gordon Francis discovers a key protein responsible for promoting cholesterol removal in atherosclerosis



Atherosclerosis is a major cause of heart disease, which is a leading cause of death in Canada and worldwide. Reverse cholesterol transport is a multi-step process that results in the removal of excess cholesterol from the body, and higher levels of transport are important for preventing and reversing the development and progression of atherosclerosis.

In a recent study funded by CIHR and the Heart and Stroke Foundation of Canada, Dr. Gordon Francis (left) and his research group discovered that a protein called lysosomal acid lipase (LAL) plays an important role in promoting reverse cholesterol transport. Importantly, supplementing the LAL-deficient models with extra LAL resulted in rescued reverse cholesterol transport.

This suggests that treatment with LAL could potentially be used to reduce the increased risk of atherosclerosis in LAL-deficient individuals.

Co-first authors Drs. Kristin Bowden and Joshua Dubland are former HLI PhD students.

Bowden KL, Dubland JA, Chan T, Xu YH, Grabowski GA, Du H, Francis GA. LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo. *Arterioscler Thromb Vasc Biol.* 2018 May;38(5):1191-1201. doi: 10.1161/ATVBAHA.117.310507. Epub 2018 Mar 29. PubMed PMID: 29599133; PubMed Central PMCID: PMC5920716.

Dr. Bradley Quon identifies a blood protein that predicts treatment response in cystic fibrosis patients

Cystic fibrosis (CF) is a genetic disorder affecting respiratory, digestive, and reproductive health. In particular, CF patients develop abnormally thick mucus linings in the lungs that can result in infections that lead to death. CF patients often experience pulmonary exacerbations, which are more severe episodes requiring additional medical treatment, and in many cases, hospitalizations.

Dr. Quon (right)'s laboratory group aimed to design a blood test to predict early in the treatment course whether a patient will respond to pulmonary exacerbation treatment. The blood test can potentially inform CF clinicians to modify treatment plan in a timely manner. Dr. Quon and his team employed multiple reaction monitoring mass spectrometry (MRM-MS) to analyze proteins in the blood of CF patients, and discovered that an increase in blood fibrinogen levels early in the treatment predicted improvement in lung function and other symptoms at the end of treatment. This is the first study to identify fibrinogen as an early predictive blood-based protein biomarker of treatment response in CF patients.



First author Dr. James Roberts is a Resident Physician at St. Paul's Hospital and a HLI Research Assistant.

Roberts JM, Dai DLY, Hollander Z, Ng RT, Tebbutt SJ, Wilcox PG, Sin DD, Quon BS. Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations. *J Cyst Fibros.* 2018 May;17(3):333-340. doi: 10.1016/j.jcf.2017.10.013. Epub 2017 Nov 22. PubMed PMID: 29174082.

HLI Principal Investigator Dr. Peter Paré



HLI INVESTIGATORS

HLI Investigators

37

PRINCIPAL INVESTIGATORS

Michael Allard
Pascal Bernatchez
John Boyd
Liam Brunham
Pat Camp
Chris Carlsten
Harvey Coxson
Denise Daley
Mari DeMarco
Del Dorscheid
Gordon Francis
David Granville
Jordan Guenette
Tillie Hackett
James Hogg
Andrew Krahn
Scott Lear
Jonathon Leipsic
Janice Leung

Honglin Luo
Paul Man
Bruce McManus
Kelly McNagny
Raymond Ng
Ma'en Obeidat
Peter Paré
Brad Quon
James Russell
Chris Ryerson
Andrew Sandford
Chun Seow
Don Sin
Wan Tan-Hogg
Scott Tebbutt
Stephan van Eeden
Keith Walley
Decheng Yang

3

EARLY CAREER INVESTIGATORS

Zachary Laksman
Michael Seidman

Andrew Thamboo

17

INVESTIGATORS

Jamil Bashir
Sammy Chan
Ed Conway
Mark Fitzgerald
Jiri Frohlich
Andy Ignazewski
Ismail Laher
Samuel Lichtenstein
John Mancini

Ed Moore
Simon Pimstone
Fabio Rossi
Robert Schellenberg
Peter Skarsgard
Stacy Skoretz
Pearce Wilcox
Jian Ye

NEW PRINCIPAL INVESTIGATOR



Kelly McNagny, PhD

Professor | Department of Medical Genetics
University of British Columbia

Dr. Kelly McNagny is a Professor in the Department of Medical Genetics at the University of British Columbia (UBC). His research program is focused on hematopoietic stem cell biology, specifically in understanding the signaling networks that regulate stem cell differentiation and how these cells interact with their microenvironment. These processes have important implications in chronic allergy, asthma, and other inflammatory diseases. Dr. McNagny's research interests also include the innate immune response, kidney function, immuno- and cell-based therapies. He is a Michael Smith Foundation for Health Research Senior Scholar, a member of the Stem Cell Network of Canada, as well as the Associate Director of the AllerGen NCE network.

PRINCIPAL AND EARLY CAREER INVESTIGATOR PROFILES



Michael Allard

*UBC Department of Pathology and
Laboratory Medicine*

Dr. Allard's research program focuses on adaptation of the heart to physiological states, such as endurance exercise, and pathological processes, such as hypertension, that result in cardiac hypertrophy. He is particularly interested in how these conditions alter substrate use by the heart and how changes in substrate use influence heart function. A major recent focus of his research has been delineation of the cellular and molecular mechanisms that account for the alterations in substrate use by the hypertrophied heart.



Pascal Bernatchez

*UBC Department of Anesthesiology,
Pharmacology, and Therapeutics*

Dr. Bernatchez's research program is aimed at the dynamic interplay between blood vessel homeostasis and chronic diseases, such as hypertension, atherosclerosis, rare muscular dystrophies and aortic aneurysm associated with Marfan syndrome, as well as exploring novel pharmacological approaches to treat and prevent endothelial dysfunction and their consequences. Dr. Bernatchez's most recent work focuses on the novel regulation mechanism of nitric oxide bioavailability and its role in vascular disease, and how plasma lipid levels influence the loss of muscle function in dystrophic patients.



John Boyd

UBC Department of Medicine

Dr. Boyd's clinical research program is focused on defining and reversing the elements of the host response that cause sudden organ failure during severe infection. In collaboration with Dr. Robert Hancock, he identified a 31 gene endotoxin tolerance profile which predicts subsequent organ failure. Following the recent discovery of the role of the PCSK9 enzyme in the clearance of pathogenic bacterial and fungal lipids from the bloodstream, he is collaborating with Drs. Keith Walley and James Russell to develop an anti-PCSK9 therapy as a novel treatment for sepsis.



Liam Brunham

*UBC Department of Medicine
Canada Research Chair Tier 2*

Dr. Brunham's research focuses on understanding how changes in specific genes contribute to differences in drug response as well as to alterations in plasma lipid levels and their relationship to metabolic and cardiovascular disease. His laboratory uses cutting-edge approaches in human genetics, including genome-wide association studies and next-generation sequencing to investigate the role of genetic variation in these phenotypes. In December 2015, Dr. Brunham started a collaboration with Dr. Simon Pimstone to launch the SAVE BC study, aiming to identify risk factors and develop new approaches for diagnosis and treatment of BC families affected by early-onset atherosclerotic heart disease.



Pat Camp
UBC Department of Physical Therapy

Dr. Camp's research interests focus on improving the physical activity of individuals with chronic lung disease. Currently, she has three main pillars of research: 1) rehabilitation for hospitalized patients with an acute exacerbation of COPD; 2) Indigenous lung health, including epidemiological studies of COPD in remote and rural First Nations communities in BC, and developing an Indigenous pulmonary rehabilitation program; and 3) health service delivery and quality indicators for pulmonary rehabilitation programs in Canada. Her research utilizes methodologies based in implementation sciences, health services delivery, community-based research and knowledge translation. Ultimately, Dr. Camp's research will lead to improved quality of life and physical activity for individuals with chronic lung disease.



Christopher Carlsten
UBC Department of Medicine
Canada Research Chair Tier 2

Dr. Carlsten's clinical and research interests centre around occupational airways disease, including the effects of inhaled exposures on asthma induction and exacerbation. His laboratory investigates the pulmonary-immunological health effects of inhaled environmental and occupational exposures, using diesel exhaust, western red cedar, and phthalates as model inhalants. His research addresses the fundamental question of the synergism of inhaled particles and allergens in mediating health effects. Dr. Carlsten's lab uses an interdisciplinary, team-focused approach to ask related questions on genetic, cellular, functional, and epidemiologic levels.



Harvey Coxson
UBC Department of Radiology

Dr. Coxson specializes in quantitative imaging of the lung, particularly computed tomography, with correlations to quantitative pathology and pulmonary function. Dr. Coxson's laboratory is the core imaging site for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study, a population based study of COPD, and was the core imaging analysis site for the international COPD study ECLIPSE. Dr. Coxson also works with investigators across Canada as part of the Thoracic Imaging Network of Canada and the Canadian Respiratory Research Network.



Denise Daley
UBC Department of Medicine
Canada Research Chair Tier 2

Dr. Daley is utilizing cutting-edge statistical, epigenetic, and bioinformatics techniques to obtain a better understanding of how inherited genetic variants and environmental exposures interact to modify the risk for developing disease. Her lab has completed several genome-wide association and sequencing studies to identify genetic susceptibility to common complex diseases such as asthma and COPD, and initiated new studies focused on the evaluation of the "epigenome", or the genome's response to environmental exposures. Dr. Daley's overall research goal is to better understand the etiology of disease and the modifiable environmental risk factors to identify individuals who are at the greatest risk and develop biomarkers and public health interventions.



Mari DeMarco

*UBC Department of Pathology and Laboratory
Medicine*

With a strong interest in bridging basic biomedical science, analytical chemistry, and laboratory medicine, Dr. DeMarco's research group specializes in new methodological approaches for identification and quantitation of protein biomarkers of health and disease. A particular focus is advancing clinical diagnostics for neurodegenerative disorders, such as Alzheimer's disease and frontotemporal dementia. This work to translate new biomedical discoveries into patient care is accomplished in collaboration with clinicians and scientists at HLI, the UBC Centre for Brain Health and the provincial Clinic for Alzheimer's Disease and Related Disorders.



Delbert Dorscheid

*UBC Department of Medicine
MSFHR Health Professional-Investigator*

Dr. Dorscheid leads an active research group investigating the role of the airway epithelium in the genesis of inflammatory airways diseases. The research program studies the role for inappropriate injury-repair cycles in the development of both chronic diseases such as asthma and acute illnesses like ALI/ARDS. Specific projects include the role of glucocorticoid-induced airway epithelial cell apoptosis, novel glycoproteins and the glycomics involved in the repair of an injured epithelium, and the expression of FasL as an immune barrier for the airway.



Gordon Francis

UBC Department of Medicine

Dr. Francis's research involves understanding the mechanisms of accumulation of cholesterol in arteries in atherosclerosis, and how to remove this cholesterol to prevent coronary heart disease and stroke. Current major projects in his lab include: (1) understanding the role of cholesterol derived from lysosomes in regulating gene expression required for cholesterol removal from cells, and whether accumulation of excess cholesterol in lysosomes is a feature of atherosclerosis; and (2) understanding the reason arterial smooth muscle cells appear to accumulate more cholesterol than arterial macrophages. His lab recently demonstrated that smooth muscle cells, rather than monocyte-derived macrophages, are the primary site of cholesterol overaccumulation in human and mouse atherosclerotic plaque, which may lead to a major paradigm shift in the understanding of the pathogenesis and treatment of ischemic vascular disease.



David Granville

*UBC Department of Pathology and Laboratory
Medicine*

Dr. Granville's research group focuses on vascular injury, inflammation, and remodeling in the context of atherosclerosis, transplant vasculopathy, atherosclerosis, and ischemia and reperfusion injury. In recent years, Dr. Granville's group discovered a key pathogenic role for a family of serine proteases known as granzymes in autoimmune and/or age-related chronic diseases. Granzymes are a family of 5 serine proteases that play unique roles in tissue injury, inflammation, vascular permeability, loss of structural integrity, and impaired remodeling. This has led to the filing of over two dozen patents, development of novel therapeutics, and the formation of a UBC spinoff company, viDA Therapeutics.



Jordan Guenette
UBC Department of Physical Therapy
MSFHR Scholar

The primary aim of Dr. Guenette's research program is to better understand the physiological factors that limit exercise tolerance across the spectrum of health and chronic lung disease. His lab uses a number of novel measurement techniques to simultaneously assess the respiratory, cardiovascular, muscular, and neuro-physiological responses to exercise. His current project aims to identify the causes of shortness of breath in patients with interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Ultimately, this research will lead to the development of more effective treatments to better manage breathlessness and improve exercise tolerance and quality of life for individuals with chronic respiratory diseases.



Tillie Hackett
UBC Department of Anesthesiology,
Pharmacology and Therapeutics
CIHR New Investigator and MSFHR Scholar

Dr. Hackett's research program is focused on understanding the disruption of normal repair processes within the epithelial-mesenchymal trophic unit (EMTU) of the lung and how this propagates inflammation and tissue remodeling in patients with obstructive lung disease. Her laboratory uses an innovative and targeted approach to isolate cells from donor lungs guided by computed tomography imaging. The goal of this research program is to further understand the airway microenvironment to determine therapeutic targets in order to prevent the initiation and perpetuation of pathological processes which contribute to obstructive airway diseases like asthma and COPD.



James Hogg
UBC Department of Pathology and Laboratory
Medicine
Order of Canada and Order of BC

Dr. Hogg has been on the staff of the University of British Columbia at St. Paul's Hospital since 1977 and is currently an Emeritus Professor of Pathology at UBC. He maintains an active research program focused on the inflammatory process in the lung with particular reference to the structure and function of the lungs in COPD. Very recently he and his colleagues used microCT to show that terminal and respiratory bronchioles are sequentially destroyed in COPD. Dr. Hogg collaborated with Dr. Avrum Spira's group at Boston University to demonstrate a 127 gene expression signature for emphysematous destruction that showed this signature could be reversed toward control levels by the tripeptide GHK. He is currently studying the lung microbiome in COPD and examining the host response to this microbiome in human lung.



Andrew Krahn
UBC Department of Medicine
Sauder Family and HSF Chair

Dr. Krahn is a Professor and Head of the Division of Cardiology at the University of British Columbia. Dr. Krahn has authored 386 peer reviewed publications, and his research is funded by the Heart and Stroke Foundation and the Canadian Institute of Health Research. Current research interests include investigation of genetic causes of arrhythmias, causes of loss of consciousness and implantable arrhythmia devices. Dr. Krahn is the founder of the Hearts in Rhythm Organization (HiRO), a Canadian network of inherited arrhythmia clinics. HiRO aims to facilitate collaborative research and engage patients and families with inherited arrhythmias, as well as ensure high quality and standardized care across Canada. He is the Sauder Family Chair and UBC Chief of Cardiology, and the Paul Bruner Chair in Heart Rhythm Disorders. He is the President of the Canadian Cardiovascular Society and second Vice President of the Heart Rhythm Society.



Zachary Laksman
UBC Division of Cardiology
MSFHR Health Professional-Investigator

Dr. Laksman's research focus is on the genetic basis for diseases of the heart muscle, heart rhythm, and sudden cardiac death. An element of Dr. Laksman's work involves using a stem cell model and growing heart cells in a dish. In doing so, Dr. Laksman's laboratory can model an individual patient's specific disease, apply medicines to it, and study the cause of the disease and the effect of treatment.



Scott Lear
Simon Fraser University Faculty of Health Sciences

Dr. Lear's research focuses on effective prevention and management policies and programs for cardiovascular and other chronic diseases. His research uses a population and health services approach to prevent and manage disease (www.CoHeaRT.ca). This work includes investigating how the "built" environment in which we live acts as either a barrier or facilitator of healthy behaviours. His Multi-cultural Community Health Assessment Trial (M-CHAT) is an ongoing investigation to identify the role of ethnic background in risk for obesity, diabetes, and cardiovascular disease. For people with disease, Dr. Lear looks at how technology can support patients in managing their chronic diseases under the umbrella of the British Columbia Alliance for Telehealth Policy and Research (www.BCATPR.ca).



Jonathon Leipsic
UBC Department of Radiology
Canada Research Chair Tier 2

Dr. Leipsic's research program is at the forefront of advanced imaging for structural heart disease and has helped guide the use of computed tomography in these procedures on a global scale. His team has published extensively in this realm as well as more broadly in the realm of coronary artery atherosclerosis, prognosis, and the interplay between ischemic heart and chronic obstructive pulmonary disease. Some of his work has informed and modified clinical practice on a global scale. He is extremely excited about the opportunity to continue to learn about how advanced imaging can help improve clinical practice at present, as well as allow for the potential for deeper understanding of the mechanisms and drivers of acute myocardial infarction, sudden cardiac death, and COPD exacerbations.



Janice Leung
UBC Department of Medicine
MSFHR Health Professional-Investigator and
CIHR-AstraZeneca Early Career Investigator

Dr. Leung is studying the clinical outcomes, manifestations, and underlying mechanisms of HIV-associated COPD. In particular, she is interested in the pathogenesis of accelerated aging in the lung and has detected signs of accelerated aging using the blood and airway epithelial cells from HIV-infected patients. Platforms for this research include next generation sequencing methylomics and transcriptomics as well as the microbiome.



Honglin Luo

*UBC Department of Pathology and Laboratory
Medicine*

The focus of Dr. Luo's research is to define the molecular and pathogenic determinants of virus-host interactions in enterovirus-induced cardiac and neurodegenerative diseases. Ongoing research projects include: (1) Understanding molecular mechanisms of impaired cardiac function in enteroviral myocarditis. This research focuses on the protein quality control system, which includes molecular chaperones and protein degradation pathways with the long-term goal of designing effective molecular therapies for this disease; (2) Determining the possible role of enteroviral infection in the development of amyotrophic lateral sclerosis (ALS); and (3) Developing coxsackievirus B3 (CVB3) as an oncolytic virus for lung cancer treatment. Using cell and mouse models, Dr. Luo's group recently found that CVB3 is an extremely potent anti-tumor virus, destroying various types of lung cancer cells with limited effects on normal cells. The present research aims to genetically engineer CVB3 to further enhance its safety and anti-tumor potency for the treatment of lung cancer.



S.F. Paul Man

UBC Department of Medicine

Dr. Man's research expertise is in clinical trials and translational research, particularly in chronic obstructive lung disease. The clinical outcomes in COPD are unexpectedly influenced by the premature development of atherosclerosis. In close collaboration with Dr. Don Sin, he has been trying to understand epidemiological observations in clinical context, and to design and execute clinical studies and trials to test specific hypotheses.



Bruce McManus

*UBC Department of Pathology and Laboratory
Medicine*
Order of Canada and Order of BC

Dr. McManus is the CEO of the Centre of Excellence for Prevention of Organ Failure (PROOF) and the Co-Director of the Institute for Heart + Lung Health. His research program is focused on the mechanisms, consequences, detection, and prevention of injury and aberrant repair involved in inflammatory diseases of the heart and blood vessels. Dr. McManus works in a cross-disciplinary fashion on translational research questions for which answers are critically enabled by computational sciences, including molecular biomarker discovery and validation, information acquisition, annotation, use, and registry development to support heart and lung research. A major focus continues to be the multi-centre clinical validation of the HEARTBiT rejection-exclusion assay. This past year, Dr. McManus received the Margolese National Heart Disorders Prize and was appointed to the Order of Canada.



Raymond Ng

UBC Department of Computer Sciences

Dr. Ng's research focuses on data mining, which can be broadly viewed as large scale data analysis. With the advancement of computer technologies and biotechnologies, data are collected and accumulated at a phenomenal rate, but our ability to collect data far exceeds the ability to analyze them. The general focus of Dr. Ng's research is to develop tools that can help domain experts analyze their data in ways that are feasible, efficient to deal with the volume of the data, and statistically sound. One focus is to perform gene expression profiling for various heart and blood vessel diseases. A specific goal is to identify genes and pathways that are critical to the development, and hence cure, of those diseases.



Ma'en Obeidat
UBC Department of Medicine
MSFHR Scholar

Dr. Obeidat's research aims at translating multi-omics data for respiratory diseases into biologically actionable knowledge for drug and biomarker discoveries. His group uses cutting edge approaches in human genetics, multi-omics, and integrative omics from multiple cell types and tissues to map causal genes and proteins underlying the risk for respiratory diseases which can be developed into therapeutic and/or biomarker solutions. To date, he has identified over 100 novel genetic loci associated with airway obstruction, and his work has resulted in 60 publications. Dr. Obeidat received fellowship awards from CIHR, Michael Smith Foundation for Health Research and the US-based Parker B. Francis Foundation. He has also been awarded research funding from CIHR, the BC Lung Association, and the Canadian Lung Association.



Peter Paré
UBC Department of Medicine
Professor Emeritus

Dr. Paré is an Emeritus Professor of Respiratory Medicine and Pathology. Dr. Paré's research expertise is in the pathophysiology and genetics of asthma and COPD. Dr. Paré and colleague Dr. Chun Seow investigated the molecular and bio-mechanical events which relate broncho-constricting stimuli to the ultimate airway narrowing in asthma and other obstructive airway diseases. They examined isotonic and isometric length-tension properties, and the plastic behaviour of smooth muscle using physiologic, morphologic, and biochemical approaches. With colleagues Drs. Don Sin and Ma'en Obeidat, he studied the genetic control of gene expression in the lung and blood of COPD patients.



Bradley Quon
UBC Department of Medicine
MSFHR Scholar

Dr. Quon is a clinician-scientist with a primary clinical and research interest in cystic fibrosis (CF). His research focuses on bridging discoveries in the basic laboratory into the clinic to improve patient outcomes. He is currently searching for novel biomarkers of inflammation and infection to improve disease monitoring in CF. He also has expertise in clinical epidemiology and is part of an international collaboration examining health outcomes for individuals with CF living in Canada and the United States using national registry data. He is also actively involved in several clinical trials investigating new therapies in CF, several of which have transformed patient care. He is also the Medical Director of the newly formed CF Canada Clinical Trial Network (CF CanACT).



James Russell
UBC Department of Medicine

Dr. Russell has published over 275 peer-reviewed articles and editorials as well as 45 book chapters; he serves on the editorial boards of five journals. Key examples this past year were a proof of principle trial of selepressin, a novel selective V1a agonist, in septic shock. He also showed that diabetic septic shock patients have similar immune and lipid responses and outcomes as non-diabetic septic patients. He also wrote the septic shock chapter for the prestigious Goldman's Cecil Medicine. Dr. Russell has three major current themes of research (1) randomized controlled trials in patients with septic shock and (2) the genomics and pharmacogenomics of septic shock. He is now developing a new theme (3) to define the operating characteristics and predictive value of short-term versus long-term outcome measures in sepsis and their utility as primary endpoints in pivotal randomized controlled trials in sepsis and septic shock. Dr. Russell has worked closely with Drs. Walley and Boyd to discover that inhibition of the enzyme PCSK9 could improve the outcome of sepsis.



Christopher Ryerson
UBC Department of Medicine
MSFHR Scholar

Dr. Ryerson specializes in interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), dyspnea, and pulmonary rehabilitation. His current research is focused on the diagnosis and prognostication of ILD, as well as how to best manage patients using non-pharmacological therapies. This area of research is particularly important given the marginal benefits and major toxicities of existing ILD pharmacotherapies, thus having the potential to significantly improve the lives of ILD patients.



Andrew Sandford
UBC Department of Medicine

The focus of Dr. Sandford's research is the genetic basis of obstructive lung disease. His current work includes identification of genetic risk factors for the development of asthma and COPD as well as genetic modifiers of disease severity in cystic fibrosis. He is also investigating the functional impact of genetic variants that have been associated with respiratory disease.



Michael Seidman
UBC Department of Pathology and Laboratory Medicine

Dr. Seidman conducts primarily collaborative research studies, and is also working on several projects of his own design aimed at improving diagnostics in cardiovascular pathology. His areas of focus are cardiovascular pathology, research histopathology, and cardiovascular genetics. His recent discoveries include the identification of biomarkers for myocarditis.



Chun Seow
UBC Department of Pathology and Laboratory Medicine

Dr. Seow specializes in smooth and skeletal muscle cell physiology, biochemistry, and pharmacology. His current research focus is on the mechanical function, ultrastructure, and biochemistry of airway and vascular smooth muscle in health and disease. He is also interested in the mechanical function and structure of isolated lungs from sheep and human donors. His other interests include skeletal muscle mechanics, ATPase cycle associated with the crossbridge cycle, energetics of muscle contraction, and mathematical modeling of muscle structure and function.



Don Sin
UBC Department of Medicine
CRC Tier 1 & De Lazzari Family Chair

Dr. Sin's research is geared towards biomarker discovery in COPD and related conditions such as lung cancer, ischemic heart disease, and stroke. His group has shown that patients with COPD experience persistent low-grade systemic inflammation, which can be assessed by interrogating their peripheral circulation. By deploying this strategy, they found that certain pneumoproteins (proteins that are synthesized predominantly in lungs but secreted into the systemic circulation) are promising biomarkers of COPD clinical endpoints. Currently, Dr. Sin's team is using high throughput and high volume proteomics and genomics platforms to accelerate biomarker discovery in COPD.



Wan Tan
UBC Department of Medicine

Dr. Tan is a co-principal investigator of the Canadian Cohort of Obstructive Lung Disease (CanCOLD), a multi-centre cohort study conducted across Canada, dedicated to increasing the understanding of COPD and related co-morbidities, to improve its management and to reduce its burden. The objectives are to characterize the severity of COPD and patient response to disease (link of structural/physiological, clinical variables, and health perception), while taking into account lifestyle risk factors (smoking and other modifiable risk factors), age and sex, and associated co-morbidities (cardiovascular diseases, osteoporosis, anxiety and depression).



Scott Tebbutt
UBC Department of Medicine

Dr. Tebbutt's research program is focused on systems biology and the use of multi-omics (genomics, transcriptomics, proteomics, metabolomics, etc.) to unravel the molecular signatures of complex disease and other health-related conditions, including asthma, allergic rhinitis, heart failure, neonatal vaccinology, and the interaction between spores of the fungus *Aspergillus fumigatus* with airway epithelial cells. His research combines hypothesis-driven studies of biological mechanisms with the development of advanced tools and technology (including bioinformatics and computational biology) to better facilitate basic and translational research. Dr. Tebbutt is also Chief Scientific Officer of the Prevention of Organ Failure (PROOF) Centre of Excellence, a not-for-profit organization dedicated to moving research findings into health care, and focused on non-invasive biomarkers that can diagnose and/or predict organ failure (heart, lung and kidney).



Andrew Thamboo
UBC Department of Surgery
MSFHR Health Professional-Investigator

Dr. Andrew Thamboo medically and surgically manages chronic sinusitis and sinonasal tumours at St. Paul's Sinus Centre and at Surrey Memorial Hospital. He also has a cross appointment with Vancouver General Hospital and Royal Columbian Hospital performing skull base procedures with the Neurosurgery team. He is the Research Director of the St. Paul's Sinus Centre. In collaboration with a team of respirologists, he has a lab associated with Centre for Heart Lung Innovation. Dr. Thamboo has an interest in areas of unified airway hypothesis, upper airway physiology, office based rhinology, and outcomes research. He is a recent recipient of the Michael Smith Foundation Health Investigator Award.



Stephan van Eeden
UBC Department of Medicine
CIHR/GSK Professorship in COPD

The focus of Dr. van Eeden's research is on the mechanisms of lung inflammation caused by infection and inhalation exposures, particularly cigarette smoking and air pollution. His group demonstrated that following exposure to ambient air pollutants, pro-inflammatory mediators are generated in the lung and spill over in the blood stream, leading to downstream adverse cardiovascular health effects. Dr. van Eeden also showed that statins, a medication commonly used to treat patients with increased blood lipid/cholesterol, significantly attenuated these adverse effects of air pollutants. These adverse effects are particularly important for subjects with underlying lung diseases such as COPD, where air pollution cause exacerbations of the disease. He currently works on understanding the molecular mechanisms underlying these exacerbations and exploring novel methods for early identification and treatment of these exacerbations.



Decheng Yang
UBC Department of Pathology and Laboratory Medicine

The first area of Dr. Yang's research is the molecular biology and pathogenesis of coxsackievirus, an RNA virus known to cause myocarditis. Dr. Yang is studying the mechanisms of host-pathogen interactions, viral translation initiation, and cardiovirulence with the aim to develop novel antiviral therapies to treat coxsackievirus-induced myocarditis. The second area of Dr. Yang's research is the study of host gene responses to viral infection. He and his team have previously identified genes, as well as microRNAs, involved in myocarditis induction. His specific focus is the roles of these selected genes and microRNAs in signal transduction pathways and epigenetic modifications leading to cardiomyocyte apoptosis or cardiac hypertrophy. These studies have great potential to discover new targets for gene therapy and molecular markers for diagnosis of viral myocarditis and other related infectious diseases.



Keith Walley
UBC Department of Medicine

Dr. Walley translates basic discoveries into clinical practice in the ICU. The focus of Dr. Walley's research is to investigate: (1) the mechanism of decreased left ventricular contractility and other organ failure during sepsis, and (2) the impact of genotype on patient outcomes in sepsis and systemic inflammatory states. Together with Drs. Russell and Boyd, he recently demonstrated that blocking the function of PCSK9, an enzyme that inhibits the clearance of endogenous cholesterol from blood, is associated with increased pathogen lipid clearance via the LDLR, a decreased inflammatory response, and improved septic shock outcome. This important discovery facilitated the emergence of anti-PCSK9 therapies as one of the most promising treatments for sepsis.

RECOGNIZING RESEARCH EXCELLENCE



Dr. Bruce McManus is appointed to the Order of Canada and receives the 2018 Margolese National Heart Disorders Prize

Dr. McManus was one of 105 new appointments to the Order of Canada, one of Canada's highest civilian honours that recognizes outstanding achievement, dedication to the community, and service to the nation. In 2018, Dr. McManus also received the Margolese National Heart Disorders Prize. He was recognized for his translational research that has led to advancements in the diagnosis and treatment of cardiovascular disease and organ failure in Canada.



Dr. Andrew Krahn receives the 2018 Margolese National Heart Disorders Prize

The Margolese National Heart Disorders Prize is awarded annually to a Canadian physician or scientist who makes outstanding contributions to the treatment, amelioration, or cure of heart disorders. Dr. Krahn was awarded this prize in recognition of his work on detecting and managing heart rhythm disorders.



Dr. Liam Brunham is awarded a Canada Research Chair

The Canada Research Chairs Program awards funding to attract and retain the world's most accomplished and promising minds to achieve research excellence in their respective fields. Dr. Liam Brunham, an Assistant Professor in the Division of General Internal Medicine, leads a research group focused on the genetics of cardiovascular disease and pharmacogenetics. In 2018, Dr. Brunham was awarded a Canada Research Chair (Tier 2) in Precision Cardiovascular Disease Prevention.



Dr. Jordan Guenette receives a New Investigator Award

Dr. Guenette's research program is focused on understanding the physiological factors that limit exercise tolerance in healthy individuals and in patients with chronic lung disease. The Canadian Society for Exercise Physiology New Investigator Award is presented annually to an individual with an excellent reputation throughout Canada and international recognition. As part of the award, Dr. Guenette also presented at the CSEP AGM and was invited to write a review for *Applied Physiology, Nutrition and Metabolism*.



Dr. Honglin Luo receives an Innovation and Translational Research Award

The Innovation and Translational Research Award from Vancouver Coastal Health Research Institute and Providence Health Care Research Institute is used to fund innovative research that will have an impact on patient care at VCH and PHC. This award will allow Dr. Luo to further develop her research program, which involves engineering a virus for treating lung cancer.



Dr. Ma'en Obeidat receives a MSFHR Scholar Award

The Michael Smith Foundation for Health Research (MSFHR) Scholar Award is given to early-career researchers to support the establishment of an independent research career and to expand their potential to make significant contributions to their field. Dr. Obeidat's research focuses on using integrative genomics to identify novel therapeutics and biomarkers for COPD.



Dr. Del Dorscheid receives a MSFHR Health Professional Investigator Award

Dr. Dorscheid is a clinician scientist whose research focuses on the molecular mechanisms of asthma. He received a HP-I award from the Michael Smith Foundation for Health Research, which will support his research in this area.



Dr. Tillie Hackett receives a Distinguished Achievement Award

In recognition of outstanding basic science research and scholarly contributions in the areas of health and life sciences, Dr. Hackett received a Distinguished Achievement Award from the University of British Columbia Faculty of Medicine.



Dr. Chris Ryerson receives a Distinguished Achievement Award

In recognition of outstanding clinical research and scholarly contributions in the areas of health and life sciences, Dr. Ryerson received a Distinguished Achievement Award from the University of British Columbia Faculty of Medicine.



Dr. Janice Leung receives a Clinical Faculty Award

In recognition of excellence in teaching by clinical faculty, Dr. Leung was awarded a Clinical Faculty Award from the University of British Columbia Faculty of Medicine.

Peer Reviewed Publications

The Centre for Heart Lung Innovation's investigators and students authored **305** publications in 2018.

In the category of Medicine, **20.5%** of publications from the Centre for Heart Lung Innovation (HLI) were in the top 5% of most cited papers. Based on the field weighted citation impact, publications by HLI researchers were cited **3.3 times** more than the average paper in a corresponding field. (Figure 2). HLI's field weighted citation impact was higher than that of UBC and other top research institutions around the world.

HLI researchers published more frequently in top 5% of most cited journals in the disciplines of medicine (**26.1%**), respiratory (**38.3%**), cardiovascular (**21.2%**), and critical care (**45.9%**) than researchers at UBC or in Canada (Figure 3). In 2018, HLI generated over 300 publications for the second year in a row (Figure 4).




Figure 2. Percentage of top-cited publications and field weighted citation impact in the field of Medicine for the Centre for Heart Lung Innovation and other top research institutions in 2018. The field weighted citation impact is a ratio of the number of citations compared to the number of expected citations for outputs of similar age, subject, and publication type. Data was obtained from SciVal.




Figure 3. In 2018, HLI investigators published more often in the top 5% of most cited journals than researchers at UBC or in Canada. The full list of all HLI publications in journals with impact factors > 10 follows. Data was obtained from SciVal.




Figure 4. Publications authored by the Centre for Heart Lung Innovation Principal Investigators - a 12-year trend. A full list of the 2018 HLI Principal Investigator publications can be found in [Appendix B](#).

HIGH IMPACT PAPERS BY HLI INVESTIGATORS IN 2018

Lancet

Impact Factor: 53.254

Journal Category:
Medicine, General and Internal

Rank Within Category:
2/155

Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, Iqbal R, Gupta R, **Lear S**, Wentzel-Viljoen E, Avezum A, Lopez-Jaramillo P, Mony P, Varma RP, Kumar R, Chifamba J, Alhabib KF, Mohammadifard N, Oguz A, Lanas F, Rozanska D, Bostrom KB, Yusoff K, Tsolkile LP, Dans A, Yusufali A, Orlandini A, Poirier P, Khatib R, Hu B, Wei L, Yin L, Deeraili A, Yeates K, Yusuf R, Ismail N, Mozaffarian D, Teo K, Anand SS, Yusuf S; Prospective Urban Rural Epidemiology (PURE) study investigators. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. *Lancet*. 2018 Nov 24;392(10161):2288-2297. doi: 10.1016/S0140-6736(18)31812-9. Epub 2018 Sep 11. PubMed PMID: 30217460.

Mente A, O'Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, **Lear S**, Ah STL, Wei L, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Mony P, Szuba A, Iqbal R, Yusuf R, Mohammadifard N, Khatib R, Yusoff K, Ismail N, Gulec S, Rosengren A, Yusufali A, Kruger L, Tsolekile LP, Chifamba J, Dans A, Alhabib KF, Yeates K, Teo K, Yusuf S. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. *Lancet*. 2018 Aug 11;392(10146):496-506. doi: 10.1016/S0140-6736(18)31376-X. Epub 2018 Aug 9. PubMed PMID: 30129465.

Nature Genetics

Impact Factor: 27.125

Journal Category:
Genetics & Heredity

Rank Within Category:
2/171

Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, Barr RG, Beaty TH, Becker AB, Beilby J, Bisgaard H, Bjornsdottir US, Bleecker E, Bønnelykke K, Boomsma DI, Bouzigon E, Brightling CE, Brossard M, Brusselle GG, Burchard E, Burkart KM, Bush A, Chan-Yeung M, Chung KF, Couto Alves A, Curtin JA, Custovic A, **Daley D**, de Jongste JC, Del-Rio-Navarro BE, Donohue KM, Duijts L, Eng C, Eriksson JG, Farrall M, Fedorova Y, Feenstra B, Ferreira MA; Australian Asthma Genetics Consortium (AAGC) collaborators, Freidin MB, Gajdos Z, Gauderman J, Gehring U, Geller F, Genuneit J, Gharib SA, Gilliland F, Granell R, Graves PE, Gudbjartsson DF, Haahtela T, Heckbert SR, Heederik D, Heinrich J, Heliövaara M, Henderson J, Himes BE, Hirose H, Hirschhorn JN, Hofman A, Holt P, Hottenga J, Hudson TJ, Hui J, Imboden M, Ivanov V, Jaddoe VWV, James A, Janson C, Jarvelin MR, Jarvis D, Jones G, Jonsdottir I, Jousilahti P, Kabesch M, Kähönen M, Kantor DB, Karunas AS, Khusnutdinova E, Koppelman GH, Kozyrskyj AL, Kreiner E, Kubo M, Kumar R, Kumar A, Kuokkanen M, Lahousse L, Laitinen T, Laprise C, Lathrop M, Lau S, Lee YA, Lehtimäki T, Letort S, Levin AM, Li G, Liang L, Loehr LR, London SJ, Loth DW, Manichaikul A, Marenholz I, Martinez FJ, Matheson MC, Mathias RA, Matsumoto K, Mbarek H, McArdle WL, Melbye M, Melén E, Meyers D, Michel S, Mohamdi H, Musk AW, Myers RA, Nieuwenhuis MAE, Noguchi E, O'Connor GT, Ogorodova LM, Palmer CD, Palotie A, Park JE, Pennell CE, Pershagen G, Polonikov A, Postma DS, Probst-Hensch N, Puzyrev VP, Raby BA, Raitakari OT, Ramasamy A, Rich SS, Robertson CF, Romieu I, Salam MT, Salomaa V, Schlünssen V, Scott R, Selivanova PA, Sigsgaard T, Simpson A, Siroux V, Smith LJ, Solodilova M, Standl M, Stefansson K, Strachan DP, Stricker BH, Takahashi A, Thompson PJ, Thorleifsson G, Thorsteinsdottir U, Tiesler CMT, Torgerson DG, Tsunoda T, Uitterlinden AG, van der Valk RJP, Vaysse A, Vedantam S, von Berg A, von Mutius E, Vonk JM, Waage J, Wareham NJ, Weiss ST, White WB, Wickman M, Widén E, Willemssen G, Williams LK, Wouters IM, Yang JJ, Zhao JH, Moffatt MF, Ober C, Nicolae DL. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat Genet*. 2018 Jan;50(1):42-53. doi: 10.1038/s41588-017-0014-7. Epub 2017 Dec 22. PubMed PMID: 29273806; PubMed Central PMCID: PMC5901974.

BMJ-British Medical Journal

Impact Factor: 23.562

Journal Category:
Medicine, General & Internal

Rank Within Category:
4/155

Eyawo O, Hull MW, Salters K, Samji H, Cescon A, Sereda P, Lima VD, Nosyk B, Whitehurst DGT, **Lear SA**, Montaner JSG, Hogg RS; Comparative Outcomes And Service Utilization Trends (COAST) Study. Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. *BMJ Open*. 2018 Jan 13;8(1):e019115. doi: 10.1136/bmjopen-2017-019115. PubMed PMID: 29331972; PubMed Central PMCID: PMC5781099.

Lear SA. Patients in research: one step in a long path. *BMJ*. 2018 Oct 24;363:k4386. doi: 10.1136/bmj.k4386. PubMed PMID: 30355642.

European Heart Journal

Impact Factor: 23.425

Journal Category:
Cardiac & Cardiovascular Systems

Rank Within Category:
1/128

Baruteau AE, Kyndt F, Behr ER, Vink AS, Lachaud M, Joong A, Schott JJ, Horie M, Denjoy I, Crotti L, Shimizu W, Bos JM, Stephenson EA, Wong L, Abrams DJ, Davis AM, Winbo A, Dubin AM, Sanatani S, Liberman L, Kaski JP, Rudic B, Kwok SY, Rieubland C, Tfelt-Hansen J, Van Hare GF, Guyomarc'h-Delasalle B, Blom NA, Wijeyeratne YD, Gourraud JB, Le Marec H, Ozawa J, Fressart V, Lupoglazoff JM, Dagradi F, Spazzolini C, Aiba T, Tester DJ, Zahavich LA, Beauséjour-Ladouceur V, Jadhav M, Skinner JR, Franciosi S, **Krahn AD**, Abdelsayed M, Ruben PC, Yung TC, Ackerman MJ, Wilde AA, Schwartz PJ, Probst V. SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. *Eur Heart J*. 2018 Aug 14;39(31):2879-2887. doi: 10.1093/eurheartj/ehy412. PubMed PMID: 30059973.

Cheung CC, **Krahn AD**. The importance of a comprehensive evaluation of survivors of cardiac arrest. *Eur Heart J*. 2018 Jun 1;39(21):1988-1991. doi: 10.1093/eurheartj/ehy160. PubMed PMID: 29584853.

Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, **Leipsic J**, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB; of the Paravalvular Leak Academic Research Consortium. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement. *Eur Heart J*. 2017 Apr 18. doi: 10.1093/eurheartj/ehx211. [Epub ahead of print]

Wang C, Bangdiwala SI, Rangarajan S, **Lear SA**, AlHabib KF, Mohan V, Teo K, Poirier P, Tse LA, Liu Z, Rosengren A, Kumar R, Lopez-Jaramillo P, Yusuf K, Monsef N, Krishnapillai V, Ismail N, Seron P, Dans AL, Kruger L, Yeates K, Leach L, Yusuf R, Orlandini A, Wolyniec M, Bahonar A, Mohan I, Khatib R, Temizhan A, Li W, Yusuf S. Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. *Eur Heart J*. 2018 Dec 5. doi: 10.1093/eurheartj/ehy695. [Epub ahead of print] PubMed PMID: 30517670.

Lancet: Respiratory Medicine

Impact Factor: 21.466

Journal Category:Critical Care Medicine
Respiratory System**Rank Within Category:**1/33
1/60

Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; **BORA study investigators**. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. *Lancet Respir Med*. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum in: *Lancet Respir Med*. 2019 Jan;7(1):e1. PubMed PMID: 30416083. **D Dorscheid is a BORA Study Investigator.**

Koo HK, Vasilescu DM, Booth S, Hsieh A, Katsamenis OL, Fishbane N, Elliott WM, Kirby M, Lackie P, Sinclair I, Warner JA, Cooper JD, **Coxson HO, Paré PD, Hogg JC, Hackett TL**. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. *Lancet Respir Med*. 2018 Aug;6(8):591-602. doi: 10.1016/S2213-2600(18)30196-6. Epub 2018 Jul 4. PubMed PMID: 30072106.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, **Ryerson CJ**, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med*. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review. PubMed PMID: 29154106.

Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raoof S, Richeldi L, **Ryerson CJ**, Ryu JH. Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. *Lancet Respir Med*. 2018 Feb;6(2):e7. doi: 10.1016/S2213-2600(18)30021-3. PubMed PMID: 29413090.

Shrine N, Portelli MA, John C, Soler Artigas M, Bennett N, Hall R, Lewis J, Henry AP, Billington CK, Ahmad A, Packer RJ, Shaw D, Pogson ZEK, Fogarty A, McKeever TM, Singapuri A, Heaney LG, Mansur AH, Chaudhuri R, Thomson NC, Holloway JW, Lockett GA, Howarth PH, Djukanovic R, Hankinson J, Niven R, Simpson A, Chung KF, Sterk PJ, Blakey JD, Adcock IM, Hu S, Guo Y, **Obeidat M, Sin DD**, van den Berge M, Nickle DC, Bossé Y, Tobin MD, Hall IP, Brightling CE, Wain LV, Sayers I. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. *Lancet Respir Med*. 2019 Jan;7(1):20-34. doi: 10.1016/S2213-2600(18)30389-8. Epub 2018 Dec 11. PubMed PMID: 30552067; PubMed Central PMCID: PMC6314966.

Sun Y, **Sin DD**. Crisis of COPD in China: the future is now. *Lancet Respir Med*. 2018 Jun;6(6):404-405. doi: 10.1016/S2213-2600(18)30133-4. Epub 2018 Apr 9. PubMed PMID: 29650406.

Journal of the American College of Cardiology

Impact Factor: 16.834

Journal Category:

Cardiac & Cardiovascular Systems

Rank Within Category:

3/128

Driessen RS, Stuijzand WJ, Raijmakers PG, Danad I, Min JK, **Leipsic JA**, Ahmadi A, Narula J, van de Ven PM, Huisman MC, Lammertsma AA, van Rossum AC, van Royen N, Knaapen P. Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve. *J Am Coll Cardiol*. 2018 Feb 6;71(5):499-509. doi: 10.1016/j.jacc.2017.11.054. PubMed PMID: 29406855.

Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, Rinne C, Coutu B, Low RA, Essebag V, Morillo C, Redfearn D, Toal S, Becker G, Degrâce M, Thibault B, Crystal E, Tung S, LeMaitre J, Sultan O, Bennett M, Bashir J, Ayala-Paredes F, Gervais P, Rioux L, Hemels MEW, Bouwels LHR, van Vlies B, Wang J, Exner DV, Dorian P, Parkash R, Alings M, Connolly SJ. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. *J Am Coll Cardiol*. 2018 Dec 18;72(24):3098-3109. doi: 10.1016/j.jacc.2018.09.068. PubMed PMID: 30545448.

Lancet: Diabetes & Endocrinology Impact Factor: 19.313

Journal Category: Endocrinology & Metabolism	Rank Within Category: 3/142
--	---------------------------------------

Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A Jr, Cheng X, Chifamba J, Dagenais G, Dans A, Egbujie BA, Gupta R, Iqbal R, Ismail N, Keskinler MV, Khatib R, Kruger L, Kumar R, Lanas F, **Lear S**, Lopez-Jaramillo P, McKee M, Mohammadifard N, Mohan V, Mony P, Orlandini A, Rosengren A, Vijayakumar K, Wei L, Yeates K, Yusoff K, Yusuf R, Yusufali A, Zatonska K, Zhou Y, Islam S, Corsi D, Rangarajan S, Teo K, Gerstein HC, Yusuf S; PURE investigators. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. *Lancet Diabetes Endocrinol.* 2018 Oct;6(10):798-808. doi: 10.1016/S2213-8587(18)30233-X. Epub 2018 Aug 28. PubMed PMID: 30170949.

Circulation Impact Factor: 18.881

Journal Category: Cardiac & Cardiovascular Systems Peripheral Vascular Disease	Rank Within Category: 2/128 1/65
---	---

Kusters DM, Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, **Francis GA**, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". *Circulation.* 2018 Feb 6;137(6):641-642. doi: 10.1161/CIRCULATIONAHA.117.031676. PubMed PMID: 29431667.

Lancet Global Health Impact Factor: 18.075

Journal Category: Public, Environmental & Occupational Health	Rank Within Category: 1/181
---	---------------------------------------

Murphy A, Palafox B, O'Donnell O, Stuckler D, Perel P, AlHabib KF, Avezum A, Bai X, Chifamba J, Chow CK, Corsi DJ, Dagenais GR, Dans AL, Diaz R, Erbakan AN, Ismail N, Iqbal R, Kelishadi R, Khatib R, Lanas F, **Lear SA**, Li W, Liu J, Lopez-Jaramillo P, Mohan V, Monsef N, Mony PK, Puoane T, Rangarajan S, Rosengren A, Schutte AE, Sintaha M, Teo KK, Wielgosz A, Yeates K, Yin L, Yusoff K, Zatońska K, Yusuf S, McKee M. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. *Lancet Glob Health.* 2018 Mar;6(3):e292-e301. doi: 10.1016/S2214-109X(18)30031-7. PubMed PMID: 29433667; PubMed Central PMCID: PMC5905400.

American Journal of Respiratory and Critical Care Medicine Impact Factor: 15.239

Journal Category: Critical Care Medicine Respiratory System	Rank Within Category: 2/33 2/60
--	--

Bhatraju PK, Zelnick LR, Herting J, Katz R, Mikacenic C, Kosamo S, Morrell ED, Robinson-Cohen C, Calfee CS, Christie JD, Liu KD, Matthay MA, Hahn WO, Dmyterko V, Slivinski NSJ, **Russell JA, Walley KR**, Christiani DC, Liles WC, Himmelfarb J, Wurfel MM. Identification of Acute Kidney Injury Sub-phenotypes with Differing Molecular Signatures and Response to Vasopressin Therapy. *Am J Respir Crit Care Med.* 2018 Oct 18. doi: 10.1164/rccm.201807-1346OC. [Epub ahead of print] PubMed PMID: 30334632.

High Impact Papers By HLI Investigators in 2018 - continued

Diab N, Gershon AS, **Sin DD, Tan WC**, Bourbeau J, Boulet LP, Aaron SD. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2018 Nov 1;198(9):1130-1139. doi: 10.1164/rccm.201804-0621CI. PubMed PMID: 29979608.

Goss CH, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, Fink A, Elbert A, **Quon BS**, Stephenson AL. Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. *Am J Respir Crit Care Med*. 2018 Mar 15;197(6):768-775. doi: 10.1164/rccm.201707-1541OC. PubMed PMID: 29099606; PubMed Central PMCID: PMC5855073.

Hurst JR, **Sin DD**. Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Disease. A View from the SUMMIT. *Am J Respir Crit Care Med*. 2018 Jul 1;198(1):2-4. doi: 10.1164/rccm.201802-0347ED. PubMed PMID: 29533679.

Kirby M, **Tan WC, Hogg JC, Coxson HO**. Reply to Hu et al.: How to Determine the Patient's Head and Neck Posture during Computed Tomography Scanning? *Am J Respir Crit Care Med*. 2018 Nov 1;198(9):1238-1239. doi: 10.1164/rccm.201806-1154LE. PubMed PMID: 30118318.

Kirby M, Tanabe N, **Tan WC**, Zhou G, **Obeidat M**, Hague CJ, **Leipsic J**, Bourbeau J, **Sin DD, Hogg JC, Coxson HO**; CanCOLD Collaborative Research Group; Canadian Respiratory Research Network; CanCOLD Collaborative Research Group, the Canadian Respiratory Research Network. Total Airway Count on Computed Tomography and the Risk of Chronic Obstructive Pulmonary Disease Progression. Findings from a Population-based Study. *Am J Respir Crit Care Med*. 2018 Jan 1;197(1):56-65. doi: 10.1164/rccm.201704-0692OC. PubMed PMID: 28886252.

Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, **Sin DD**, Voelkel N, Olschewski H. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? *Am J Respir Crit Care Med*. 2018 Oct 15;198(8):1000-1011. doi: 10.1164/rccm.201801-0095PP. PubMed PMID: 29746142.

Leitao Filho FS, Alotaibi NM, Ngan D, Tam S, Yang J, Hollander Z, Chen V, FitzGerald JM, Nislow C, **Leung JM, Man SFP, Sin DD**. Sputum Microbiome is Associated with 1-Year Mortality Following COPD Hospitalizations. *Am J Respir Crit Care Med*. 2018 Oct 30. doi: 10.1164/rccm.201806-1135OC. [Epub ahead of print] PubMed PMID: 30376356.

McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, Marshall J, Dos Santos C, **Walley KR**, Winston BW, Schlosser K, Fergusson DA; Canadian Critical Care Trials Group; Canadian Critical Care Translational Biology Group. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. *Am J Respir Crit Care Med*. 2018 Feb 1;197(3):337-347. doi: 10.1164/rccm.201705-1006OC. PubMed PMID: 28960096.

Piyadasa H, Hemshekhar M, **Carlsten C**, Mookherjee N. Inhaled Diesel Exhaust Decreases the Antimicrobial Peptides α -Defensin and S100A7 in Human Bronchial Secretions. *Am J Respir Crit Care Med*. 2018 May 15;197(10):1358-1361. doi: 10.1164/rccm.201708-1714LE. PubMed PMID: 29244524.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, **Ryerson CJ**, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. PubMed PMID: 30168753.

Ryerson CJ, Denton CP. The Fine Line between Success and Failure in Scleroderma Lung Fibrosis Trials. *Am J Respir Crit Care Med*. 2018 Mar 1;197(5):553-554. doi: 10.1164/rccm.201711-2268ED. PubMed PMID: 29186664.

High Impact Papers By HLI Investigators in 2018 - continued

Ryerson CJ, Walsh SLF, Collard HR; all authors. Reply to Moodley: A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. *Am J Respir Crit Care Med*. 2018 May 15;197(10):1366-1367. doi: 10.1164/rccm.201712-2515LE. PubMed PMID: 29342368.

Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, Gauvreau GM, FitzGerald JM, Boulet LP, O'Byrne PM, **Tebbutt SJ**. Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response. *Am J Respir Crit Care Med*. 2018 Feb 15;197(4):450-462. doi: 10.1164/rccm.201701-0110OC. PubMed PMID: 29087730.

Tan WC, Bourbeau J, Aaron SD, Zhou G, Maltais F, Hernandez P, Fitzgerald JM, Marciniuk DD, Walker BL, **Sin DD**. Global Initiative for Chronic Obstructive Lung Disease 2017 Classification and Lung Function Decline in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2018 Mar 1;197(5):670-673. doi: 10.1164/rccm.201706-1154LE. PubMed PMID: 28858570.

Trinder M, Genga KR, Kong HJ, Blauw LL, Lo C, Li X, Cirstea M, Wang Y, Rensen PCN, **Russell JA**, **Walley KR**, **Boyd JH**, **Brunham LR**. Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. *Am J Respir Crit Care Med*. 2018 Oct 15. doi: 10.1164/rccm.201806-1157OC. [Epub ahead of print] PubMed PMID: 30321485.

Vancheri C, Kreuter M, Richeldi L, **Ryerson CJ**, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. *Am J Respir Crit Care Med*. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC. PubMed PMID: 28889759.

Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, Make BJ, Crapo JD, DeMeo DL, Silverman EK; **COPDGene Investigators**. Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. *Am J Respir Crit Care Med*. 2018 Dec 1;198(11):1397-1405. doi: 10.1164/rccm.201804-0663OC. PubMed PMID: 29874098; PubMed Central PMCID: PMC6290948. **H Coxson is a COPDGene Investigator.**

Wu AC, Kiley JP, Noel PJ, Amur S, Burchard EG, Clancy JP, Galanter J, Inada M, Jones TK, Kropski JA, Loyd JE, Noguee LM, Raby BA, Rogers AJ, Schwartz DA, **Sin DD**, Spira A, Weiss ST, Young LR, Himes BE. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. *Am J Respir Crit Care Med*. 2018 Dec 15;198(12):e116-e136. doi: 10.1164/rccm.201810-1895ST. PubMed PMID: 30640517.

Intensive Care Medicine

Impact Factor: 15.008

Journal Category:

Critical Care Medicine

Rank Within Category:

3/33

Annane D, Ouanes-Besbes L, de Backer D, DU B, Gordon AC, Hernández G, Olsen KM, Osborn TM, Peake S, **Russell JA**, Cavazzoni SZ. A global perspective on vasoactive agents in shock. *Intensive Care Med*. 2018 Jun;44(6):833-846. doi: 10.1007/s00134-018-5242-5. Epub 2018 Jun 4. Review. PubMed PMID: 29868972.

Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Umberto Meduri G, Olsen KM, Rodgers S, **Russell JA**, Van den Berghe G. Correction to: Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Intensive Care Med*. 2018 Mar;44(3):401-402. doi: 10.1007/s00134-018-5071-6. PubMed PMID: 29476199.

Gordon AC, **Russell JA**. Innovation and safety in critical care: should we collaborate with the industry? *Pro. Intensive Care Med*. 2018 Dec;44(12):2276-2278. doi: 10.1007/s00134-018-5306-6. Epub 2018 Nov 8. PubMed PMID: 30406806.

High Impact Papers By HLI Investigators in 2018 - continued

Pickkers P, **Russell JA**. Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy? *Intensive Care Med*. 2019 Feb;45(2):282-283. doi: 10.1007/s00134-018-5481-5. Epub 2018 Dec 3. PubMed PMID: 30511248.

Russell JA, Spronk P, **Walley KR**. Using multiple 'omics strategies for novel therapies in sepsis. *Intensive Care Med*. 2018 Apr;44(4):509-511. doi: 10.1007/s00134-018-5122-z. Epub 2018 Mar 15. PubMed PMID: 29546534.

Teboul JL, Duranteau J, **Russell JA**. Intensive care medicine in 2050: vasopressors in sepsis. *Intensive Care Med*. 2018 Jul;44(7):1130-1132. doi: 10.1007/s00134-017-4909-7. Epub 2017 Aug 31. PubMed PMID: 28861671.

Vieillard-Baron A, **Boyd J**. Non-antiarrhythmic interventions in new onset and paroxysmal sepsis-related atrial fibrillation. *Intensive Care Med*. 2018 Jan;44(1):94-97. doi: 10.1007/s00134-017-4986-7. Epub 2017 Nov 7. PubMed PMID: 29116333.

The Journal of Allergy and Clinical Immunology

Impact Factor: 13.258

Journal Category:

Allergy
Immunology

Rank Within Category:

1/27
6/155

Huff RD, Rider CF, Yan D, Newton R, Giembycz MA, **Carlsten C**, Hirota JA. Inhibition of ABCC4 potentiates combination beta agonist and glucocorticoid responses in human airway epithelial cells. *J Allergy Clin Immunol*. 2018 Mar;141(3):1127-1130.e5. doi: 10.1016/j.jaci.2017.10.011. Epub 2017 Dec 6. PubMed PMID: 29103996.

Leitao Filho FS, Ra SW, Mattman A, **Schellenberg RS**, **Sin DD**. Reply. *J Allergy Clin Immunol*. 2018 Feb;141(2):831. doi: 10.1016/j.jaci.2017.10.013. Epub 2017 Dec 6. PubMed PMID: 29221816.

Robinson RK, Birrell MA, Adcock JJ, Wortley MA, Dubuis ED, Chen S, McGilvery CM, Hu S, Shaffer MSP, Bonvini SJ, Maher SA, Mudway IS, Porter AE, **Carlsten C**, Tetley TD, Belvisi MG. Mechanistic link between diesel exhaust particles and respiratory reflexes. *J Allergy Clin Immunol*. 2018 Mar;141(3):1074-1084.e9. doi: 10.1016/j.jaci.2017.04.038. Epub 2017 May 19. PubMed PMID: 28532657; PubMed Central PMCID: PMC5840514.

Sehmi R, Lim HF, Mukherjee M, Huang C, Radford K, Newbold P, Boulet LP, **Dorscheid D**, Martin JG, Nair P. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. *J Allergy Clin Immunol*. 2018 Apr;141(4):1529-1532.e8. doi: 10.1016/j.jaci.2018.01.008. Epub 2018 Jan 31. PubMed PMID: 29382593.

Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, Becker AB, Mandhane PJ, Turvey SE, Sears MR; **Canadian Healthy Infant Longitudinal Development Study investigators**. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. *J Allergy Clin Immunol*. 2018 Feb;141(2):601-607.e8. doi: 10.1016/j.jaci.2017.08.024. Epub 2017 Nov 15. PubMed PMID: 29153857. **D Daley, P Paré, A Sandford, and S Tebbutt are CHILD Study Investigators.**

Nature Communications

Impact Factor: 12.353

Journal Category:

Multidisciplinary Sciences

Rank Within Category:

3/64

Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböllner H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemenev LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemegaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHF, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orłowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston R, McLaughlin J, Stevens V, Nickle DC, **Obeidat M**, Timens W, Zhu B, Song L, Artigas MS, Tobin MD, Wain LV, Gu F, Byun J, Kamal A, Zhu D, Tyndale RF, Wei WQ, Chanock S, Brennan P, Amos CI. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. *Nat Commun*. 2018 Aug 13;9(1):3221. doi: 10.1038/s41467-018-05074-y. PubMed PMID: 30104567; PubMed Central PMCID: PMC6089967.

Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, Latourelle JC, Smith AV, Bartz TM, Feitosa MF, Gao W, Ahluwalia TS, Tang W, Oldmeadow C, Duan Q, de Jong K, Wojczynski MK, Wang XQ, Noordam R, Hartwig FP, Jackson VE, Wang T, **Obeidat M**, Hobbs BD, Huan T, Gui H, Parker MM, Hu D, Mogil LS, Kichaev G, Jin J, Graff M, Harris TB, Kalhan R, Heckbert SR, Paternoster L, Burkart KM, Liu Y, Holliday EG, Wilson JG, Vonk JM, Sanders JL, Barr RG, de Mutsert R, Menezes AMB, Adams HHH, van den Berge M, Joehanes R, Levin AM, Liberto J, Launer LJ, Morrison AC, Sitlani CM, Celedón JC, Kritchevsky SB, Scott RJ, Christensen K, Rotter JJ, Bonten TN, Wehrmeister FC, Bossé Y, Xiao S, Oh S, Franceschini N, Brody JA, Kaplan RC, Lohman K, McEvoy M, Province MA, Rosendaal FR, Taylor KD, Nickle DC, Williams LK, Burchard EG, Wheeler HE, **Sin DD**, Gudnason V, North KE, Fornage M, Psaty BM, Myers RH, O'Connor G, Hansen T, Laurie CC, Cassano PA, Sung J, Kim WJ, Attia JR, Lange L, Boezen HM, Thyagarajan B, Rich SS, Mook-Kanamori DO, Horta BL, Uitterlinden AG, Im HK, Cho MH, Brusselle GG, Gharib SA, Dupuis J, Manichaikul A, London SJ. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. *Nat Commun*. 2018 Jul 30;9(1):2976. doi: 10.1038/s41467-018-05369-0. PubMed PMID: 30061609; PubMed Central PMCID: PMC6065313.

European Respiratory Journal

Impact Factor: 12.244

Journal Category:

Respiratory System

Rank Within Category:

3/60

Khalil N, Manganas H, **Ryerson CJ**, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. *Eur Respir J*. 2018 Dec 21. pii: 1800663. doi: 10.1183/13993003.00663-2018. [Epub ahead of print] PubMed PMID: 30578394.

Leung JM, Sin DD. Inhaled corticosteroids in COPD: the final verdict is.... *Eur Respir J*. 2018 Dec 13;52(6). pii: 1801940. doi: 10.1183/13993003.01940-2018. Print 2018 Dec. PubMed PMID: 30545961.

Mookherjee N, Piyadasa H, Ryu MH, Rider CF, Ezzati P, Spicer V, **Carlsten C**. Inhaled diesel exhaust alters the allergen-induced bronchial secretome in humans. *Eur Respir J*. 2018 Jan 25;51(1). pii: 1701385. doi: 10.1183/13993003.01385-2017. Print 2018 Jan. PubMed PMID: 29371381.

High Impact Papers By HLI Investigators in 2018 - continued

Ryerson CJ, Kolb M. The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy? *Eur Respir J*. 2018 Jan 18;51(1). pii: 1702420. doi: 10.1183/13993003.02420-2017. Print 2018 Jan. PubMed PMID: 29348187.

Sauler M, Lamontagne M, Finnemore E, Herazo-Maya JD, Tedrow J, Zhang X, Morneau JE, Scirba F, Timens W, **Paré PD**, Lee PJ, Kaminski N, Bossé Y, Gomez JL. The DNA repair transcriptome in severe COPD. *Eur Respir J*. 2018 Oct 4;52(4). pii: 1701994. doi: 10.1183/13993003.01994-2017. Print 2018 Oct. PubMed PMID: 30190272.

Schaeffer MR, **Ryerson CJ**, Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, Mitchell RA, Sheel AW, Khalil N, **Camp PG**, **Guenette JA**. Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. *Eur Respir J*. 2018 Jan 18;51(1). pii: 1701726. doi: 10.1183/13993003.01726-2017. Print 2018 Jan. PubMed PMID: 29348183.

Tanabe N, Vasilescu DM, Kirby M, **Coxson HO**, Verleden SE, Vanaudenaerde BM, Kinose D, Nakano Y, **Paré PD**, **Hogg JC**. Analysis of airway pathology in COPD using a combination of computed tomography, micro-computed tomography and histology. *Eur Respir J*. 2018 Feb 14;51(2). pii: 1701245. doi: 10.1183/13993003.01245-2017. Print 2018 Feb. PubMed PMID: 29444912.

Autophagy

Impact Factor: 11.100

Journal Category:

Cell Biology

Rank Within Category:

13/190

Corona AK, Mohamud Y, Jackson WT, **Luo H**. Oh, SNAP! How enteroviruses redirect autophagic traffic away from degradation. *Autophagy*. 2018;14(8):1469-1471. doi: 10.1080/15548627.2018.1480849. Epub 2018 Jul 21. PubMed PMID: 30032704; PubMed Central PMCID: PMC6103677.

JACC: Cardiovascular Imaging

Impact Factor: 10.247

Journal Category:

Cardiac & Cardiovascular Systems

Radiology, Nuclear Medicine & Medical Imaging

Rank Within Category:

7/128

1/129

Kim U, **Leipsic JA**, Sellers SL, Shao M, Blanke P, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, Shin S, Choi JH, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Chang HJ. Natural History of Diabetic Coronary Atherosclerosis by Quantitative Measurement of Serial Coronary Computed Tomographic Angiography: Results of the PARADIGM Study. *JACC Cardiovasc Imaging*. 2018 Oct;11(10):1461-1471. doi: 10.1016/j.jcmg.2018.04.009. Epub 2018 May 16. PubMed PMID: 29778853.

Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, **Leipsic JA**, Shin S, Choi JH, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. *JACC Cardiovasc Imaging*. 2018 Oct;11(10):1475-1484. doi: 10.1016/j.jcmg.2018.04.015. Epub 2018 Jun 13. PubMed PMID: 29909109.

Sellers SL, Turner CT, Sathananthan J, Carlidge TRG, Sin F, Bouchareb R, Mooney J, Nørgaard BL, Bax JJ, **Bernatchez PN**, Dweck MR, **Granville DJ**, Newby DE, Lauck S, Webb JG, Payne GW, Pibarot P, Blanke P, **Seidman MA**, **Leipsic JA**. Transcatheter Aortic Heart Valves: Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration. *JACC Cardiovasc Imaging*. 2019 Jan;12(1):135-145. doi: 10.1016/j.jcmg.2018.06.028. Epub 2018 Nov 15. PubMed PMID: 30448122.




KNOWLEDGE TRANSLATION

Drs. Jordan Guenette and Michele Schaeffer featured in BC Lung Association's Lung Month Celebration

Interstitial lung disease is a category of disorders that cause scarring, or fibrosis of the lungs. People who suffer from interstitial lung disease often experience shortness of breath, which leads them to avoid or minimize physical activity. This in turn makes them weaker and can lead to even more severe symptoms of breathlessness.

In a [video](#) made by BC Lung Association, Dr. Jordan Guenette, a clinical exercise physiologist, and his trainee Dr. Michele Schaeffer explained their idea to give these patients extra oxygen to reduce their symptoms of breathlessness.




In this study, Drs. Guenette and Schaeffer found that patients who were given supplemental oxygen improved dramatically. With these results, they have secured over \$2.1 million to take this intervention across the nation, launching a multi-centre clinical trial at eight different sites. This video was shown at the BC Lung Association's Lung Month Celebration in November 2018.

Read more about Dr. Guenette's research at Providence Health Care's [The Daily Scan](#) and in the [Research Spotlight](#).

Dr. Don Sin comments on air quality during the BC wildfire season

In the summer of 2018, much of BC – including Vancouver and the Lower Mainland – had air quality advisories in effect. With over 500 wildfires burning across the province, the city was covered in a thick, smoky haze and air levels of particulate matter were 10 to 20 times higher than normally expected.

In an interview with CBC, Dr. Don Sin, a respirologist at St. Paul's Hospital and a Professor of Medicine in the HLI, commented that the air quality was like "smoking continuous cigarettes". Continued exposure to these conditions may cause long-term health problems in up to 10% of people.



During interviews with [Global News](#) and [Breakfast Television](#), Dr. Sin commented that around 10 to 20% of the population were particularly susceptible to poor air quality, such as those who have chronic obstructive pulmonary disease (COPD), asthma, or underlying heart conditions. In the emergency room and other urgent clinics, there was an increase in the number of patients with symptoms of chest tightness, heart issues, breathing trouble, and cough.

To minimize exposure, Dr. Sin recommended that individuals avoid physical activity outdoors and to use properly fitted N95 masks that can properly filter out particles from the air. Surgical masks, on the other hand, may do more harm than good, as they can cause quicker rates of breathing and increase exposure to particulate matter.

Read more on Dr. Sin's recommendations in [CBC News](#), [Global News](#), and [News 1130](#).

Dr. Liam Brunham educates the public on using stem cells to study adverse drug reactions



Adverse drug reactions, or side effects from prescribed medications, are the fourth leading cause of death in Canada and the United States. These undesired effects arise from variabilities in how different individuals respond to the same drug, which could be related to their age, sex, weight, and most importantly, underlying genetic differences.

During a [Public Salon](#) in June 2018, Dr. Liam Brunham explained to a public audience how his research group is developing tools to predict and prevent adverse drug reactions. Using inducible pluripotent stem cells derived from the patients' blood, Dr. Brunham and his team tested the response of specific cell types to drugs, and found that the cells' responses closely mimicked how the actual patients responded to the drug.

This finding has the potential to shift the paradigm of how medications are prescribed by allowing physicians to predict whether adverse drug reactions will occur before patients are actually treated.

Dr. Chris Carlsten warns about the unknown effects of long term vaping

Vaping, or the act of inhaling the vapour produced by e-cigarettes and similar devices, is rising in popularity as a less harmful alternative to smoking tobacco. However, emerging evidence suggests that the potential for harm reduction is not being realized to the extent that was hoped for.

Dr. Chris Carlsten, a Professor in Respiratory Medicine and the Director of UBC's Occupational Lung Disease Clinic, commented on the current vaping trend in a [CBC radio interview](#).

Because e-cigarettes deliver nicotine very efficiently – approximately 15 to 20 times more than normal cigarettes – Dr. Carlsten believes young people are becoming more addicted to nicotine. In fact, individuals under the age of 21 are 10 times more likely to develop a dependence on nicotine, compared to those who start to use nicotine at an older age.



During the interview, Dr. Carlsten also draws attention to the parallels between the past popularity of cigarettes and the current trend of e-cigarettes. Similar to when cigarettes first came to market, he believes “the product is ahead of the science”, and that potential longer term health effects will not be realized until decades later.

In order to fully understand the risks and benefits associated with vaping, more research is needed, but until then, Dr. Carlsten believes that proper education is critical, and that government regulations and policies should be put in place to ensure that only the products that are backed up by robust, concrete data be let into the marketplace.

Read more on Dr. Carlsten's interview in [CBC News](#).

Dr. Simon Pimstone discusses the diagnosis and treatment of individuals with early onset cardiovascular disease

Heart disease is a leading cause of death in Canada. Although the rates of incidence have stabilized in older populations, the numbers are still climbing for the young. For patients with early onset heart disease – males under 50 years old and females under 55 years old – their immediate family is at even greater risk of developing heart disease, up to 10 times higher than normal.

Last May, in interviews with [Global News](#) and [CityTV Breakfast Television](#), Dr. Pimstone commented that heart disease is generally known to be a male disease, resulting in underdiagnosis and undertreatment in women.

SAVE BC (Study to Avoid cardiovascular disease in British Columbia) is a study that was launched in 2015 by Drs. Simon Pimstone and Liam Brunham to identify ways to predict, treat, and reduce cardiovascular disease in these high-risk patients and families.

The SAVE BC study currently has over 600 enrolled participants, and the team hopes to roll out the program to the rest of BC and eventually to the rest of Canada.



Dr. Scott Lear: Exercise is medicine

Exercise is key to preventing chronic illnesses and has important benefits in treating diseases. For example, it reduces prevents early death and risks of depression, type 2 diabetes, heart disease, stroke, and many cancers. According to the World Health Organization, physical inactivity is the fourth leading cause of death in the world, and current guidelines for physical activity is a minimum of 150 minutes per week.

In a commentary published in [The Conversation](#) and [Global News](#), Dr. Scott Lear, a Professor in the Faculty of Health Sciences at SFU, discusses the importance of prescribing exercise as medicine.

For example, exercise is currently used in cardiac rehabilitation for patients who have suffered a heart attack, and in Australia, the Clinical Oncology Society released a position statement recommending exercise as part of standard-of-care. Current and future physicians will need to be educated on when and how to prescribe exercise to their patients, which will hopefully reduce the global burden of chronic diseases on the healthcare system.



Dr. Lear is the Pfizer/Heart & Stroke Foundation Chair in Cardiovascular Prevention Research. He is actively involved in knowledge translation – articles and podcasts can be found at <https://drscottlear.com/>.

The Airway Centre creates interdisciplinary dialogue at its inaugural conference

Chronic obstructive pulmonary disease (COPD) is currently the leading cause of hospitalizations in Canada, affecting over 2.5 million Canadians. The inaugural Creation of a Pan-Canadian Airway Network Conference, hosted by the Airway Centre in November 2018, brought together over 130 faculty, industrial and government partners, and trainees. These included panel experts such as Drs. Jonathon Leipsic (UBC), Grace Parraga (Robarts Research Institute), Jonathan Rayment (BC Children's), Karen Cheung (UBC), Edmond Young (U. Toronto), Jeremy Hirota (McMaster), Ma'en Obeidat (UBC), Maxwell Libbrecht (SFU), Yohan Bosse (Laval), Chris Carlsten (UBC), Mohsen Sadatsafavi (UBC), and Shawn Aaron (U. Ottawa).



Through brief presentations and extended open-forum discussions, the conference was designed to consolidate and implement multidisciplinary research strategies to accelerate the discovery of COPD drugs and biomarkers. Each of the Airway Centre's four major research themes were featured: 1) Bioimaging, 2) Biomedical Engineering, 3) Genetics/ Genomics, and 4) Clinical Translation. Based on these discussions, several sites were identified as important nodes for the four research themes, and multi-centre, interdisciplinary projects are underway to improve COPD care across all the national sites.

The [Airway Centre](#) was founded in 2017 by respirologist and HLI Director, Dr. Don Sin, the current and first Tier 1 Canada Research Chair for COPD, to bring new biomarker and therapeutic solutions to patients with COPD and related airway conditions.



Spin-off Companies

To date, the HLI has launched five UBC spin-off companies: Cyon Therapeutics, viDA Therapeutics Inc, Aspect Biosystems, Black Tusk, and PROOF Centre.



Cyon Therapeutics: Better Outcomes in Sepsis

Driven by the knowledge that better outcomes in sepsis are possible, Cyon Therapeutics Inc. was formed in 2014 to make this a reality. Led by a team of HLI scientists and critical care physicians, Drs. Keith Walley, Jim Russell and John Boyd, and supported by two CEOs, the goal of the company is to bring a novel treatment platform to sepsis. Through their groundbreaking scientific discoveries, the team is developing the means to boost the body's natural ability to clear infectious toxins from the bloodstream.

viDA Therapeutics: Novel Treatments for Inflammatory and Age-related Diseases



Founded in 2008 by Dr. David Granville, viDA Therapeutics is committed to the discovery, development, and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age-related diseases. Their unique discovery platform is based on novel research regarding a distinctly different and recently identified extracellular role for Granzymes in the destruction and inflammation of tissues.



Aspect Biosystems: Human Tissues on Demand

Dr. Sam Wadsworth, leading cell biologist at the HLI, co-founded the award-winning biotechnology company, Aspect Biosystems Ltd., with Dr. Konrad Walus' research group in November 2013. Aspect Biosystems specializes in 3D bioprinting and tissue engineering, bringing together a multi-talented team of individuals to develop cutting-edge custom human tissue technology for use in the life sciences.



PROOF Centre: Biomarkers to prevent organ failure

The PROOF (Prevention of Organ Failure) Centre is a not-for-profit organization that develops blood tests to better predict, diagnose, manage, and treat heart, lung and kidney disease. PROOF is a cross-disciplinary biosignature development engine of partners representing academia, health care, government, industry, patients, and the public. The PROOF Centre, led by HLI PI and former HLI Director Dr. Bruce McManus, was initially established by the Networks of Centres of Excellence Secretariat under the Centre of Excellence for Commercialization and Research (NCE CECR) Program, and is co-hosted by the University of British Columbia and Providence Health Care in Vancouver, British Columbia, Canada.

BLACK TUSK

Black Tusk Research Group Inc.

Founded in 2014 by HLI Clinical Research Core Manager Ms. Lynda Lazosky and HLI PI Dr. John Boyd, Black Tusk Research Group Inc. is a site monitoring organization supporting clinical trials and biobanking. BTRG supports Principal Investigators by initiating and managing pharmaceutical clinical trials (phase II, III, IV) and academic grant funded clinical research projects.

Dr. Bruce McManus with graduate students



TRAINING THE NEXT GENERATION

The HLI prides itself on its success in attracting international trainees and research personnel from all over the world. In the past 5 years, the HLI has hosted trainees and research personnel from **39 countries** and **6 continents**.



HLI Summer Student Research Program

About the HLI-SSRP

Throughout the year, numerous undergraduate students are trained at the HLI through co-operative education programs, directed studies programs, or other opportunities. Our busiest time of year is May to August, when undergraduate students participate in our Summer Student Research Program (HLI-SSRP). Students are mentored by a senior professor and an immediate research supervisor, and gain hands-on, basic science laboratory experience while working on a research project. Not only does each student learn, in detail, one or two techniques per four-month or eight-month fellowship, but, more importantly for this formative period of learning, students develop critical thinking abilities, team and communications skills, and a passion for scientific research.

In addition to technical and scientific training, students learn to present their original work at the Summer Student Research Day, a one-day conference featuring both oral and poster presentations by student researchers.

In 2018, the HLI hosted **43 summer students** through our Summer Student Research Program.

Over the last 10 years the HLI has hosted over 600 undergraduate students

Summer Student Research Day



The annual Summer Student Research Day took place on August 10, 2018, at St. Paul's Hospital. During this one-day event, summer students – mostly undergraduates and a few high school students – had the opportunity to present their research findings to their peers and other researchers at the Centre. For many students, this is one of their first opportunities to showcase their most exciting research findings to a large audience.

This year, a total of 16 students gave oral presentations in three categories: heart, lung, and innovation. An additional 15 students presented posters on their research. Topics ranged from basic science research on asthma and chronic obstructive pulmonary disease (COPD), to clinical studies on heart disease.

The 2018 SSRD was once again a huge success, with thanks to the generous event sponsors: St. Paul's Hospital Foundation, Providence Health Care Research Institute, Michael Smith Foundation for Health Research, and the HLI. The oral and poster presentations were judged by a panel of HLI senior investigators, and awards were presented to the outstanding students below. Congratulations to all of our next generation of researchers!

2018 Dr. Bruce McManus Presentation Awards

Award	Recipient	HLI Supervisor
Top Heart Oral Presentation	Antyrah de Guzman	Keith Walley, Alex Leung
Top Lung Oral Presentation	Aileen Hsieh	Tillie Hackett
Top Innovation Oral Presentation	Sophie Guo	Liam Brunham
Top Poster	Katrina Besler	Gordon Francis

Heart + Lung FEST

The annual Heart + Lung Health FEST is developed and hosted by the community-wide umbrella organization, the Institute for Heart + Lung Health. FEST is an opportunity for HLI trainees to present their ongoing research and engage and learn alongside professionals from all relevant heart and lung domains. The 2018 FEST was held February 6 - 7th at the Sheraton Vancouver Wall Centre Hotel.

HLI Trainee Research Day

On October 16, 2018, the HLI hosted the second annual Trainee Research Day. During this exciting day of science and discovery, HLI trainees presented their research and progress towards finding cures for heart, lung, vessel, and critical care disease. Dr. Jim Hogg delivered the keynote presentation of the day, "Why the small conducting airways are the 'Achilles heel' of the lungs". This event was generously sponsored by Providence Health Care Research Institute, St. Paul's Foundation, and Michael Smith Foundation for Health Research.

Trainees presented in three categories: Heart, Lung and Innovation. Congratulations to the award recipients!

Heart

1st prize: Arash Tehrani (Bernatchez lab)

Runner-up: Yasir Mohamud (Luo lab)

Lung

1st prize: Steve Booth (Hackett lab)

Runner-up: Kimia Shahangian (Sin lab)

Innovation

1st prize: Stephanie Sellers (Leipsic lab)

Runner-up: Tim Xue (Luo lab)

Poster


1st prize: Amy Nguyen (DeMarco lab) | 2nd prize: Alex Leung (Boyd lab) | 3rd prize: Feng Xu (Hogg lab)



Participants in the HLI Trainee Research Day were invited to apply for a Travel Award to attend a conference of their choice.

The awards were presented to **Mark Trinder** (Brunham Lab) to attend the European Atherosclerosis Society Congress in the Netherlands, and **Yasir Mohamud** (Luo Lab) to attend the International Conference on Regulators of Autophagy and Cell Biology in Osaka, Japan.

HLI Career Day



Every year the HLI holds a Career Day for trainees. In 2018, the focus of Career Day was to provide trainees with career options in science and research. Seminars on preparing posters and writing scientific journal articles were also offered.

High School Science Week

In the spring and fall each year, high school students participate in the High School Science Week hosted by the HLI. Eight students are invited to participate in laboratory sessions and seminars. This program is a unique opportunity for highschool students to receive hands-on biomedical lab experience that can help shape their future aspirations.

Students who participate in the High School Science Week are eligible to apply for the \$2,000 **Peter D. Paré Scholarship**, an eight-week summer internship at the HLI.

The Peter D. Paré Scholarship recipient for 2018 was **Nima Toussi**. Nima worked in Dr. Chun Seow's lab with Dr. Lu Wang to test a structure model for a smooth muscle contractile unit. Nima presented his research at the 2018 HLI Summer Student Research Day.



HLI Weekly Seminars

The Centre for Heart Lung Innovation holds two weekly seminars, the Research in Progress Seminar Series and the HLI Friday Seminar Series, both of which run from September through June each year.

The HLI Friday Seminar Series features research presentations from local and international experts to foster education and collaboration. Detailed information about the 2018 HLI Friday Seminars can be found in [Appendix C](#). The Research in Progress seminar series provides graduate students and post-doctoral fellows at the HLI a forum to present their ongoing research to other HLI researchers. These seminars provide trainees access to a critical but supportive audience with varied expertise throughout the their research programs. A full schedule of the 2018 Research in Progress Seminars can be found in [Appendix D](#).

HLI Trainee Association

As part of an effort to enhance the current training environment, Dr. Scott Tebbutt, newly appointed HLI Educational Director, spearheaded the formation of the first HLI Trainee Association. The inaugural meeting of the Association was held in December 2018. The Association established the following mission statement:

"We aim to enhance the academic experience of all trainees by providing an environment to foster enhanced collaboration, education, professional growth, and career success."



Trainee Awards in 2018

Trainee Fellowships and Scholarships

Name	Award	Awarding Body
Alyson Wong	Clinical Fellowship	Canadian Pulmonary Fibrosis Foundation
Anna Siedlecki	Microgrant	Rare Disease Foundation
Anna Siedlecki	Affiliation Bursary Award	UBC
Anna Siedlecki	Graduate Award	UBC Faculty of Medicine
Arash Tehrani	Microgrant	Rare Disease Foundation
Arash Tehrani	Graduate Award	UBC Faculty of Medicine
Chris Turner	Young Investigator of the Year	Australasian Wound & Tissue Repair Society
Christopher Qi	Summer Studentship	AllerGen
Daniela Castillo-Saldana	Microgrant	Rare Disease Foundation
Daniela Castillo-Saldana	Graduate Award	UBC Faculty of Medicine
Guangze Zhao	C. L. Wang Memorial Scholarship	UBC
Guangze Zhao	Graduate Award	UBC Faculty of Medicine
Julia Yang	JSPS Summer Student Program	Mitacs
Junyan Shi	Research Trainee Fellowship	Michael Smith Foundation for Health Research
Lauren Forgrave	CGS-M	Canadian Institutes of Health Research
Marissa Lee	Summer Studentship	Cystic Fibrosis Canada
Nafeez Syed	BAO Allied Health Fellowship	Lung Association
Nancy Yang	Graduate Award	UBC Faculty of Medicine
Paul Hanson	Research Trainee Fellowship	Michael Smith Foundation for Health Research
Reid Mitchell	Postgraduate Scholarship - Doctoral	NSERC
Reid Mitchell	4-year Fellowship	UBC
Sameer Desai	Research Fellowship	Cystic Fibrosis Canada
Sameer Desai	Doctoral Studentship	Cystic Fibrosis Canada
Sameer Desai	Health System Impact Fellowship	Canadian Institutes of Health Research
Serena Singh	Research Trainee Fellowship	Michael Smith Foundation for Health Research
Stephanie Sellers	Research Trainee Fellowship	Michael Smith Foundation for Health Research
Tony Guo	Summer Studentship	AllerGen
Yannick Molgat-Seon	Research Trainee Fellowship	Michael Smith Foundation for Health Research
Yannick Molgat-Seon	Respiratory Rehabilitation Fellowship	BC Lung Association
Yaroslav Uryumtsev	Summer Studentship	UBC Faculty of Medicine
Yasir Mohamud	Doctoral Fellowship	ALS Canada Brain Canada

Other Trainee and Staff Awards and Recognitions

Name	Award	Awarding Body
Aida Eslami	Travel Award	CIHR - Institute Community Support
Amy Nguyen	Honours, student/fellow competition	Alzheimer's Association International Conference
Andrew Ramsook	Student Travel Award	Canadian Society of Exercise Physiology
Andrew Ramsook	Travel Award	CIHR - Institute Community Support
Anna Siedlecki	Travel Award	CIHR - Institute Community Support
Anthony Tam	Travel Award	CIHR - Institute Community Support
Arash Tehrani	Travel Award	CIHR - Institute Community Support
Chris Turner	Travel and Oral Presentation Award	2018 Wound Healing Society
Chris Turner	Top Science Presentation	2018 UBC Plastic Surgery Day
Chris Turner	Travel Award	CIHR Institute of Aging
Daniela Castillo-Saldana	Travel Award	CIHR - Institute Community Support
Diana Vikulova	Travel Award	CIHR - Institute Community Support
Emmanuel Osei	Travel Award	AllerGen
Feng Xu	Travel Award	CIHR - Institute Community Support
Fernando Studart	2018 Sreedhar Nair Early Stage Investigator Award in COPD	ATS Assembly on Clinical Problems
Fernando Studart	Abstract Scholarship	American Thoracic Society
Fernando Studart	Travel Award	CIHR - Institute Community Support
Gurpreet Singhera	Travel Award	AllerGen
Josh Dubland	Travel Award for Young Investigators	ATVB
Josh Dubland	Travel Award	CIHR - Institute Community Support
Junyan Shi	Travel Award	CIHR - Institute Community Support
Keerit Tauh	Travel Award	CIHR - Institute Community Support
Keerit Tauh	Best Science Poster	Canadian Cardiovascular Congress
Keir Martyn	Top Undergraduate Student Poster	UBC Pathology Day
Kelly Genga	Travel Award	CIHR - Institute Community Support
Kimia Shahangian	Travel Award	CIHR - Institute Community Support
Mark Trinder	Travel Award	CIHR - Institute Community Support
Minhee Jin	Travel Award	CIHR - Institute Community Support
Miranda Kirby	Travel Award	CIHR - Institute Community Support
Paul Hanson	Trainee Travel Award	ASIP Histochemical Society
Serena Singh	Postdoctoral Research Lecture	UBC Pathology Day
Tatjana Milacic	Travel Fellowship	CALAS Pacific
Yasir Mohamud	Presentation Award	ALS Meeting

TRAINEE CAREER PATHS

The HLI is dedicated to training the next generation of leaders in heart, lung, and blood vessel research. Here are some current careers and positions of former HLI graduate students and postdoctoral fellows who completed their programs in 2018.

Trainee	Supervisor	HLI End Date	Degree/Study Level	Present Position
Nawaf Alotaibi	Don Sin	March 2018	MSc Student	Physician
Kamel Boukais	Gordon Francis	February 2018	Postdoctorate	Pharmaceutical Company Scientist, Paris
Ju Yi Cho	Don Sin	February 2018	Visiting Professor	Assistant Professor, Medicine, Gyeongsang National University Hospital, Korea
Josh Dubland	Gordon Francis	December 2018	PhD Student	Clinical Assistant Professor, BC Children's Hospital
Sabina Guler	Chris Ryerson	March 2018	Postdoctorate	Attending Physician and Clinical Researcher, Pulmonary Medicine, University Hospital Insepsital Bern, Switzerland
Seo Am Hur	Chris Ryerson	June 2018	MSc Student	Medical Student, UBC
Young Woong Kim	Scott Tebbutt	May 2018	PhD Student	Postdoctoral Fellow
Richard Munthali	Denise Daley	September 2018	Postdoctorate	Research Statistician, Wits Reproductive Health and HIV Institute, South Africa
Amreen Toor	Scott Tebbutt	May 2018	MSc Student	PhD Student
Kei Yamasaki	Stephan van Eeden	December 2018	Postdoctorate	Assistant Professor, Respiratory Medicine, University of Occupational and Environmental Health Japan, Kitakyusyu, Fukuoka, Japan

HLI OPERATIONS



Centre Operational Highlights

In 2018, the HLI Operations Team began procurement of equipment for our latest Canada Foundation for Innovation grant, including:

- -80C freezers to aid in our ever expanding heart and lung tissue registry inventories
- a new mass spectrometer for protein analysis
- Xenon gas lung imaging pieces for a new Magnetic Resonance Imaging system at St. Paul's Hospital

Our maintenance team successfully handled over 130 work request tickets, providing ongoing maintenance service to staff and students in over 50,000 square feet of office, wet lab, and dry lab spaces. Some highlights from our Core service groups are listed below.

Molecular Phenotyping Core Laboratory

The Molecular Phenotyping Core Laboratory (MPCL) participated in large projects with Providence Health Care, Vancouver Coastal Health Research Institute, and UBC Departments of Gastroenterology, Surgery, Cardiology, and Respiriology. In 2018, the team supported the creation of a BC Glomerulonephritis Biobank, a pilot study for kidney transplant recipients, and a multinational respirology study.

The MPCL team provides expertise in molecular biology by mentoring and training students and staff on sample preparation and lab equipment usage. The team's goal is to promote proper collection and storage of specimens that are used in downstream applications such as flow cytometry, protein, and DNA/RNA analysis.

Cellular Imaging and Biophysics Core

The Cellular Imaging and Biophysics Core (CIB) had a productive year, with many significant projects wrapping up and producing important clinical and scientific findings. Using microCT imaging at the CIB core, HLI researchers made important discoveries that has resulted in a paradigm shift in the understanding of COPD. This was published in Lancet Respiratory Medicine. For more details, see the [Research Spotlight](#) section.

The CIB also recently developed a multiphoton, super-resolution imaging technique that will enable increased sensitivity in future measurements. In the coming year, the CIB will be involved in imaging projects examining idiopathic pulmonary fibrosis, cancer, and prosthetic heart valve degeneration.

Preclinical Services

The Preclinical Services, also called Genetically Engineered Models (GEM), Team made significant contributions to developing new therapeutic strategies for Amyotrophic Lateral Sclerosis, Marfan's Syndrome, COPD, sepsis, Coxsackievirus B infection, and atherosclerosis.

IT Services

In 2018, HLI's Information Technology team overcame many challenges related to power outages and infrastructure renovation issues. They updated caching software and expanded HLI's storage to keep up with ever increasing demands, handling over 2,100 service tickets. Registry database features were also improved for the benefit of coordinators and registry managers.

Safety and Environment

The Faculty of Medicine Joint Occupation Health and Safety Committee (FoM JOHSC) was formed in 2017 and is comprised of the Centre for Heart Lung Innovation (HLI) and other FoM members.

Reporting to the Provost & VP Academic, the FoM JOHSC is one of 23 JOHSCs that oversees and works to improve occupational health and safety at UBC. These committees were created in consultation with WorkSafeBC to serve the exponentially growing number of employees in the University.

In support of the FoM JOHSC, HLI's Local Safety Team (LST) met monthly in 2018 to advise on and facilitate all matters of health and safety within HLI, improving the occupational health and safety of all HLI members. All recommendations and policies developed by the HLI LST were reviewed and approved by the FoM JOHSC.



The HLI Safety committee was also worked with Providence Health Care and the St. Paul's Hospital Joint Occupational Health and Safety Committee (SPH JOHSC) to assist in integrating safety policies. To date, several policies have been aligned across all centres at St. Paul's Hospital. The HLI Safety webpage has been used as a model for other research groups.

This year, our Safety Team completed the clearing out and disposing of 400 kg chemical waste. They also successfully completed Transport Canada and UBC Radiation Safety inspections.

Mental Health Initiatives

Take 5 Cafes

In 2018, HLI's Training and Environment team continued our Mental Initiative program, which is funded by UBC THRIVE'S Healthy Workplace Healthy Initiative Program. "Take 5 Cafes" encourage staff and students to take a 5-minute break and socialize with their colleagues in a fun, informal setting. Take 5 Cafes were held throughout the year with different themes, games, and activities to create conversations on and emphasize the importance of addressing mental health in the workplace.



Pink Shirt Day, 2018.

Providence in the Park care packages drive



As part of the HLI Mental Health Initiative program, staff and students donated supplies and built hundreds of basic care packages for Providence in the Park, a bi-annual Providence Health Care outreach program that distributes the packages to those who need them the most.

Diversity by Design Workshop



On October 24, the HLI hosted UBC Equity and Inclusion Office's Diversity by Design Workshop to learn how to better understand and celebrate the differences and similarities in our community.

Scleroderma Ride for Research

The HLI team rode together at the 7th Annual Scleroderma Ride for Research to raise awareness and funds for the Scleroderma Association of BC.



Lights of Hope Campaign



The St. Paul's Hospital Foundation's Lights of Hope campaign raises critical funds for the greatest needs of patients, caregivers, residents, and families. The HLI once again achieved a Gold Star on the annual Lights of Hope display. In total, the HLI community raised \$34,760 for the 21st annual fundraiser.



Centre for Heart Lung Innovation

Core and Technical Services



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

The Centre for Heart Lung Innovation staff have extensive training and experience to provide consistent and reliable results with minimal turnover time. Some of our services, equipment and tools available are:

HLI Cardiovascular and Lung Tissue Registries

- Tissue and sample archiving
- Gross and microscopic specimen images
- Gross specimen photography
- New expanded formalin storage facility

Cellular Imaging & Biophysics

- Automatic tissue processing capabilities
- Nikon Model XTH225ST Micro Computed Tomography System
- Pelco BioWave Microwave Processor
- Image processing work stations
- Wide Field Fluorescence Microscope
- Leica Upright Fluorescence Microscope with Fast Confocal Scanner and CCD camera
- Leica Inverted Fluorescence microscope with Confocal Scanner
- Tunable Ultra-short pulse Infrared Laser for Two-Photon Excitation microscopy

Imaging Services

- Digital slide scanning
- Poster and banner printing

Histology

- Processing and embedding
- Staining and Sectioning
- Immunohistochemistry
- Immuno-peroxidase
- Immuno-alkaline phosphatase
- FITC immunofluorescence
- TUNEL staining
- In situ Hybridization (ISH)

Molecular Phenotyping

- BeckmanCoulter Astrios EQ® high speed cell sorter
- Laser Capture Microdissection Pixcell II
- Siemens Advia 2120 Hematology analyzer
- BeckmanCoulter Gallios® Flow Cytometer
- Miltenyi AutoMACS
- ABI ViiA 7 Real-Time PCR
- Luminex IS100 XYP
- NanoString nCounter System
- Biobanking services
- SpectraMax i3 Plate Reader

Preclinical Services

- Contract animal research projects
- Flexivent Lung Function system
- DSI Telemetry
- Visualsonics Echocardiography
- Mouse Specifics Gait Analyzer
- Level 2 Containment suite
- Colony management services
- Microsurgical / Tech services

Clinical Research

- Consultation and project management
- Assistance with ethics applications




Information Technology

- Advanced computing services
- Hosting of physical servers, virtual servers
- Secured and controlled access
- Long term storage
- Custom database and data management services
- Secure web development

For more information contact:

Claire Smits, Operations Director

t: 604.806.8852 | e: claire.smits@hli.ubc.ca



a place of mind



Partnerships and Acknowledgements

The HLI is grateful to our patients, donors, and funding partners: Canada Foundation for Innovation, British Columbia Knowledge Development Fund, Providence Health Care, University of British Columbia, Heart and Stroke Foundation of Canada, BC Lung Association, the St. Paul's Hospital Foundation, Michael Smith Foundation for Health Research, and many vendors and industry collaborators, for their crucial support of our ongoing programs.

We wish to thank our current partners:

Adiga Life Sciences Inc.
Agartee Technology Inc.
AllerGen
Alpha-1 Foundation
Alzheimer Society of Canada
Amarin Pharma Inc.
AMGEN Canada Inc.
Asahi Kasei Pharma America
AstraZeneca Canada Inc.
Bayer AG
Boehringer Ingelheim (Canada) Ltd.
British Columbia Knowledge Development Fund (BCKDF)
British Columbia Lung Association
British Columbia Proteomics Network
Canada Foundation for Innovation
Canada Research Chairs
Canadian Diabetes Association
Canadian Foundation for AIDS Research
Canadian Institutes of Health Research (CIHR)
Cyon Therapeutics Inc.
Cystic Fibrosis Canada
Cystic Fibrosis Foundation (US)
Genentech Inc.
Genome British Columbia
Gilead Sciences Inc.
GlaxoSmithKline
Grifols Shared Services North America Inc.
Heart and Stroke Foundation of British Columbia and Yukon
Heart and Stroke Foundation of Canada
Hoffmann-La Roche Ltd. (Canada)
Networks of Centres of Excellence (NCE)
Industry Canada
Interior Health Authority
InterMune Inc.
Ionis Pharmaceuticals, Inc.
Janssen Inc.
Juvenile Diabetes Research Foundation International
La Jolla Pharmaceutical Company
Leading Biosciences Inc.
MedImmune LLC
Merck Sharp & Dohme Corp.
Michael Smith Foundation for Health Research
National Institutes of Health
National Research Council
Natural Sciences and Engineering Research Council of Canada (NSERC)
Novartis Pharmaceuticals Canada Inc.
Octapharma Canada Inc.
Pfizer Canada Inc.
Pharmaxis Ltd.
ProMetic Life Sciences Inc.
PROOF Centre of Excellence
Providence Health Care Research Institute (PHCRI)
Province of British Columbia
Respivert Ltd.
RxSource Corp.
sanofi-aventis Canada Inc.
St. Paul's Hospital Foundation
The Lung Association
Trius Therapeutics Inc.
UBC Department of Medicine
UBC Department of Physical Therapy
University of Calgary
Vertex Pharmaceuticals Inc.
viDA Therapeutics Inc.

We are grateful to the following individuals for their assistance in the creation of this report: Vivienne Chan, Karen Jung, Claire Smits, Chris Robinson, Gwen Sin, Bryan Wong, Ivan Leversage, Dr. Don Sin and all the HLI Principal investigators.

Supporting our fight against heart and lung diseases

Heart and lung diseases combined are still the world's number one cause of death and disability. Help us win this fight.

The Centre for Heart Lung Innovation has been extremely successful at attracting infrastructure grants and government research dollars. However, attracting funds to allow us to retain our expertly trained staff and purchase new equipment remains a challenge. We actively seek interest and donations from private and individual donors whose interests are in alignment with our research, with the help of the following organizations.




St. Paul's Foundation
178 – 1081 Burrard Street
Vancouver, BC V6Z 1Y6
Phone (for residents of Metro Vancouver): 604-682-8206
Phone (toll-free number for residents of rest of BC): 1-800-720-2983
sphfoundation@providencehealth.bc.ca
www.helpstpauls.com



a place of mind
THE UNIVERSITY OF BRITISH COLUMBIA

University of British Columbia
Development and Alumni Engagement
500 - 5950 University Blvd
Vancouver, BC Canada V6T 1Z3
Phone: 604-822-8900
info@startanevolution.ubc.ca
<https://startanevolution.ubc.ca/category/projects-by-faculty/faculty-of-medicine>



APPENDICES

APPENDIX A: HLI GRANTS, CONTRACTS, CLINICAL TRIALS AND AGREEMENTS* (April 2018 – March 2019)

*Trainee grants are listed with their respective PIs

Principal Investigator	Funding Agency	Award Amount	Project Title	Award Type
Bernatchez, Pascal	Heart and Stroke Foundation of Canada	\$99,500.00	The role of endothelial function in the pathogenesis and management of Marfan syndrome-associated aortic disease	Grant
Bernatchez, Pascal	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Heterogeneity of angiotensin II receptor blockers in the inhibition of Marfan-associated aortic root dilation independent of blood pressure effects	Grant
Bernatchez, Pascal	Innovation, Science and Economic Development Canada	\$5,000.00	Optimization of angiotensin II receptor type 1 blockers (ARBs) in chronic obstructive pulmonary disease (COPD)	Grant
Bernatchez, Pascal	Providence Health Care	\$8,333.33	Optimization of angiotensin II receptor type 1 blockers (ARBs) in chronic obstructive pulmonary disease (COPD)	Grant
Bernatchez, Pascal	Province of British Columbia	\$5,000.00	Optimization of angiotensin II receptor type 1 blockers (ARBs) in chronic obstructive pulmonary disease (COPD)	Grant
Boyd, John	Michael Smith Foundation for Health Research	\$41,500.00	The role of PCSK9 in the clearance of bacterial lipids and the development of anti-PCSK9 treatment for sepsis	Grant
Boyd, John	Canadian Institutes of Health Research (CIHR)	\$100,980.00	Organ donation after cardiac death: optimizing the donor heart.	Grant
Boyd, John	Canadian Institutes of Health Research (CIHR)	\$1,000.00	PCSK9 loss-of-function (LOF) genotype is associated with decreased readmission or death in sepsis associated with stock and/or pulmonary dysfunction	Grant
Boyd, John	Takeda Pharmaceutical Company Limited	\$7,994.00	A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance	Clinical Trial
Brunham, Liam	Providence Health Care Research Institute (PHCRI)	\$6,352.66	Targeted next generation sequencing to improve the diagnosis and treatment of familial hypercholesterolemia in British Columbia	Grant
Brunham, Liam	AMGEN Canada Inc.	\$1,995.00	Guidelines Oriented Approach to Lipid lowering in Canada (GOAL I & II)	Clinical Trial

Brunham, Liam	Cerenis Therapeutics	\$17,751.70	Phase III, Multi-Center, Randomized, 48 Weeks, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients with Genetically Defined Familial Primary Hypoalphalipoproteine	Clinical Trial
Brunham, Liam	Canada Foundation for Innovation	\$47,437.00	Harnessing advances in genomics to improve the care of patients with dyslipidemias	Grant
Brunham, Liam	Canadian Institutes of Health Research (CIHR)	\$116,280.00	Investigating pharmacogenetic mechanisms of doxorubicin-induced cardiotoxicity in human pluripotent stem cell-serviced cardiomyocytes	Grant
Brunham, Liam	The Medicines Co.	\$8,611.15	An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-3)	Clinical Trial
Brunham, Liam	Genome British Columbia	\$85,331.00	Using genomics to improve the care of patients with familial hypercholesterolemia	Agreement
Brunham, Liam	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Genetic variation in the cholesteryl ester transfer protein (CETP) gene influences HDL cholesterol levels and clinical outcomes in sepsis	Grant
Brunham, Liam	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Very premature atherosclerotic cardiovascular disease in British Columbia: A cohort study of 12,519 individuals over a 16 year period	Grant
Camp, Pat	Canada Foundation for Innovation	\$7,500.00	CFI Infrastructure Operating Fund	Grant
Camp, Pat	British Columbia Lung Association	\$12,500.00	Pulmonary rehabilitation in rural BC: Engaging with communities to create novel telehealth approaches	Grant
Camp, Pat	British Columbia Lung Association	\$25,000.00	"Bayis Il Tus - A Strong Breath" A community-based research project to improve lung health in remote and rural First Nations communities in British Columbia	Grant
Camp, Pat	Canadian Institutes of Health Research (CIHR)	\$160,650.00	Niw'h Yizt'iyh Hilht'iz Nets'eelh'iyh - Strengthening our Bodies: A Community-based Research Project to Create Pulmonary Tele-Rehabilitation in Remote and Rural First Nations Communities in Northern British Columbia	Grant

Camp, Pat	Canadian Institutes of Health Research (CIHR)	\$106,355.00	Bayis II Tus - a strong breath: a community-based research to identify the prevalence of and contributors to chronic obstructive pulmonary disease in remote and rural First Nations communities in British Columbia	Grant
Coxson, Harvey	British Columbia Lung Association	\$25,000.00	Development and validation of novel non-invasive imaging tools to enhance our understanding of airways in asthma	Grant
Daley, Denise	Michael Smith Foundation for Health Research	\$22,458.33	Development of hierarchical models to investigate the role of long non coding RNA regions in the etiology of asthma	Grant
Daley, Denise	Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence (NCE)	\$107,500.00	Causes and Prevention: Identifying the genetic basis of peanut allergy	Grant
Daley, Denise	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Genome wide meta-analysis of parent-of-origin effects of asthma, atopy and airway hyperresponsiveness in four cohorts	Grant
DeMarco, Mari	Brain Canada	\$246,486.33	Translating research into practice: Investigating the impact of Alzheimer's disease diagnostics in Canada (IMPACT-AD)	Grant
DeMarco, Mari	Canadian Institutes of Health Research (CIHR)	\$1,000.00	A new LC-MS/MS assay for rapid quantitation of apolipoprotein A1 targeting the fast-forming proteotypic peptide in human plasma	Grant
Demarco, Mari	Ministry of Health	\$50,000.00	Clinical mass spectrometry teaching laboratory	Grant
Demarco, Mari	St. Paul's Hospital Foundation	\$4,975.00	Testing guidance for the BC Influximab therapeutic drug monitoring program	Grant
Dorscheid, Delbert	Novartis Pharmaceuticals Canada Inc.	\$4,664.00	REal-LIfe Effectiveness and safety of omalizumab in patients with severe allergic asthma: The Latin American and Canadian experience (RELIEF)	Clinical Trial
Dorscheid, Delbert	AstraZeneca Canada Inc.	\$3,292.81	A Multicentre, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting Å2 Agonist	Clinical Trial
Dorscheid, Delbert	sanofi-aventis Canada Inc.	\$5,176.89	A randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of dupilumab in patients with severe steroid dependent asthma	Clinical Trial

Dorscheid, Delbert	Novartis Pharmaceuticals Canada Inc.	\$21,058.00	A 52-week, multicenter, randomized, double-blind, placebo- controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma	Clinical Trial
Dorscheid, Delbert	Novartis Pharmaceuticals Canada Inc.	\$2,998.00	A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma	Clinical Trial
Dorscheid, Delbert	AstraZeneca Canada Inc.	\$47,028.67	A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment	Clinical Trial
Dorscheid, Delbert	British Columbia Lung Association	\$25,000.00	IgE-mediated inflammation generated by the airway epithelium is antigen independent - a cause of a novel asthma phenotype	Grant
Dorscheid, Delbert	GlaxoSmithKline (Canada) Inc.	\$15,663.38	A randomized, double-blind, parallel group, multicenter, stratified study evaluating the efficacy and safety of repeat doses of GSK3772847 compared with placebo in participants with moderately severe asthma	Clinical Trial
Dorscheid, Delbert	Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence (NCE)	\$15,000.00	Clinical investigator collaborative - Severe asthma	Grant
Dorscheid, Delbert	Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence (NCE)	\$3,500.00	Airway epithelial repair: cell subtypes or differentiation dependent?	Grant
Dorscheid, Delbert	AstraZeneca Canada Inc.	\$8,825.00	PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High-Dose Inhaled Corticosteroid	Clinical Trial
Francis, Gordon	Canada Foundation for Innovation	\$81,114.99	Molecules to man: enhanced phenotyping for the discovery, prevention and treatment of heart, lung and blood vessel disease	Grant

Francis, Gordon	Canada Foundation for Innovation	\$2,789.75	Molecules to man: enhanced phenotyping for the discovery, prevention and treatment of heart, lung and blood vessel disease	Grant
Francis, Gordon	Canada Foundation for Innovation	\$166,303.00	Molecules to human: enhanced phenotyping for discovery, prevention, & treatment of heart, lung, & blood vessel disease	Grant
Francis, Gordon	Canadian Institutes of Health Research (CIHR)	\$163,756.00	The unrecognized importance of smooth muscle foam cells in atherosclerosis development and treatment	Grant
Francis, Gordon	Ionis Pharmaceuticals, Inc.	\$29,553.28	An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)	Clinical Trial
Francis, Gordon	Canadian Institutes of Health Research (CIHR)	\$102,510.00	Relative deficiency of lysosomal acid lipase in arterial smooth muscle cells as a novel target for atherosclerosis treatment and prevention	Grant
Francis, Gordon	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Lysosomal dysfunction in smooth muscle cells relative to macrophages provides new insights into foam cell lipid accumulation	Grant
Frohlich, Jiri	AMGEN Canada Inc.	\$5,118.43	Creation and implementation of a Registry for Familial Hypercholesterolemia	Grant
Guenette, Jordan	Natural Sciences and Engineering Research Council of Canada (NSERC)	\$30,000.00	Sex-differences in respiratory sensation and muscle function during conditions of physiological stress	Grant
Guenette, Jordan	Canada Foundation for Innovation	\$7,500.00	CFI Infrastructure Operating Fund	Grant
Guenette, Jordan	British Columbia Lung Association	\$25,000.00	A double-blind placebo-controlled crossover study to assess the effects of bronchodilation on dyspnea, ventilatory responses, and exercise tolerance in adults with cystic fibrosis	Grant
Guenette, Jordan	British Columbia Lung Association	\$10,000.00	Impact of diesel exhaust on exercise endurance, breathlessness and airway physiology in mild-to-moderate chronic obstructive pulmonary disease	Grant
Guenette, Jordan	Michael Smith Foundation for Health Research	\$24,208.33	Investigating the role of skeletal muscle dysfunction on dyspnea and exercise intolerance in interstitial lung disease	Grant
Guenette, Jordan	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Ventilatory and sensory responses during exercise in adults with a Fontan circulation	Grant
Hackett, Tillie Louise	Canadian Institutes of Health Research (CIHR)	\$44,269.00	Molecular determinants of small airway obstruction in COPD	Grant

Hackett, Tillie Louise	Canada Foundation for Innovation	\$199.00	Molecular determinants of obstructive lung disease	Grant
Hackett, Tillie Louise	Canada Foundation for Innovation	\$395.00	Molecular determinants of obstructive lung disease	Grant
Hackett, Tillie Louise	Canadian Institutes of Health Research (CIHR)	\$40,000.00	Multimodal characterization of airway remodeling with label-free nonlinear optical imaging and spectroscopy	Grant
Hackett, Tillie Louise	Canadian Institutes of Health Research (CIHR)	\$5,000.00	Multimodal characterization of airway remodeling with label-free nonlinear optical imaging and spectroscopy	Grant
Hackett, Tillie Louise	Canadian Institutes of Health Research (CIHR)	\$135,068.00	The Role of Small Airways Disease Heterogeneity in Asthma	Grant
Hackett, Tillie Louise	Innovation, Science and Economic Development Canada	\$3,000.00	Apply deep neural network to detect malignant lung nodules in CT scans	Grant
Hackett, Tillie Louise	Province of British Columbia	\$3,000.00	Apply deep neural network to detect malignant lung nodules in CT scans	Grant
Hogg, James	National Institutes of Health	\$146,761.95	Parametric response mapping in COPD	Agreement
Hogg, James	British Columbia Lung Association	\$45,000.00	Hyperpolarized 129Xe MRI in symptomatic smokers with preserved pulmonary function	Grant
Hogg, James	Canadian Institutes of Health Research (CIHR)	\$1,000.00	The nature of the hot spot for issue destruction in COPD	Grant
Hogg, James	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Computed tomography total airway count predicts disease changes in the quiet zone in severe COPD	Grant
Hogg, James	British Columbia Lung Association	\$25,000.00	Analysis of airway pathology in interstitial lung disease using a combination of computed tomography, micro-computed tomography, histology, and gene expression	Grant
Laksman, Zachary	St. Paul's Foundation	\$160,542.55	Research and administrative costs account	Grant
Leipsic, Jonathon	Michael Smith Foundation for Health Research	\$24,208.33	Structural valve degeneration in bioprosthetic heart valves	Grant
Leipsic, Jonathon	Medtronic	\$216,666.66	Post-implant LT sub study core lab	Contract
Leipsic, Jonathon	Edwards Lifesciences	\$375,000.00	Impact CT imaging core lab low risk trial	Clinical Trial
Leipsic, Jonathon	London Drug Radiology Research	\$11,250.00	Mechanisms and prediction of bioprosthetic valve structural degeneration	Grant
Leung, Janice	Canadian Institutes of Health Research (CIHR)	\$181,072.00	Epigenetic and transcriptomic disturbances in HIV-associated COPD	Grant

Leung, Janice	British Columbia Lung Association	\$25,000.00	The role of the gut-lung axis in the aging HIV lung	Grant
Leung, Janice	National Institutes of Health	\$3,925.20	Sphingolipids in HIV-associated chronic obstructive pulmonary disease	Agreement
Leung, Janice	Canadian Institutes of Health Research	\$114,762.00	An 'Omics Approach to Understanding COPD Phenotypes and Endotypes	Grant
Luo, Honglin	Heart and Stroke Foundation of Canada	\$92,460.00	Molecular chaperones in viral cardiomyopathy	Grant
Luo, Honglin	Natural Sciences and Engineering Research Council of Canada (NSERC)	\$44,000.00	Understanding the interplay between coxsackieviruses and the host ubiquitin-proteasome system	Grant
Luo, Honglin	Heart and Stroke Foundation of Canada	\$75,750.00	Enteroviral control of autophagy: Relevance to heart failure	Grant
Luo, Honglin	British Columbia Lung Association	\$25,000.00	Engineering coxsackievirus B3 for KRAS-driven lung cancer therapy	Grant
Luo, Honglin	Canadian Institutes of Health Research (CIHR)	\$253,878.50	Role of enteroviral infection in amyotrophic lateral sclerosis	Grant
Luo, Honglin	Innovation, Science and Economic Development Canada	\$7,500.00	Development of coxsackievirus B3 as an oncolytic virus for KRAS-mutant lung cancer treatment	Grant
Luo, Honglin	Province of British Columbia	\$7,500.00	Development of coxsackievirus B3 as an oncolytic virus for KRAS-mutant lung cancer treatment	Grant
Luo, Honglin	Virogin Biotech Canada Ltd.	\$15,000.00	Development of coxsackievirus B3 as an oncolytic virus for KRAS-mutant lung cancer treatment	Grant
Luo, Honglin	Amyotrophic Lateral Sclerosis Society of Canada	\$25,000.00	Characterizing enterovirus disruption of autophagy as a disease mechanism for ALS	Agreement
McManus, Bruce	Canada Foundation for Innovation	\$5,622.00	CFI Infrastructure Operating Fund	Grant
McManus, Bruce	Michael Smith Foundation for Health Research	\$41,500.00	Development and validation of blood-based biomarkers for improved heart failure management	Grant
McManus, Bruce	Canadian Institutes of Health Research (CIHR)	\$436,050.00	HEARTBiT: A novel multi-marker blood test for management of acute cardiac allograft rejection	Grant
McManus, Bruce	Myocarditis Foundation	\$52,530.00	Personalizing myocarditis diagnostics through novel biomarkers	Agreement
McManus, Bruce	Michael Smith Foundation for Health Research	\$6,708.33	Personalizing myocarditis diagnostics through novel biomarkers	Grant

Obeidat, Ma'en	Canadian Institutes of Health Research (CIHR)	\$75,000.00	Gene by sex interactions in COPD	Grant
Obeidat, Ma'en	British Columbia Lung Association	\$25,000.00	The interaction of genes and sex in COPD	Grant
Obeidat, Ma'en	UBC Faculty of Medicine	\$10,000.00	Integrative genomics to identify novel therapeutics and biomarkers for COPD	Grant
Obeidat, Ma'en	Mitacs & Providence Airway Centre	\$30,000.00	The Genetics of Blood Biomarkers in COPD	Grant
Obeidat, Ma'en	Mitacs & Providence Airway Centre	\$15,000.00	Developing statistical methods to discover genetic variants underlying longitudinal decline in lung function	Grant
Quon, Bradley	Canada Foundation for Innovation	\$5,000.00	CFI Infrastructure Operating Fund	Grant
Quon, Bradley	Vertex Pharmaceuticals (Canada) Inc.	\$32,849.91	A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-C	Clinical Trial
Quon, Bradley	Cystic Fibrosis Canada	\$21,327.00	Randomized Controlled Trial of Prednisone in Cystic Fibrosis (CF) Pulmonary Exacerbations (PIPE Study)	Clinical Trial
Quon, Bradley	Proteostasis Therapeutics, Inc.	\$14,150.00	A Phase I, multi-center, randomized, placebo-controlled, study designed to assess the safety, tolerability, and pharmacokinetics of PTI-428 in subjects with cystic fibrosis	Clinical Trial
Quon, Bradley	Cystic Fibrosis Canada	\$91,919.00	PIPE-CF Biomarker Study	Grant
Quon, Bradley	ProMetic BioSciences, Inc.	\$1,525.00	A Phase 2, Double Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients with Abnormal Glucose Tolerance	Clinical Trial
Quon, Bradley	Novoteris LLC	\$83,410.45	Prospective, randomized, placebo controlled trial of the efficacy and safety of inhaled nitric oxide (NO) in cystic fibrosis (CF) patients	Clinical Trial
Quon, Bradley	Cystic Fibrosis Foundation (US)	\$59,790.00	Host RNA biosignatures to predict imminent CF pulmonary exacerbations	Grant
Quon, Bradley	Proteostasis Therapeutics, Inc.	\$3,815.90	A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and P	Clinical Trial

Quon, Bradley	British Columbia Lung Association	\$25,000.00	TH2 inflammation during cystic fibrosis pulmonary exacerbations	Grant
Quon, Bradley	Cystic Fibrosis Canada	\$4,000.00	Barriers and facilitators to research participation for individuals with CF	Grant
Quon, Bradley	Corbus Pharmaceuticals	\$9,025.00	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis	Clinical Trial
Quon, Bradley	Canadian Institutes of Health Research (CIHR)	\$21,875.00	Improving cystic fibrosis care in British Columbia epidemiological, clinical and economic trends - a model for other highly complex chronic conditions	Grant
Quon, Bradley	Michael Smith Foundation for Health Research	\$15,000.00	Improving cystic fibrosis care in British Columbia epidemiological, clinical and economic trends - a model for other highly complex chronic conditions	Grant
Quon, Bradley	Proteostasis Therapeutics, Inc.	\$6,885.00	A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis	Clinical Trial
Quon, Bradley	Vertex Pharmaceuticals Inc.	\$93,974.80	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	Clinical Trial
Quon, Bradley	Cystic Fibrosis Canada	\$75,000.00	Cystic Fibrosis Canada Accelerating Clinical Trials Network (CFCanAct)	Grant
Quon, Bradley	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Cystic fibrosis, asthma or ABPA? - Unravelling the chaos of pulmonary exacerbations	Grant
Quon, Bradley	Vertex Pharmaceuticals (Canada) Inc.	\$7,950.00	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation	Clinical Trial
Ryerson, Chris	InterMune Inc.	\$2,000.00	A Prospective Observational Study to Evaluate Adherence and Treatment Outcomes in Patients with Idiopathic Pulmonary Fibrosis (IPF) treated with Esbriet® (pirfenidone) in Canada	Clinical Trial
Ryerson, Chris	Boehringer Ingelheim (Canada) Ltd.	\$287,142.86	The Canadian Cohort for Pulmonary Fibrosis	Clinical Trial
Ryerson, Chris	Boehringer Ingelheim (Canada) Ltd.	\$236,250.00	High Oxygen Delivery to Preserve Exercise Capacity in PIF Patients Treated with Nintedanib: The HOPE-IPF Study	Clinical Trial

Ryerson, Chris	Boehringer Ingelheim (Canada) Ltd.	\$8,552.30	A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis	Clinical Trial
Ryerson, Chris	Hoffmann-La Roche Ltd. (Canada)	\$37,981.26	Multicenter, international, doubleblind, two-arm, randomized, placebo controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD	Clinical Trial
Ryerson, Chris	British Columbia Lung Association	\$25,000.00	Quantitative computed tomography in hypersensitivity puenmonitis	Grant
Ryerson, Chris	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Quantitative computed tomography in systemic sclerosis-associated interstitial lung disease	Grant
Sandford, Andrew	British Columbia Lung Association	\$50,000.00	Genetic variants of TSLP in asthma	Grant
Seow, Chun	Canadian Institutes of Health Research (CIHR)	\$132,345.00	Mechanisms underlying the bronchodilatory effect of deep inspiration in health and asthma: from airway smooth muscle to the whole lung	Grant
Seow, Chun	Natural Sciences and Engineering Research Council of Canada (NSERC)	\$48,000.00	Molecular mechanisms for length adaptation in smooth muscle cells	Grant
Seow, Chun	British Columbia Lung Association	\$25,000.00	Cytoskeletal stiffness of airway smooth muscle - A new target of asthma therapy	Grant
Sin, Don	AstraZeneca Canada Inc.	\$13,771.00	A randomised, double-blind, chronic dosing (56 week), placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with moderate to very severe Chroni	Clinical Trial
Sin, Don	AstraZeneca Canada Inc.	\$80,000.00	A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota	Clinical Trial
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$292,381.00	Using multi-omics to discover novel biomarkers and therapeutic targets fo chronic obstructive pulmonary disease	Grant
Sin, Don	Francis Family Foundation	\$63,022.50	integrative genomics to identify novel therapeutic targets and biomarkers for COPD	Grant

Sin, Don	CSA Medical Inc	\$35,133.76	A Prospective Safety and Feasibility Study of the RejuvenAir [®] , [®] System Metered Cryospray Therapy for Chronic Bronchitis Patients	Clinical Trial
Sin, Don	IKOMED Technologies Inc.	\$93,897.30	Frequency Treatment for Emphysema Rat Model	Contract
Sin, Don	St. Paul's Foundation	\$65,384.46	Providence Airway Centre (PAC)	Grant
Sin, Don	British Columbia Knowledge Development Fund (BCKDF)	\$2,206,311.00	TORCH (Towards omics and imaging to revolutionize COPD and asthma health) in Canada	Grant
Sin, Don	Canada Foundation for Innovation	\$12,545.73	TORCH (Towards omics and imaging to revolutionize COPD and asthma health) in Canada	Grant
Sin, Don	Canada Foundation for Innovation	\$2,206,311.00	TORCH (Towards omics and imaging to revolutionize COPD and asthma health) in Canada	Grant
Sin, Don	Canada Foundation for Innovation	\$7,745.09	TORCH (Towards omics and imaging to revolutionize COPD and asthma health) in Canada	Grant
Sin, Don	St. Paul's Hospital Foundation	\$280,345.00	TORCH (Towards omics and imaging to revolutionize COPD and asthma health) in Canada	Grant
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$100,000.00	The role of genes and sex in determining therapeutic responses in chronic obstructive pulmonary disease (COPD)	Grant
Sin, Don	Innovation, Science and Economic Development Canada	\$1,500.00	Role of smoking-induced surfactant protein-D in inflammatory bowel disease	Grant
Sin, Don	Province of British Columbia	\$1,500.00	Role of smoking-induced surfactant protein-D in inflammatory bowel disease	Grant
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Biological role of FAM13A in lipopolysacchande-induced inflammatory response	Grant
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Sputum microbiome is associated with 1-year mortality in COPD exacerbations	Grant
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$1,000.00	Murine sensitization with house-dust mite extract alters the immune response towards H1N1	Grant
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$1,000.00	The expression of Diacetyl/L-Xylulose Reductase (DCXR) in airway epithelium in chronic obstructive pulmonary disease (COPD)	Grant
Sin, Don	IKOMED Technologies Inc.	\$45,000.00	Radiofrequency treatment for emphysema in rat model	Grant

Sin, Don	Innovation, Science and Economic Development Canada	\$22,500.00	Radiofrequency treatment for emphysema in rat model	Grant
Sin, Don	Province of British Columbia	\$22,500.00	Radiofrequency treatment for emphysema in rat model	Grant
Sin, Don	Canadian Institutes of Health Research (CIHR)	\$10,000.00	Creation of a pan-Canadian airway network	Grant
Sin, Don	UBC VP Research & Innovation	\$170,000.00	Airway centre	Grant
Sin, Don	Mitacs & IKOMED Technologies	\$90,000.00	Radiofrequency treatment for emphysema in rat model	Grant
Sin, Don	Mitacs & Providence Airway Centre	\$45,000.00	In vitro validation of candidate therapeutic targets for chronic obstructive pulmonary disorder (COPD)	Grant
Sin, Don	Mitacs & Providence Airway Centre	\$26,666.67	Simulation of nanoparticle adsorption and transport in microfluidic lung-on-a-chip devices	Grant
Tebbutt, Scott	Natural Sciences and Engineering Research Council of Canada (NSERC)	\$34,000.00	When human and fungal worlds collide - a systems biology approach to understanding the dynamic interactions between human bronchial epithelial cells and conidiospores of <i>Aspergillus fumigatus</i>	Grant
Tebbutt, Scott	National Institutes of Health	\$84,088.19	Systems biology to identify biomarkers of neonatal vaccine immunogenicity: Project 1 - InnovativeOMIC integration to predict immunogenicity	Agreement
Tebbutt, Scott	National Institutes of Health	\$33,122.75	Systems biology to identify biomarkers of neonatal vaccine immunogenicity: DMC	Agreement
Tebbutt, Scott	Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence (NCE)	\$50,000.00	Biomarker development for monitoring responses in CIC clinical trials	Grant
Tebbutt, Scott	British Columbia Lung Association	\$25,000.00	Novel diagnosis of Western Red Cedar Asthma	Grant
Tebbutt, Scott	National Institutes of Health	\$16,642.94	Dengue Human Immunology Project Consortium (DHIPC)	Agreement
Tebbutt, Scott	Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence (NCE)	\$3,500.00	Diagnosis of western red cedar asthma using a blood-based biomarker test	Grant

Tebbutt, Scott	Allergy, Genes and Environment Network (AllerGen) - Networks of Centres of Excellence (NCE)	\$50,000.00	OMIC data integration and visualization for biomarkers and mechanistic insights of the late-phase asthmatic response: an interactive data tool to enhance AllerGen's clinical investigator collaborative	Grant
Tebbutt, Scott	UBC Faculty of Medicine	\$100,000.00	Career Development Initiative: Preparing the Next Generation of Heart and Lung Health Researchers for Careers Beyond Academia	Grant
Walley, Keith	Canadian Institutes of Health Research (CIHR)	\$545,653.00	Translational research to improve sepsis outcomes	Grant
Yang, Decheng	Heart and Stroke Foundation of Canada	\$76,432.00	Role of translation initiation factor DAP5 in viral myocarditis	Grant
Yang, Decheng	Natural Sciences and Engineering Research Council of Canada (NSERC)	\$34,000.00	Mechanisms of selective host gene translation regulation in picornavirus infection	Grant

APPENDIX B: PUBLICATIONS BY PIs AND ECIs IN 2018

1. Abdel-Razek O, Sadananda SN, Li X, Cermakova L, Frohlich J, **Brunham LR**. Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1. *J Clin Lipidol*. 2018 Jan - Feb;12(1):116-121. doi: 10.1016/j.jacl.2017.10.010. Epub 2017 Nov 10. PubMed PMID: 29150341.
2. Allahverdian S, Chaabane C, Boukais K, **Francis GA**, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. *Cardiovasc Res*. 2018 Mar 15;114(4):540-550. doi: 10.1093/cvr/cvy022. PubMed PMID: 29385543; PubMed Central PMCID: PMC5852505.
3. Alotaibi NM, Chen V, Hollander Z, Hague CJ, Murphy DT, **Leipsic JA, DeMarco ML, FitzGerald JM, McManus BM, Ng RT, Sin DD**. Phenotyping COPD exacerbations using imaging and blood-based biomarkers. *Int J Chron Obstruct Pulmon Dis*. 2018 Jan 8;13:217-229. doi: 10.2147/COPD.S152484. eCollection 2018. PubMed PMID: 29386890; PubMed Central PMCID: PMC5764289.
4. Andrade JG, MacGillivray J, Macle L, Yao RJR, Bennett M, Fordyce CB, Hawkins N, **Krahn A**, Jue J, Ramanathan K, Tsang T, Gin K, Deyell MW. Clinical effectiveness of a systematic "pill-in-the-pocket" approach for the management of paroxysmal atrial fibrillation. *Heart Rhythm*. 2018 Jan;15(1):9-16. doi: 10.1016/j.hrthm.2017.10.002. PubMed PMID: 29304952.
5. Annane D, Mira JP, Ware LB, Gordon AC, Hinds CJ, Christiani DC, Sevransky J, Barnes K, Buchman TG, Heagerty PJ, Balshaw R, Lesnikova N, de Nobrega K, Wellman HF, Neira M, Mancini ADJ, **Walley KR, Russell JA**. Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis. *Ann Intensive Care*. 2018 Jan 31;8(1):16. doi: 10.1186/s13613-018-0353-2. PubMed PMID: 29388048; PubMed Central PMCID: PMC5792380.
6. Annane D, Ouanes-Besbes L, de Backer D, DU B, Gordon AC, Hernández G, Olsen KM, Osborn TM, Peake S, **Russell JA**, Cavazzoni SZ. A global perspective on vasoactive agents in shock. *Intensive Care Med*. 2018 Jun;44(6):833-846. doi: 10.1007/s00134-018-5242-5. Epub 2018 Jun 4. Review. PubMed PMID: 29868972.
7. "Annane D, Pastores SM, Rochweg B, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Umberto Meduri G, Olsen KM, Rodgers S, **Russell JA**, Van den Berghe G. Correction to: Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Intensive Care Med*. 2018 Mar;44(3):401-402. doi: 10.1007/s00134-018-5071-6. PubMed PMID: 29476199."
8. Asai Y, Eslami A, van Ginkel CD, Akhabor L, Wan M, Ellis G, Ben-Shoshan M, Martino D, Ferreira MA, Allen K, Mazer B, de Groot H, de Jong NW, Gerth van Wijk RN, Dubois AEJ, Chin R, Cheuk S, Hoffman J, Jorgensen E, Witte JS, Melles RB, Hong X, Wang X, Hui J, Musk AWB, Hunter M, James AL, Koppelman GH, **Sandford AJ**, Clarke AE, **Daley D**. Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy. *J Allergy Clin Immunol*. 2018 Mar;141(3):991-1001. doi: 10.1016/j.jaci.2017.09.015. Epub 2017 Oct 10. PubMed PMID: 29030101.
9. Asai Y, Eslami A, van Ginkel CD, Akhabor L, Wan M, Yin D, Ellis G, Ben-Shoshan M, Marenholz I, Martino D, Ferreira MA, Allen K, Mazer B, de Groot H, de Jong NW, Gerth van Wijk R, Dubois AEJ, Grosche S, Ashley S, Rüschemdorf F, Kalb B, Beyer K, Nöthen MM, Lee YA, Chin R, Cheuk S, Hoffman J, Jorgensen E, Witte JS, Melles RB, Hong X, Wang X, Hui J, Musk AWB, Hunter M, James AL, Koppelman GH, **Sandford AJ**, Clarke AE, **Daley D**. A Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma. *J Allergy Clin Immunol*. 2018 Apr;141(4):1513-1516. doi: 10.1016/j.jaci.2017.10.047. Epub 2018 Jan 8. PubMed PMID: 29325868.
10. Barichello S, Roberts JD, Backx P, Boyle PM, **Laksman Z**. Personalizing therapy for atrial fibrillation: the role of stem cell and in silico disease models. *Cardiovasc Res*. 2018 Jun 1;114(7):931-943. doi: 10.1093/cvr/cvy090. PubMed PMID: 29648634.
11. Bartels W, Adamson S, Leung L, **Sin DD, van Eeden SF**. Emergency department management of acute exacerbations of chronic obstructive pulmonary disease: factors predicting readmission. *Int J Chron Obstruct Pulmon Dis*. 2018 May 23;13:1647-1654. doi: 10.2147/COPD.S163250. eCollection 2018. PubMed PMID: 29872284; PubMed Central PMCID: PMC5973381.

12. Baruteau AE, Kyndt F, Behr ER, Vink AS, Lachaud M, Joong A, Schott JJ, Horie M, Denjoy I, Crotti L, Shimizu W, Bos JM, Stephenson EA, Wong L, Abrams DJ, Davis AM, Winbo A, Dubin AM, Sanatani S, Liberman L, Kaski JP, Rudic B, Kwok SY, Rieubland C, Tfelt-Hansen J, Van Hare GF, Guyomarc'h-Delasalle B, Blom NA, Wijeyeratne YD, Gourraud JB, Le Marec H, Ozawa J, Fressart V, Lupoglazoff JM, Dagradi F, Spazzolini C, Aiba T, Tester DJ, Zahavich LA, Beauséjour-Ladouceur V, Jadhav M, Skinner JR, Franciosi S, **Krahn AD**, Abdelsayed M, Ruben PC, Yung TC, Ackerman MJ, Wilde AA, Schwartz PJ, Probst V. SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. *Eur Heart J*. 2018 Aug 14;39(31):2879-2887. doi: 10.1093/eurheartj/ehy412. PubMed PMID: 30059973.
13. Bennett MT, Leader N, Sapp J, Parkash R, Gardner M, Healey JS, Thibault B, Sterns L, Essebag V, Birnie D, Sivakumaran S, Nery P, Andrade JG, **Krahn AD**, Tang A. Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. *Circ Arrhythm Electrophysiol*. 2018 Apr;11(4):e005921. doi: 10.1161/CIRCEP.117.005921. PubMed PMID: 29618476.
14. Bhatraju PK, Zelnick LR, Herting J, Katz R, Mikacenic C, Kosamo S, Morrell ED, Robinson-Cohen C, Calfee CS, Christie JD, Liu KD, Matthay MA, Hahn WO, Dmyterko V, Slivinski NSJ, **Russell JA, Walley KR**, Christiani DC, Liles WC, Himmelfarb J, Wurfel MM. Identification of Acute Kidney Injury Sub-phenotypes with Differing Molecular Signatures and Response to Vasopressin Therapy. *Am J Respir Crit Care Med*. 2018 Oct 18. doi: 10.1164/rccm.201807-1346OC. [Epub ahead of print] PubMed PMID: 30334632.
15. Bom MJ, Levin E, Driessen RS, Danad I, Van Kuijk CC, van Rossum AC, Narula J, Min JK, **Leipsic JA**, Belo Pereira JP, Taylor CA, Nieuwdorp M, Rajmakers PG, Koenig W, Groen AK, Stroes ESG, Knaapen P. Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. *EBioMedicine*. 2019 Jan;39:109-117. doi: 10.1016/j.ebiom.2018.12.033. Epub 2018 Dec 23. PubMed PMID: 30587458; PubMed Central PMCID: PMC6355456.
16. Booth S, **Hackett TL**. Gene expression signature of the ageing lung: breathing new life into COPD. *Thorax*. 2018 Feb 15. pii: thoraxjnl-2017-211173. doi: 10.1136/thoraxjnl-2017-211173. [Epub ahead of print] PubMed PMID: 29449438.
17. Boueiz A, Chang Y, Cho MH, Washko GR, San José Estépar R, Bowler RP, Crapo JD, DeMeo DL, Dy JG, Silverman EK, Castaldi PJ; **COPD Gene Investigators**. Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. *Chest*. 2018 Jan;153(1):65-76. doi: 10.1016/j.chest.2017.09.022. Epub 2017 Sep 21. PubMed PMID: 28943279; PubMed Central PMCID: PMC6026264. **HO Coxson is a COPD Gene Investigator**.
18. Bowden KL, Dubland JA, Chan T, Xu YH, Grabowski GA, Du H, **Francis GA**. LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo. *Arterioscler Thromb Vasc Biol*. 2018 May;38(5):1191-1201. doi: 10.1161/ATVBAHA.117.310507. Epub 2018 Mar 29. PubMed PMID: 29599133; PubMed Central PMCID: PMC5920716.
19. Brook JR, Setton EM, Seed E, Shoostari M, Doiron D; **CANUE – The Canadian Urban Environmental Health Research Consortium**. The Canadian Urban Environmental Health Research Consortium - a protocol for building a national environmental exposure data platform for integrated analyses of urban form and health. *BMC Public Health*. 2018 Jan 8;18(1):114. doi: 10.1186/s12889-017-5001-5. PubMed PMID: 29310629; PubMed Central PMCID: PMC5759244. **C Carlsten is a CANUE Investigator**.
20. **Brunham LR**, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. *Cardiovasc Res*. 2018 Jul 1;114(8):1073-1081. doi: 10.1093/cvr/cvy119. PubMed PMID: 29878063; PubMed Central PMCID: PMC6014181.
21. **Brunham LR**, Lynch K, English A, Sutherland R, Weng J, Cho R, Wong GC, Anis AH, **Francis GA**, Khan NA, **McManus B**, Wood D, **Walley KR, Leipsic J**, Humphries KH, Hoens A, **Krahn AD**, John Mancini GB, Pimstone S. The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. *Clin Cardiol*. 2018 Jul;41(7):888-895. doi: 10.1002/clc.22959. Epub 2018 Jun 11. PubMed PMID: 29635745.
22. **Brunham LR**, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta M, Couture P, Pearson GJ, Bergeron J, **Francis GA**, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J, Goguen J, Gaudet D, Paré G, Romney J, Ransom T, Bernard S, Katz P, Joy TR, Bewick D, Brophy J. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. *Can J Cardiol*. 2018 Dec;34(12):1553-1563. doi: 10.1016/j.cjca.2018.09.005. PubMed PMID: 30527143.
23. **Brunham LR**, Ruel I, Khoury E, Hegele RA, Couture P, Bergeron J, Baass A, Dufour R, **Francis GA**, Cermakova L, Mancini GBJ, Brophy JM, Brisson D, Gaudet D, Genest J. Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. *Atherosclerosis*. 2018 Oct;277:419-424. doi: 10.1016/j.atherosclerosis.2018.05.040. PubMed PMID: 30270080.

24. Burlinson CEG, Sirounis D, **Walley KR**, Chau A. Sepsis in pregnancy and the puerperium. *Int J Obstet Anesth*. 2018 Nov;36:96-107. doi: 10.1016/j.ijoa.2018.04.010. Epub 2018 Jun 18. Review. PubMed PMID: 29921485.
25. Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; **BORA study investigators**. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. *Lancet Respir Med*. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Erratum in: *Lancet Respir Med*. 2019 Jan;7(1):e1. PubMed PMID: 30416083. **D Dorscheid is a BORA Study Investigator**.
26. Cait A, Hughes MR, Antignano F, Cait J, Dimitriu PA, Maas KR, Reynolds LA, Hacker L, Mohr J, Finlay BB, Zaph C, **McNagny KM**, Mohn WW. Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids. *Mucosal Immunol*. 2018 May;11(3):785-795. doi: 10.1038/mi.2017.75. Epub 2017 Oct 25. PubMed PMID: 29067994.
27. **Camp PG**, Cheung W. Are We Delivering Optimal Pulmonary Rehabilitation? The Importance of Quality Indicators in Evaluating Clinical Practice. *Phys Ther*. 2018 Jul 1;98(7):541-548. doi: 10.1093/ptj/pzy046. PubMed PMID: 29635637.
28. **Carlsten C**. Artemisia species pollen (mugwort) as a major vector for ambient LPS: Brothers in harm? *J Allergy Clin Immunol*. 2019 Jan;143(1):94-95. doi: 10.1016/j.jaci.2018.08.034. Epub 2018 Sep 11. PubMed PMID: 30213626.
29. **Carlsten C**. Synergistic Environmental Exposures and the Airways Capturing Complexity in Humans: An Underappreciated World of Complex Exposures. *Chest*. 2018 Oct;154(4):918-924. doi: 10.1016/j.chest.2018.06.004. Epub 2018 Jun 15. Review. PubMed PMID: 29909283.
30. Chan SL, Ng HY, Sung C, Chan A, Winther MD, **Brunham LR**, Wee HL. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. *Pharmacogenomics J*. 2018 Sep 24. doi: 10.1038/s41397-018-0053-1. [Epub ahead of print] PubMed PMID: 30250149.
31. Chan SL, Ng LS, Goh X, Siow CH, Goh HL, Goh BC, Cheo T, Loh KS, **Brunham LR**. Time course and clinical characterization of cisplatin-induced ototoxicity after treatment for nasopharyngeal carcinoma in a South East Asian population. *Head Neck*. 2018 Jul;40(7):1425-1433. doi: 10.1002/hed.25112. Epub 2018 Feb 16. PubMed PMID: 29451951.
32. Charlton JM, Hatfield GL, **Guenette JA**, Hunt MA. Ankle Joint and Rearfoot Biomechanics During Toe-In and Toe-Out Walking in People With Medial Compartment Knee Osteoarthritis. *PM R*. 2018 Sep 7. pii: S1934-1482(18)30863-3. doi: 10.1016/j.pmrj.2018.08.388. [Epub ahead of print] PubMed PMID: 30195708.
33. Charlton JM, Hatfield GL, **Guenette JA**, Hunt MA. Toe-in and toe-out walking require different lower limb neuromuscular patterns in people with knee osteoarthritis. *J Biomech*. 2018 Jul 25;76:112-118. doi: 10.1016/j.jbiomech.2018.05.041. Epub 2018 Jun 18. PubMed PMID: 29914739.
34. Charlton JM, Krowchuk NM, Hatfield GL, **Guenette JA**, Hunt MA. Contralateral limb foot rotation during unilateral toe-in or toe-out walking in people with knee osteoarthritis. *Gait Posture*. 2018 May;62:132-134. doi: 10.1016/j.gaitpost.2018.03.013. Epub 2018 Mar 6. PubMed PMID: 29547793.
35. Chen W, FitzGerald JM, Lynd LD, **Sin DD**, Sadatsafavi M. Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression. *J Allergy Clin Immunol Pract*. 2018 Nov - Dec;6(6):2024-2032.e5. doi: 10.1016/j.jaip.2018.04.027. Epub 2018 May 7. PubMed PMID: 29746917.
36. Chen W, **Sin DD**, FitzGerald JM, Sadatsafavi M; Canadian Respiratory Research Network. The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis. *J Gen Intern Med*. 2018 Sep;33(9):1528-1535. doi: 10.1007/s11606-018-4406-x. Epub 2018 Apr 2. PubMed PMID: 29611088; PubMed Central PMCID: PMC6109016.
37. Chen YW, **Camp PG**, **Coxson HO**, Road JD, **Guenette JA**, Hunt MA, Reid WD. A Comparison of Pain, Fatigue, Dyspnea and their Impact on Quality of Life in Pulmonary Rehabilitation Participants with Chronic Obstructive Pulmonary Disease. *COPD*. 2018 Feb;15(1):65-72. doi: 10.1080/15412555.2017.1401990. Epub 2017 Dec 11. PubMed PMID: 29227712.
38. Chen YW, **Coxson HO**, Coupal TM, Lam S, Munk PL, **Leipsic J**, Reid WD. The contribution of thoracic vertebral deformity and arthropathy to trunk pain in patients with chronic obstructive pulmonary disease (COPD). *Respir Med*. 2018 Apr;137:115-122. doi: 10.1016/j.rmed.2018.03.007. Epub 2018 Mar 3. PubMed PMID: 29605193.
39. Chen YW, HajGhanbari B, Road JD, **Coxson HO**, **Camp PG**, Reid WD. Reliability and validity of the Brief Pain Inventory in individuals with chronic obstructive pulmonary disease. *Eur J Pain*. 2018 Nov;22(10):1718-1726. doi: 10.1002/ejp.1258. Epub 2018 Jun 22. PubMed PMID: 29883526.

40. Cheung CC, **Krahn AD**, Andrade JG. The Emerging Role of Wearable Technologies in Detection of Arrhythmia. *Can J Cardiol*. 2018 Aug;34(8):1083-1087. doi: 10.1016/j.cjca.2018.05.003. Epub 2018 May 9. PubMed PMID: 30049358.
41. Cheung CC, **Krahn AD**. The importance of a comprehensive evaluation of survivors of cardiac arrest. *Eur Heart J*. 2018 Jun 1;39(21):1988-1991. doi: 10.1093/eurheartj/ehy160. PubMed PMID: 29584853.
42. Cho YJ, **Sin DD**. Inhaled Corticosteroids and Fractures in COPD: Can We Finally Put This to Bed? *Chest*. 2018 Feb;153(2):293-294. doi: 10.1016/j.chest.2017.08.027. PubMed PMID: 29406210.
43. Choby G, **Thamboo A**, Won TB, Kim J, Shih LC, Hwang PH. Computed tomography analysis of frontal cell prevalence according to the International Frontal Sinus Anatomy Classification. *Int Forum Allergy Rhinol*. 2018 Jul;8(7):825-830. doi: 10.1002/alr.22105. Epub 2018 Feb 19. PubMed PMID: 29457874.
44. Chotirmall SH, Dahlén SE, **Carlsten C**, Wong WSF, Chung KF, Gosens R, Knight DA; Singapore International Respiratory Consortium. International research collaboration: The way forward. *Respirology*. 2018 Jul;23(7):654-655. doi: 10.1111/resp.13327. Epub 2018 May 17. PubMed PMID: 29770983.
45. Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A Jr, Cheng X, Chifamba J, Dagenais G, Dans A, Egbujie BA, Gupta R, Iqbal R, Ismail N, Keskinler MV, Khatib R, Kruger L, Kumar R, Lanas F, **Lear S**, Lopez-Jaramillo P, McKee M, Mohammadifard N, Mohan V, Mony P, Orlandini A, Rosengren A, Vijayakumar K, Wei L, Yeates K, Yusoff K, Yusuf R, Yusufali A, Zatonska K, Zhou Y, Islam S, Corsi D, Rangarajan S, Teo K, Gerstein HC, Yusuf S; PURE investigators. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. *Lancet Diabetes Endocrinol*. 2018 Oct;6(10):798-808. doi: 10.1016/S2213-8587(18)30233-X. Epub 2018 Aug 28. PubMed PMID: 30170949.
46. Christidi E, Huang HM, **Brunham LR**. CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening. *Drug Discov Today Technol*. 2018 Aug;28:13-21. doi: 10.1016/j.ddtec.2018.06.002. Epub 2018 Jun 25. Review. PubMed PMID: 30205876.
47. Clemenceau A, Boucherat O, Landry-Truchon K, Lamontagne M, Biardel S, Joubert P, Gobeil S, Secco B, Laplante M, Morissette M, **Obeidat M**, Timens W, Jeannotte L, Bossé Y. Lung cancer susceptibility genetic variants modulate HOXB2 expression in the lung. *Int J Dev Biol*. 2018;62(11-12):857-864. doi: 10.1387/ijdb.180210yb. PubMed PMID: 30604855."
48. Clifford RL, Fishbane N, Patel J, Maclsaac JL, McEwen LM, Fisher AJ, Brandsma CA, Nair P, Kobor MS, **Hackett TL**, Knox AJ. Altered DNA methylation is associated with aberrant gene expression in parenchymal but not airway fibroblasts isolated from individuals with COPD. *Clin Epigenetics*. 2018 Mar 5;10:32. doi: 10.1186/s13148-018-0464-5. eCollection 2018. PubMed PMID: 29527240; PubMed Central PMCID: PMC5838860.
49. Coats V, Després JP, Alméras N, Martin M, **Sin DD**, Rabasa-Lhoret R, Larose É, **Tan WC**, Bourbeau J, Maltais F; CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network. Ectopic adiposity and cardiometabolic health in COPD. *Int J Chron Obstruct Pulmon Dis*. 2018 Oct 15;13:3331-3340. doi: 10.2147/COPD.S168963. eCollection 2018. PubMed PMID: 30410322; PubMed Central PMCID: PMC6197246.
50. Cole CA, **Carlsten C**, Koehle M, Brauer M. Particulate matter exposure and health impacts of urban cyclists: a randomized crossover study. *Environ Health*. 2018 Nov 14;17(1):78. doi: 10.1186/s12940-018-0424-8. PubMed PMID: 30428890; PubMed Central PMCID: PMC6237024.
51. Corona AK, Mohamud Y, Jackson WT, **Luo H**. Oh, SNAP! How enteroviruses redirect autophagic traffic away from degradation. *Autophagy*. 2018;14(8):1469-1471. doi: 10.1080/15548627.2018.1480849. Epub 2018 Jul 21. PubMed PMID: 30032704; PubMed Central PMCID: PMC6103677.
52. Curran J, Cliff R, Sinnen N, Koehle M, **Carlsten C**. Acute diesel exhaust exposure and postural stability: a controlled crossover experiment. *J Occup Med Toxicol*. 2018 Jan 8;13:2. doi: 10.1186/s12995-017-0182-5. eCollection 2018. PubMed PMID: 29339966; PubMed Central PMCID: PMC5759364.
53. Cusack L, Sbihi H, Larkin A, Chow A, Brook JR, Moraes T, Mandhane PJ, Becker AB, Azad MB, Subbarao P, Kozyrskyj A, Takaro TK, Sears MR, Turvey SE, Hystad P; **CHILD Study Investigators**. Residential green space and pathways to term birth weight in the Canadian Healthy Infant Longitudinal Development (CHILD) Study. *Int J Health Geogr*. 2018 Dec 4;17(1):43. doi: 10.1186/s12942-018-0160-x. PubMed PMID: 30514315; PubMed Central PMCID: PMC6280529. **D Daley, P Paré, A Sandford, and S Tebbutt are CHILD Study Investigators.**

54. Darras P, Mattman A, **Francis GA**. Nonfasting lipid testing: the new standard for cardiovascular risk assessment. *CMAJ*. 2018 Nov 12;190(45):E1317-E1318. doi: 10.1503/cmaj.180804. PubMed PMID: 30420386; PubMed Central PMCID: PMC6232011.
55. Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, Iqbal R, Gupta R, **Lear S**, Wentzel-Viljoen E, Avezum A, Lopez-Jaramillo P, Mony P, Varma RP, Kumar R, Chifamba J, Alhabib KF, Mohammadifard N, Oguz A, Lanas F, Rozanska D, Bostrom KB, Yusoff K, Tsoikile LP, Dans A, Yusufali A, Orlandini A, Poirier P, Khatib R, Hu B, Wei L, Yin L, Deeraili A, Yeates K, Yusuf R, Ismail N, Mozaffarian D, Teo K, Anand SS, Yusuf S; Prospective Urban Rural Epidemiology (PURE) study investigators. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. *Lancet*. 2018 Nov 24;392(10161):2288-2297. doi: 10.1016/S0140-6736(18)31812-9. Epub 2018 Sep 11. PubMed PMID: 30217460.
56. Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, Barr RG, Beaty TH, Becker AB, Beilby J, Bisgaard H, Bjornsdottir US, Bleecker E, Bønnelykke K, Boomsma DI, Bouzigon E, Brightling CE, Brossard M, Brusselle GG, Burchard E, Burkart KM, Bush A, Chan-Yeung M, Chung KF, Couto Alves A, Curtin JA, Custovic A, **Daley D**, de Jongste JC, Del-Rio-Navarro BE, Donohue KM, Duijts L, Eng C, Eriksson JG, Farrall M, Fedorova Y, Feenstra B, Ferreira MA; Australian Asthma Genetics Consortium (AAGC) collaborators, Freidin MB, Gajdos Z, Gauderman J, Gehring U, Geller F, Genuneit J, Gharib SA, Gilliland F, Granel R, Graves PE, Gudbjartsson DF, Haahtela T, Heckbert SR, Heederik D, Heinrich J, Heliövaara M, Henderson J, Himes BE, Hirose H, Hirschhorn JN, Hofman A, Holt P, Hottenga J, Hudson TJ, Hui J, Imboden M, Ivanov V, Jaddoe VVW, James A, Janson C, Jarvelin MR, Jarvis D, Jones G, Jonsdottir I, Jousilahti P, Kabesch M, Kähönen M, Kantor DB, Karunas AS, Khusnutdinova E, Koppelman GH, Kozyrskiy AL, Kreiner E, Kubo M, Kumar R, Kumar A, Kuokkanen M, Lahousse L, Laitinen T, Laprise C, Lathrop M, Lau S, Lee YA, Lehtimäki T, Letort S, Levin AM, Li G, Liang L, Loehr LR, London SJ, Loth DW, Manichaikul A, Marenholz I, Martinez FJ, Matheson MC, Mathias RA, Matsumoto K, Mbarek H, McArdle WL, Melbye M, Melén E, Meyers D, Michel S, Mohamdi H, Musk AW, Myers RA, Nieuwenhuis MAE, Noguchi E, O'Connor GT, Ogorodova LM, Palmer CD, Palotie A, Park JE, Pennell CE, Pershagen G, Polonikov A, Postma DS, Probst-Hensch N, Puzyrev VP, Raby BA, Raitakari OT, Ramasamy A, Rich SS, Robertson CF, Romieu I, Salam MT, Salomaa V, Schlünssen V, Scott R, Selivanova PA, Sigsgaard T, Simpson A, Siroux V, Smith LJ, Solodilova M, Standl M, Stefansson K, Strachan DP, Stricker BH, Takahashi A, Thompson PJ, Thorleifsson G, Thorsteinsdottir U, Tiesler CMT, Torgerson DG, Tsunoda T, Uitterlinden AG, van der Valk RJP, Vaysse A, Vedantam S, von Berg A, von Mutius E, Vonk JM, Waage J, Wareham NJ, Weiss ST, White WB, Wickman M, Widén E, Willemsen G, Williams LK, Wouters IM, Yang JJ, Zhao JH, Moffatt MF, Ober C, Nicolae DL. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat Genet*. 2018 Jan;50(1):42-53. doi: 10.1038/s41588-017-0014-7. Epub 2017 Dec 22. PubMed PMID: 29273806; PubMed Central PMCID: PMC5901974.
57. Desai S, Wong H, Sykes J, Stephenson AL, Singer J, **Quon BS**. Clinical Characteristics and Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis. Analysis of the Canadian CF Registry. *Ann Am Thorac Soc*. 2018 Oct;15(10):1177-1185. doi: 10.1513/AnnalsATS.201801-037OC. PubMed PMID: 29944384.
58. Dharma C, Lefebvre DL, Tran MM, Lou WYW, Subbarao P, Becker AB, Mandhane PJ, Turvey SE, Sears MR; **CHILD Study investigators**. Patterns of allergic sensitization and atopic dermatitis from 1 to 3 years: Effects on allergic diseases. *Clin Exp Allergy*. 2018 Jan;48(1):48-59. doi: 10.1111/cea.13063. Epub 2017 Dec 15. PubMed PMID: 29143385. **D Daley, P Paré, A Sandford, and S Tebbutt are CHILD Study Investigators.**
59. Dharma C, Lefebvre DL, Tran MM, Lu Z, Lou WYW, Subbarao P, Becker AB, Mandhane PJ, Turvey SE, Moraes TJ, Azad MB, Sears MR; **CHILD Study Investigators**. Diagnosing atopic dermatitis in infancy: Questionnaire reports vs criteria-based assessment. *Paediatr Perinat Epidemiol*. 2018 Nov;32(6):556-567. doi: 10.1111/ppe.12525. Epub 2018 Nov 21. PubMed PMID: 30461044. **D Daley, P Paré, A Sandford, and S Tebbutt are CHILD Study Investigators.**
60. Diab N, Gershon AS, **Sin DD, Tan WC**, Bourbeau J, Boulet LP, Aaron SD. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2018 Nov 1;198(9):1130-1139. doi: 10.1164/rccm.201804-0621CI. PubMed PMID: 29979608.
61. Diaz AA, Strand M, **Coxson HO**, Ross JC, San Jose Estepar R, Lynch D, van Rikxoort EM, Rosas IO, Hunninghake GM, Putman RK, Hatabu H, Yen A, Kinney GL, Hokanson JE, Silverman EK, Crapo J, Washko GR. Disease Severity Dependence of the Longitudinal Association Between CT Lung Density and Lung Function in Smokers. *Chest*. 2018 Mar;153(3):638-645. doi: 10.1016/j.chest.2017.10.012. Epub 2017 Oct 21. PubMed PMID: 29066389; PubMed Central PMCID: PMC5989632.

62. Driessen RS, Raijmakers PG, Danad I, Stuijzand WJ, Schumacher SP, **Leipsic JA**, Min JK, Knuuti J, Lammertsma AA, van Rossum AC, van Royen N, Underwood SR, Knaapen P. Automated SPECT analysis compared with expert visual scoring for the detection of FFR-defined coronary artery disease. *Eur J Nucl Med Mol Imaging*. 2018 Jul;45(7):1091-1100. doi: 10.1007/s00259-018-3951-1. Epub 2018 Feb 22. PubMed PMID: 29470616; PubMed Central PMCID: PMC5954003.
63. Driessen RS, Stuijzand WJ, Raijmakers PG, Danad I, Min JK, **Leipsic JA**, Ahmadi A, Narula J, van de Ven PM, Huisman MC, Lammertsma AA, van Rossum AC, van Royen N, Knaapen P. Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve. *J Am Coll Cardiol*. 2018 Feb 6;71(5):499-509. doi: 10.1016/j.jacc.2017.11.054. PubMed PMID: 29406855.
64. Du Plessis JP, Fernandes S, Jamal R, **Camp P**, Johannson K, Schaeffer M, Wilcox PG, **Guenette JA, Ryerson CJ**. Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. *Respirology*. 2018 Apr;23(4):392-398. doi: 10.1111/resp.13226. Epub 2017 Nov 28. PubMed PMID: 29193512.
65. Dutta A, Vasilescu D, **Hogg JC**, Phillion AB, Brinkerhoff JR. Simulation of Airflow in an Idealized Emphysematous Human Acinus. *J Biomech Eng*. 2018 Mar 21. doi: 10.1115/1.4039680. [Epub ahead of print] PubMed PMID: 29570757.
66. Everaerts S, Lammertyn EJ, Martens DS, De Sadeleer LJ, Maes K, van Batenburg AA, Goldschmeding R, van Moorsel CHM, Dupont LJ, Wuyts WA, Vos R, Gayan-Ramirez G, Kaminski N, **Hogg JC**, Janssens W, Verleden GM, Nawrot TS, Verleden SE, McDonough JE, Vanaudenaerde BM. The aging lung: tissue telomere shortening in health and disease. *Respir Res*. 2018 May 11;19(1):95. doi: 10.1186/s12931-018-0794-z. PubMed PMID: 29751799; PubMed Central PMCID: PMC5948770.
67. Expert Panel on Cardiac Imaging:, Shah AB, Kirsch J, Bolen MA, Batlle JC, Brown RKJ, Eberhardt RT, Hurwitz LM, Inacio JR, Jin JO, Krishnamurthy R, **Leipsic JA**, Rajiah P, Singh SP, White RD, Zimmerman SL, Abbara S. ACR Appropriateness Criteria(®) Chronic Chest Pain-Noncardiac Etiology Unlikely-Low to Intermediate Probability of Coronary Artery Disease. *J Am Coll Radiol*. 2018 Nov;15(11S):S283-S290. doi: 10.1016/j.jacr.2018.09.021. PubMed PMID: 30392597.
68. Expert Panel on Cardiac Imaging:, White RD, Kirsch J, Bolen MA, Batlle JC, Brown RKJ, Eberhardt RT, Hurwitz LM, Inacio JR, Jin JO, Krishnamurthy R, **Leipsic JA**, Rajiah P, Shah AB, Singh SP, Villines TC, Zimmerman SL, Abbara S. ACR Appropriateness Criteria(®) Suspected New-Onset and Known Nonacute Heart Failure. *J Am Coll Radiol*. 2018 Nov;15(11S):S418-S431. doi: 10.1016/j.jacr.2018.09.031. PubMed PMID: 30392610.
69. Eyawo O, Hull MW, Salters K, Samji H, Cescon A, Sereda P, Lima VD, Nosyk B, Whitehurst DGT, **Lear SA**, Montaner JSG, Hogg RS; Comparative Outcomes And Service Utilization Trends (COAST) Study. Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. *BMJ Open*. 2018 Jan 13;8(1):e019115. doi: 10.1136/bmjopen-2017-019115. PubMed PMID: 29331972; PubMed Central PMCID: PMC5781099.
70. Farias-Godoy A, Chan S, Claydon VE, Ignaszewski A, Mendell J, Park JE, Singer J, **Lear SA**. The Impact of Reduced Cardiac Rehabilitation on Maximal Treadmill Exercise Time: A RANDOMIZED CONTROLLED TRIAL. *J Cardiopulm Rehabil Prev*. 2018 Jan;38(1):24-30. doi: 10.1097/HCR.000000000000269. PubMed PMID: 28885279.
71. Fisher J, Linder A, Bentzer P, **Boyd J**, Kong HJ, Lee T, **Walley KR, Russell JA**. Is Heparin-Binding Protein Inhibition a Mechanism of Albumin's Efficacy in Human Septic Shock? *Crit Care Med*. 2018 May;46(5):e364-e374. doi: 10.1097/CCM.0000000000002996. PubMed PMID: 29406419.
72. Fowokan AO, Black JL, Holmes E, Seto D, **Lear SA**. Examining risk factors for cardiovascular disease among food bank members in Vancouver. *Prev Med Rep*. 2018 Apr 23;10:359-362. doi: 10.1016/j.pmedr.2018.04.015. eCollection 2018 Jun. PubMed PMID: 29868392; PubMed Central PMCID: PMC5984241.
73. Fowokan AO, Sakakibara BM, Onsel N, Punthakee Z, Waddell C, Rosin M, **Lear SA**. Correlates of elevated blood pressure in healthy children: a systematic review. *Clin Obes*. 2018 Oct;8(5):366-381. doi: 10.1111/cob.12271. Epub 2018 Jul 31. PubMed PMID: 30066442.
74. Genga KR, Lo C, Cirstea MS, Leitao Filho FS, **Walley KR, Russell JA**, Linder A, **Francis GA, Boyd JH**. Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors. *EBioMedicine*. 2018 Dec;38:257-264. doi: 10.1016/j.ebiom.2018.11.032. Epub 2018 Nov 23. PubMed PMID: 30473376; PubMed Central PMCID: PMC6306489.
75. Genga KR, Shimada T, **Boyd JH, Walley KR, Russell JA**. The Understanding and Management of Organism Toxicity in Septic Shock. *J Innate Immun*. 2018;10(5-6):502-514. doi: 10.1159/000487818. Epub 2018 May 15. Review. PubMed PMID: 29763894.

76. Genga KR, Trinder M, Kong HJ, Li X, Leung AKK, Shimada T, **Walley KR, Russell JA, Francis GA, Brunham LR, Boyd JH**. CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. *Sci Rep*. 2018 Nov 13;8(1):16764. doi: 10.1038/s41598-018-35261-2. PubMed PMID: 30425299; PubMed Central PMCID: PMC6233165.
77. Giles LV, **Carlsten C**, Koehle MS. The pulmonary and autonomic effects of high-intensity and low-intensity exercise in diesel exhaust. *Environ Health*. 2018 Dec 13;17(1):87. doi: 10.1186/s12940-018-0434-6. PubMed PMID: 30541575; PubMed Central PMCID: PMC6292001.
78. Giles LV, **Tebbutt SJ, Carlsten C**, Koehle MS. The effect of low and high-intensity cycling in diesel exhaust on flow-mediated dilation, circulating NOx, endothelin-1 and blood pressure. *PLoS One*. 2018 Feb 21;13(2):e0192419. doi: 10.1371/journal.pone.0192419. eCollection 2018. PubMed PMID: 29466393; PubMed Central PMCID: PMC5821322.
79. Gordon AC, **Russell JA**. Innovation and safety in critical care: should we collaborate with the industry? *Pro. Intensive Care Med*. 2018 Dec;44(12):2276-2278. doi: 10.1007/s00134-018-5306-6. Epub 2018 Nov 8. PubMed PMID: 30406806.
80. Goss CH, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, Fink A, Elbert A, **Quon BS**, Stephenson AL. Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. *Am J Respir Crit Care Med*. 2018 Mar 15;197(6):768-775. doi: 10.1164/rccm.201707-1541OC. PubMed PMID: 29099606; PubMed Central PMCID: PMC5855073.
81. Grover R, Ohana M, Arepalli CD, Sellers SL, Mooney J, Kueh SH, Kim U, Blanke P, **Leipsic JA**. Role of MDCT Imaging in Planning Mitral Valve Intervention. *Curr Cardiol Rep*. 2018 Mar 6;20(3):16. doi: 10.1007/s11886-018-0960-4. Review. PubMed PMID: 29511849.
82. Grunau GL, **Leipsic JA**, Sellers SL, **Seidman MA**. Cardiac Fibroma in an Adult AIRP Best Cases in Radiologic-Pathologic Correlation. *Radiographics*. 2018 Jul-Aug;38(4):1022-2026. doi: 10.1148/rq.2018170205. PubMed PMID: 29995616.
83. **Guenette JA**, Ramsook AH, Dhillon SS, Puyat JH, Riahi M, Opotowsky AR, Grewal J. Ventilatory and sensory responses to incremental exercise in adults with a Fontan circulation. *Am J Physiol Heart Circ Physiol*. 2019 Feb 1;316(2):H335-H344. doi: 10.1152/ajpheart.00322.2018. Epub 2018 Nov 2. PubMed PMID: 30388023.
84. Guerra B, Haile SR, Lamprecht B, Ramírez AS, Martínez-Cambor P, Kaiser B, Alfageme I, Almagro P, Casanova C, Esteban-González C, Soler-Cataluña JJ, de-Torres JP, Miravittles M, Celli BR, Marin JM, Ter Riet G, Sobradillo P, Lange P, Garcia-Aymerich J, Antó JM, Turner AM, Han MK, Langhammer A, Leivseth L, Bakke P, Johannessen A, Oga T, Cosio B, Ancochea-Bermúdez J, Echazarreta A, Roche N, Burgel PR, **Sin DD**, Soriano JB, Puhan MA; 3CIA collaboration. Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. *BMC Med*. 2018 Mar 2;16(1):33. doi: 10.1186/s12916-018-1013-y. PubMed PMID: 29495970; PubMed Central PMCID: PMC5833113.
85. Guler SA, Ellison K, Algamdi M, Collard HR, **Ryerson CJ**. Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. *Ann Am Thorac Soc*. 2018 Jul;15(7):854-863. doi: 10.1513/AnnalsATS.201801-067OC. PubMed PMID: 29779392.
86. Guler SA, **Ryerson CJ**. Unclassifiable interstitial lung disease: from phenotyping to possible treatments. *Curr Opin Pulm Med*. 2018 Sep;24(5):461-468. doi: 10.1097/MCP.0000000000000509. PubMed PMID: 30004990.
87. Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, Li KH, Dunne J, Wilcox PG, **Ryerson CJ**. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. *Ann Am Thorac Soc*. 2018 Dec;15(12):1427-1433. doi: 10.1513/AnnalsATS.201806-362OC. PubMed PMID: 30188737.
88. Haage A, Goodwin K, Whitewood A, Camp D, Bogutz A, Turner CT, **Granville DJ**, Lefebvre L, Plotnikov S, Goult BT, Tanentzapf G. Talin Autoinhibition Regulates Cell-ECM Adhesion Dynamics and Wound Healing In Vivo. *Cell Rep*. 2018 Nov 27;25(9):2401-2416.e5. doi: 10.1016/j.celrep.2018.10.098. PubMed PMID: 30485809.
89. Halaschek-Wiener J, Tindale LC, Collins JA, Leach S, **McManus B**, Madden K, Meneilly G, Le ND, Connors JM, Brooks-Wilson AR. The Super-Seniors Study: Phenotypic characterization of a healthy 85+ population. *PLoS One*. 2018 May 24;13(5):e0197578. doi: 10.1371/journal.pone.0197578. eCollection 2018. PubMed PMID: 29795606; PubMed Central PMCID: PMC5967696.
90. Halperin L, Mellor G, Talajic M, **Krahn A**, Tadros R, **Laksman Z**. Quinidine effective for the management of ventricular and atrial arrhythmias associated with Brugada syndrome. *HeartRhythm Case Rep*. 2018 Apr 30;4(7):270-272. doi: 10.1016/j.hrcr.2018.01.008. eCollection 2018 Jul. PubMed PMID: 30023269; PubMed Central PMCID: PMC6050440.

91. Hayden LP, Cho MH, Raby BA, Beaty TH, Silverman EK, Hersh CP; **COPDGene Investigators**. Childhood asthma is associated with COPD and known asthma variants in COPDGene: a genome-wide association study. *Respir Res*. 2018 Oct 29;19(1):209. doi: 10.1186/s12931-018-0890-0. PubMed PMID: 30373671; PubMed Central PMCID: PMC6206739. **HO Coxson is a COPDGene Investigator**.
92. Hayden LP, Hardin ME, Qiu W, Lynch DA, Strand MJ, van Beek EJ, Crapo JD, Silverman EK, Hersh CP; **COPDGene Investigators**. Asthma Is a Risk Factor for Respiratory Exacerbations Without Increased Rate of Lung Function Decline: Five-Year Follow-up in Adult Smokers From the COPDGene Study. *Chest*. 2018 Feb;153(2):368-377. doi: 10.1016/j.chest.2017.11.038. Epub 2017 Dec 15. PubMed PMID: 29248621; PubMed Central PMCID: PMC5815872. **HO Coxson is a COPDGene Investigator**.
93. **Hogg JC, Hackett TL**. Structure and Function Relationships in Diseases of the Small Airways. *Ann Am Thorac Soc*. 2018 Feb;15(Supplement_1):S18-S25. doi: 10.1513/AnnalsATS.201710-809KV. PubMed PMID: 29461883.
94. Holmes E, Black JL, Heckelman A, **Lear SA**, Seto D, Fowokan A, Wittman H. "Nothing is going to change three months from now": A mixed methods characterization of food bank use in Greater Vancouver. *Soc Sci Med*. 2018 Mar;200:129-136. doi: 10.1016/j.socscimed.2018.01.029. Epub 2018 Jan 31. PubMed PMID: 29421459.
95. Hosford K, Fuller D, **Lear SA**, Teschke K, Gauvin L, Brauer M, Winters M. Evaluation of the impact of a public bicycle share program on population bicycling in Vancouver, BC. *Prev Med Rep*. 2018 Oct 3;12:176-181. doi: 10.1016/j.pmedr.2018.09.014. eCollection 2018 Dec. PubMed PMID: 30306014; PubMed Central PMCID: PMC6174831.
96. Hosford K, **Lear SA**, Fuller D, Teschke K, Therrien S, Winters M. Who is in the near market for bicycle sharing? Identifying current, potential, and unlikely users of a public bicycle share program in Vancouver, Canada. *BMC Public Health*. 2018 Nov 29;18(1):1326. doi: 10.1186/s12889-018-6246-3. PubMed PMID: 30497439; PubMed Central PMCID: PMC6267823.
97. Huff RD, Rider CF, Yan D, Newton R, Giembycz MA, **Carlsten C**, Hirota JA. Inhibition of ABCC4 potentiates combination beta agonist and glucocorticoid responses in human airway epithelial cells. *J Allergy Clin Immunol*. 2018 Mar;141(3):1127-1130.e5. doi: 10.1016/j.jaci.2017.10.011. Epub 2017 Dec 6. PubMed PMID: 29103996.
98. Hüls A, Klümper C, MacIntyre EA, Brauer M, Melén E, Bauer M, Berdel D, Bergström A, Brunekreef B, Chan-Yeung M, Fuertes E, Gehring U, Gref A, Heinrich J, Standl M, Lehmann I, Kerkhof M, Koppelman GH, Kozyrskyj AL, Pershagen G, **Carlsten C**, Krämer U, Schikowski T; TAG Study Group. Atopic dermatitis: Interaction between genetic variants of GSTP1, TNF, TLR2, and TLR4 and air pollution in early life. *Pediatr Allergy Immunol*. 2018 Sep;29(6):596-605. doi: 10.1111/pai.12903. Epub 2018 May 7. PubMed PMID: 29624745.
99. Hurst JR, **Sin DD**. Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Disease. A View from the SUMMIT. *Am J Respir Crit Care Med*. 2018 Jul 1;198(1):2-4. doi: 10.1164/rccm.201802-0347ED. PubMed PMID: 29533679."
100. Inskip JA, Lauscher HN, Li LC, Dumont GA, Garde A, Ho K, Hoens AM, Road JD, **Ryerson CJ, Camp PG**. Patient and health care professional perspectives on using telehealth to deliver pulmonary rehabilitation. *Chron Respir Dis*. 2018 Feb;15(1):71-80. doi: 10.1177/1479972317709643. Epub 2017 Jun 1. PubMed PMID: 28569116; PubMed Central PMCID: PMC5802656.
101. Jackson VE, Latourelle JC, Wain LV, Smith AV, Grove ML, Bartz TM, Obeidat M, Province MA, Gao W, Qaiser B, Porteous DJ, Cassano PA, Ahluwalia TS, Grarup N, Li J, Altmaier E, Marten J, Harris SE, Manichaikul A, Pottinger TD, Li-Gao R, Lind-Thomsen A, Mahajan A, Lahousse L, Imboden M, Teumer A, Prins B, Lyytikäinen LP, Eiriksdottir G, Franceschini N, Sitlani CM, Brody JA, Bossé Y, Timens W, Kraja A, Loukola A, Tang W, Liu Y, Bork-Jensen J, Justesen JM, Linneberg A, Lange LA, Rawal R, Karrasch S, Huffman JE, Smith BH, Davies G, Burkart KM, Mychaleckyj JC, Bonten TN, Enroth S, Lind L, Brusselle GG, Kumar A, Stubbe B; Understanding Society Scientific Group, Kähönen M, Wyss AB, Psaty BM, Heckbert SR, Hao K, Rantanen T, Kritchevsky SB, Lohman K, Skaaby T, Pisinger C, Hansen T, Schulz H, Polasek O, Campbell A, Starr JM, Rich SS, Mook-Kanamori DO, Johansson Å, Ingelsson E, Uitterlinden AG, Weiss S, Raitakari OT, Gudnason V, North KE, Gharib SA, **Sin DD**, Taylor KD, O'Connor GT, Kaprio J, Harris TB, Pederson O, Vestergaard H, Wilson JG, Strauch K, Hayward C, Kerr S, Deary IJ, Barr RG, de Mutsert R, Gyllenstein U, Morris AP, Ikram MA, Probst-Hensch N, Gläser S, Zeggini E, Lehtimäki T, Strachan DP, Dupuis J, Morrison AC, Hall IP, Tobin MD, London SJ. Meta-analysis of exome array data identifies six novel genetic loci for lung function. *Wellcome Open Res*. 2018 Jan 12;3:4. doi: 10.12688/wellcomeopenres.12583.3. eCollection 2018. PubMed PMID: 30175238; PubMed Central PMCID: PMC6081985."

102. Jagdeo JM, Dufour A, Klein T, Solis N, Kleinfeld O, Kizhakkedathu J, **Luo H**, Overall CM, Jan E. N-Terminomics TAILS Identifies Host Cell Substrates of Poliovirus and Coxsackievirus B3 3C Proteinases That Modulate Virus Infection. *J Virol*. 2018 Mar 28;92(8). pii: e02211-17. doi: 10.1128/JVI.02211-17. Print 2018 Apr 15. PubMed PMID: 29437971; PubMed Central PMCID: PMC5874412."
103. Janzen ML, Malhi N, **Laksman ZWM**, Puyat J, **Krahn AD**, Hawkins NM. The QT Interval in Anorexia Nervosa: A Meta-Analysis. *JACC Clin Electrophysiol*. 2018 Jun;4(6):839-841. doi: 10.1016/j.jacep.2018.01.019. Epub 2018 Mar 28. PubMed PMID: 29929679.
104. Jensen D, Schaeffer MR, **Guenette JA**. Pathophysiological mechanisms of exertional breathlessness in chronic obstructive pulmonary disease and interstitial lung disease. *Curr Opin Support Palliat Care*. 2018 Sep;12(3):237-245. doi: 10.1097/SPC.0000000000000377. PubMed PMID: 30074922.
105. Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböllner H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemeny LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Møller P, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHF, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulos A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orłowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston R, McLaughlin J, Stevens V, Nickle DC, **Obeidat M**, Timens W, Zhu B, Song L, Artigas MS, Tobin MD, Wain LV, Gu F, Byun J, Kamal A, Zhu D, Tyndale RF, Wei WQ, Chanock S, Brennan P, Amos CI. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. *Nat Commun*. 2018 Aug 13;9(1):3221. doi: 10.1038/s41467-018-05074-y. PubMed PMID: 30104567; PubMed Central PMCID: PMC6089967.
106. Jin M, Lee EC, Ra SW, Fishbane N, Tam S, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Aaron SD, Reed RM, **Man SFP**, **Leung JM**, **Sin DD**. Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. *Chest*. 2018 Aug;154(2):266-273. doi: 10.1016/j.chest.2018.05.022. Epub 2018 Jul 12. PubMed PMID: 30017346.
107. Jin Z, Collier TS, Dai DLY, Chen V, Hollander Z, **Ng RT**, **McManus BM**, Balshaw R, Apostolidou S, Penn MS, Bystrom C. Development and Validation of Apolipoprotein AI-Associated Lipoprotein Proteome Panel for the Prediction of Cholesterol Efflux Capacity and Coronary Artery Disease. *Clin Chem*. 2019 Feb;65(2):282-290. doi: 10.1373/clinchem.2018.291922. Epub 2018 Nov 21. PubMed PMID: 30463841.
108. Johnson KM, Bryan S, Ghanbarian S, **Sin DD**, Sadatsafavi M. Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Respir Res*. 2018 Feb 7;19(1):26. doi: 10.1186/s12931-018-0731-1. Review. PubMed PMID: 29415723; PubMed Central PMCID: PMC5803996.
109. Johnson KM, Safari A, **Tan WC**, Bourbeau J, FitzGerald JM, Sadatsafavi M, Study OBOTCCOOLDC; Canadian Respiratory Research Network. Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. *Int J Chron Obstruct Pulmon Dis*. 2018 Dec 13;13:3983-3995. doi: 10.2147/COPD.S184424. eCollection 2018. PubMed PMID: 30587954; PubMed Central PMCID: PMC6296193.
110. Johnson KM, **Tan WC**, Bourbeau J, **Sin DD**, Sadatsafavi M; Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network. The diagnostic performance of patient symptoms in screening for COPD. *Respir Res*. 2018 Aug 3;19(1):147. doi: 10.1186/s12931-018-0853-5. PubMed PMID: 30075717; PubMed Central PMCID: PMC6090694.
111. Johri AM, Poirier P, Dorian P, Fournier A, Goodman JM, McKinney J, Moulson N, Pipe A, Philippon F, Taylor T, Connelly K, Baggish AL, **Krahn A**, Sharma S. Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes. *Can J Cardiol*. 2019 Jan;35(1):1-11. doi: 10.1016/j.cjca.2018.10.016. Epub 2018 Nov 22. PubMed PMID: 30595170.
112. Joseph P, Yusuf S, Lee SF, Ibrahim Q, Teo K, Rangarajan S, Gupta R, Rosengren A, **Lear SA**, Avezum A, Lopez-Jaramillo P, Gulec S, Yusufali A, Chifamba J, Lanus F, Kumar R, Mohammadifard N, Mohan V, Mony P, Kruger A, Liu X, Guo B, Zhao W, Yang Y, Pillai R, Diaz R, Krishnapillai A, Iqbal R, Yusuf R, Szuba A, Anand SS; PURE INVESTIGATORS. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. *Heart*. 2018 Apr;104(7):581-587. doi: 10.1136/heartjnl-2017-311609. Epub 2017 Oct 24. PubMed PMID: 29066611; PubMed Central PMCID: PMC5861396.

113. Kandola DK, Banner D, Araki Y, Bates J, Hadi H, **Lear SA**. The Participant Recruitment Outcomes (PRO) study: Exploring contemporary perspectives of telehealth trial non-participation through insights from patients, clinicians, study investigators, and study staff. *Contemp Clin Trials Commun*. 2018 May 4;11:75-82. doi: 10.1016/j.conctc.2018.05.005. eCollection 2018 Sep. PubMed PMID: 29998203; PubMed Central PMCID: MC6008707.
114. Kearns MJ, **Walley KR**. Tamponade: Hemodynamic and Echocardiographic Diagnosis. *Chest*. 2018 May;153(5):1266-1275. doi: 10.1016/j.chest.2017.11.003. Epub 2017 Nov 11. Review. PubMed PMID: 29137910.
115. Khalil N, Manganas H, **Ryerson CJ**, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. *Eur Respir J*. 2018 Dec 21. pii: 1800663. doi: 10.1183/13993003.00663-2018. [Epub ahead of print] PubMed PMID: 30578394.
116. Kim U, Blanke P, Windecker S, Kasel AM, Schäfer U, Walters D, Linke A, Le Breton H, Schymik G, Spence MS, Søndergaard L, Abdel-Wahab M, Worthley S, Tchéché D, Reichenspurner H, Ohana M, Sellers SL, **Leipsic JA**. Computed tomography-based oversizing and incidence of paravalvular aortic regurgitation and permanent pacemaker implantation with a new-generation self-expanding transcatheter heart valve. *EuroIntervention*. 2018 Aug 3;14(5):e511-e518. doi: 10.4244/EIJ-D-17-01040. PubMed PMID: 29741486.
117. Kim U, **Leipsic JA**, Sellers SL, Shao M, Blanke P, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, Shin S, Choi JH, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Chang HJ. Natural History of Diabetic Coronary Atherosclerosis by Quantitative Measurement of Serial Coronary Computed Tomographic Angiography: Results of the PARADIGM Study. *JACC Cardiovasc Imaging*. 2018 Oct;11(10):1461-1471. doi: 10.1016/j.jcmg.2018.04.009. Epub 2018 May 16. PubMed PMID: 29778853.
118. Kirby M, **Coxson HO**. Who Is at Risk? The Role of Airway Imaging in Chronic Lung Disease Risk Assessment. *Ann Am Thorac Soc*. 2018 Jun;15(6):669-670. doi: 10.1513/AnnalsATS.201804-244ED. PubMed PMID: 29856248.
119. Kirby M, **Sin DD**. Imaging End Points in COPD Clinical Trials: Are We There Yet? *Chest*. 2018 Jul;154(1):3-5. doi: 10.1016/j.chest.2018.01.050. PubMed PMID: 30044745.
120. Kirby M, **Tan WC, Hogg JC, Coxson HO**. Reply to Hu et al.: How to Determine the Patient's Head and Neck Posture during Computed Tomography Scanning? *Am J Respir Crit Care Med*. 2018 Nov 1;198(9):1238-1239. doi: 10.1164/rccm.201806-1154LE. PubMed PMID: 30118318.
121. Kirby M, Tanabe N, **Tan WC**, Zhou G, **Obeidat M**, Hague CJ, **Leipsic J**, Bourbeau J, **Sin DD, Hogg JC, Coxson HO**; CanCOLD Collaborative Research Group; Canadian Respiratory Research Network; CanCOLD Collaborative Research Group, the Canadian Respiratory Research Network. Total Airway Count on Computed Tomography and the Risk of Chronic Obstructive Pulmonary Disease Progression. Findings from a Population-based Study. *Am J Respir Crit Care Med*. 2018 Jan 1;197(1):56-65. doi: 10.1164/rccm.201704-0692OC. PubMed PMID: 28886252.
122. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quresma M, Stowasser S, Martinez FJ; **INSTAGE Investigators**. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. PubMed PMID: 30220235. **CJ Ryerson is an INSTAGE Investigator.**
123. Koo HK, Vasilescu DM, Booth S, Hsieh A, Katsamenis OL, Fishbane N, Elliott WM, Kirby M, Lackie P, Sinclair I, Warner JA, Cooper JD, **Coxson HO, Paré PD, Hogg JC, Hackett TL**. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. *Lancet Respir Med*. 2018 Aug;6(8):591-602. doi: 10.1016/S2213-2600(18)30196-6. Epub 2018 Jul 4. PubMed PMID: 30072106.
124. Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, **Sin DD**, Voelkel N, Olschewski H. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? *Am J Respir Crit Care Med*. 2018 Oct 15;198(8):1000-1011. doi: 10.1164/rccm.201801-0095PP. PubMed PMID: 29746142.
125. **Krahn AD**, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, Rinne C, Coutu B, Low RA, Essebag V, Morillo C, Redfearn D, Toal S, Becker G, Degrâce M, Thibault B, Crystal E, Tung S, LeMaitre J, Sultan O, Bennett M, Bashir J, Ayala-Paredes F, Gervais P, Rioux L, Hemels MEW, Bouwels LHR, van Vlies B, Wang J, Exner DV, Dorian P, Parkash R, Alings M, Connolly SJ. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. *J Am Coll Cardiol*. 2018 Dec 18;72(24):3098-3109. doi: 10.1016/j.jacc.2018.09.068. PubMed PMID: 30545448.

126. Kusters DM, Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, **Francis GA**, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". *Circulation*. 2018 Feb 6;137(6):641-642. doi: 10.1161/CIRCULATIONAHA.117.031676. PubMed PMID: 29431667.
127. Lamontagne M, Bérubé JC, **Obeidat M**, Cho MH, Hobbs BD, Sakornsakolpat P, de Jong K, Boezen HM; International COPD Genetics Consortium, Nickle D, Hao K, Timens W, van den Berge M, Joubert P, Laviolette M, Sin DD, Paré PD, Bossé Y. Leveraging lung tissue transcriptome to uncover candidate causal genes in COPD genetic associations. *Hum Mol Genet*. 2018 May 15;27(10):1819-1829. doi: 10.1093/hmg/ddy091. PubMed PMID: 29547942; PubMed Central PMCID: PMC5932553.
128. **Lear SA**. Patients in research: one step in a long path. *BMJ*. 2018 Oct 24;363:k4386. doi: 10.1136/bmj.k4386. PubMed PMID: 30355642.
129. **Lear SA**. The Delivery of Cardiac Rehabilitation Using Communications Technologies: The "Virtual" Cardiac Rehabilitation Program. *Can J Cardiol*. 2018 Oct;34(10S2):S278-S283. doi: 10.1016/j.cjca.2018.07.009. Epub 2018 Jul 18. Review. PubMed PMID: 30274638.
130. Lee JGH, Genga KR, Pisitsak C, **Boyd JH**, Leung AKK, **Russell JA**, **Walley KR**. Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis. *Crit Care*. 2018 Mar 6;22(1):58. doi: 10.1186/s13054-018-1985-1. PubMed PMID: 29510719; PubMed Central PMCID: PMC5840798.
131. Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, **Leipsic JA**, Shin S, Choi JH, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. *JACC Cardiovasc Imaging*. 2018 Oct;11(10):1475-1484. doi: 10.1016/j.jcmg.2018.04.015. Epub 2018 Jun 13. PubMed PMID: 29909109.
132. Lee SE, Sung JM, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, **Leipsic JA**, Shin S, Hyun Choi J, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Chang HJ. Quantification of Coronary Atherosclerosis in the Assessment of Coronary Artery Disease. *Circ Cardiovasc Imaging*. 2018 Jul;11(7):e007562. doi: 10.1161/CIRCIMAGING.117.007562. PubMed PMID: 30012825.
133. **Leipsic JA**, Hurwitz Koweek L. CT Fractional Flow Reserve for Stable Coronary Artery Disease: The Ongoing Journey. *Radiology*. 2018 Apr;287(1):85-86. doi: 10.1148/radiol.2018172838. PubMed PMID: 29558312.
134. Leitao Filho FS, Alotaibi NM, Ngan D, Tam S, Yang J, Hollander Z, Chen V, FitzGerald JM, Nislow C, **Leung JM**, **Man SFP**, **Sin DD**. Sputum Microbiome is Associated with 1-Year Mortality Following COPD Hospitalizations. *Am J Respir Crit Care Med*. 2018 Oct 30. doi: 10.1164/rccm.201806-1135OC. [Epub ahead of print] PubMed PMID: 30376356.
135. Leitao Filho FS, Alotaibi NM, Yamasaki K, Ngan DA, **Sin DD**. The role of beta-blockers in the management of chronic obstructive pulmonary disease. *Expert Rev Respir Med*. 2018 Feb;12(2):125-135. doi: 10.1080/17476348.2018.1419869. Epub 2017 Dec 27. PubMed PMID: 29258360.
136. Leitao Filho FS, Ra SW, Mattman A, **Schellenberg RS**, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, **Leung JM**, **Paul Man SF**, Aaron SD, Reed RM, **Sin DD**; Canadian Respiratory Research Network (CRRN). Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. *Respir Res*. 2018 Feb 14;19(1):30. doi: 10.1186/s12931-018-0733-z. PubMed PMID: 29444682; PubMed Central PMCID: PMC5813358.
137. Leitao Filho FS, Ra SW, Mattman A, **Schellenberg RS**, **Sin DD**. Reply. *J Allergy Clin Immunol*. 2018 Feb;141(2):831. doi: 10.1016/j.jaci.2017.10.013. Epub 2017 Dec 6. PubMed PMID: 29221816.
138. Leitao Filho FS, **Sin DD**. COPD and cardiovascular diseases: now is the time for action! *Thorax*. 2018 Sep;73(9):799-800. doi: 10.1136/thoraxjnl-2018-211553. Epub 2018 Apr 5. PubMed PMID: 29622696.
139. **Leung JM**, **Sin DD**. Inhaled corticosteroids in COPD: the final verdict is.... *Eur Respir J*. 2018 Dec 13;52(6). pii: 1801940. doi: 10.1183/13993003.01940-2018. Print 2018 Dec. PubMed PMID: 30545961.
140. Lewis RJ, Angus DC, Laterre PF, Kjølbye AL, van der Meulen E, Blemings A, Graves T, **Russell JA**, Carlsen JE, Jacobsen K, Yealy DM, Opal SM, Windeløv NA, François B, Perner A, Pickkers P, Berry SM. Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial. *Ann Am Thorac Soc*. 2018 Feb;15(2):250-257. doi: 10.1513/AnnalsATS.201708-669SD. PubMed PMID: 29388815.

141. Li P, Xu L, Yang L, Wang R, Hsieh J, Sun Z, Fan Z, **Leipsic JA**. Blooming Artifact Reduction in Coronary Artery Calcification by A New De-blooming Algorithm: Initial Study. *Sci Rep*. 2018 May 2;8(1):6945. doi: 10.1038/s41598-018-25352-5. PubMed PMID: 29720611; PubMed Central PMCID: PMC5931966.
142. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, **Ryerson CJ**, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med*. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review. PubMed PMID: 29154106.
143. Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raoof S, Richeldi L, **Ryerson CJ**, Ryu JH. Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. *Lancet Respir Med*. 2018 Feb;6(2):e7. doi: 10.1016/S2213-2600(18)30021-3. PubMed PMID: 29413090.
144. Maestre-Batlle D, Pena OM, Huff RD, Randhawa A, **Carlsten C**, Bølling AK. Dibutyl phthalate modulates phenotype of granulocytes in human blood in response to inflammatory stimuli. *Toxicol Lett*. 2018 Oct 15;296:23-30. doi: 10.1016/j.toxlet.2018.07.046. Epub 2018 Jul 27. PubMed PMID: 30059708.
145. Malhi N, Hawkins NM, Andrade JG, **Krahn AD**, Deyell MW. Catheter ablation of atrial fibrillation in heart failure with reduced ejection fraction. *J Cardiovasc Electrophysiol*. 2018 Jul;29(7):1049-1058. doi: 10.1111/jce.13497. Epub 2018 Apr 23. Review. PubMed PMID: 29630760.
146. Malhi N, So PP, Cheung CC, **Laksman ZWM**, Healey JS, Chauhan VS, Green MS, Champagne J, Steinberg C, Sanatani S, Angaran P, Duff H, Roberts JD, Arbour L, Leather R, Simpson CS, Tadros R, Talajic M, Gardner M, Siefer C, **Krahn AD**. Early Repolarization Pattern Inheritance in the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). *JACC Clin Electrophysiol*. 2018 Nov;4(11):1473-1479. doi: 10.1016/j.jacep.2018.07.001. Epub 2018 Aug 29. PubMed PMID: 30466855.
147. Manji J, Habib AR, Amanian AA, Alsaleh S, **Thamboo A**, Javer AR. Potential risk factors associated with the development of synechiae following functional endoscopic sinus surgery. *Eur Arch Otorhinolaryngol*. 2018 May;275(5):1175-1181. doi: 10.1007/s00405-018-4936-1. Epub 2018 Mar 15. PubMed PMID: 29546557.
148. Manji J, Nayak JV, **Thamboo A**. The functional and psychological burden of empty nose syndrome. *Int Forum Allergy Rhinol*. 2018 Jun;8(6):707-712. doi: 10.1002/alr.22097. Epub 2018 Feb 14. PubMed PMID: 29443458.
149. Manji J, **Thamboo A**, Sunkaraneni V, Singh A, **Tebbutt S**, Garnis C, Javer A. The association of Leptospermum honey with cytokine expression in the sinonasal epithelium of chronic rhinosinusitis patients. *World J Otorhinolaryngol Head Neck Surg*. 2018 Sep 7;5(1):19-25. doi: 10.1016/j.wjorl.2018.07.004. eCollection 2019 Mar. PubMed PMID: 30775697; PubMed Central PMCID: PMC6364513.
150. Manji J, **Thamboo A**, Tacey M, Garnis C, Chadha NK. The presence of Interleukin-13 in nasal lavage may be a predictor of nasal polyposis in pediatric patients with cystic fibrosis. *Rhinology*. 2018 Sep 1;56(3):261-267. doi: 10.4193/Rhin17.007. PubMed PMID: 29561922.
151. Manku S, Wong W, Luo Z, **Seidman MA**, Alabdurbalnabi Z, Rey K, Enns W, Avina-Zubieta JA, Shojania K, Choy JC. IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis. *Cardiovasc Pathol*. 2018 Mar - Apr;33:55-61. doi: 10.1016/j.carpath.2018.01.004. Epub 2018 Jan 9. PubMed PMID: 29414433.
152. Mattman A, Chen LYC, van der Gugten G, Chin A, Carruthers M, **DeMarco ML**, Holmes DT. Comment on: IgG4-related disease presenting with raised serum IgG2-real timeline of IgG4-RD? *Rheumatology (Oxford)*. 2018 Jun 1;57(6):1125-1126. doi: 10.1093/rheumatology/key044. PubMed PMID: 29584907.
153. McDonough JE, Kaminski N, Thienpont B, **Hogg JC**, Vanaudenaerde BM, Wuyts WA. Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis. *Thorax*. 2019 Feb;74(2):132-140. doi: 10.1136/thoraxjnl-2018-211929. Epub 2018 Oct 26. PubMed PMID: 30366970.
154. McDonough JE, Martens DS, Tanabe N, Ahangari F, Verleden SE, Maes K, Verleden GM, Kaminski N, **Hogg JC**, Nawrot TS, Wuyts WA, Vanaudenaerde BM. A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis. *Respir Res*. 2018 Jul 9;19(1):132. doi: 10.1186/s12931-018-0838-4. PubMed PMID: 29986708; PubMed Central PMCID: PMC6038197.
155. McEwen LM, Jones MJ, Lin DTS, Edgar RD, Husquin LT, Maclsaac JL, Ramadori KE, Morin AM, Rider CF, **Carlsten C**, Quintana-Murci L, Horvath S, Kobor MS. Systematic evaluation of DNA methylation age estimation with common preprocessing methods and the Infinium MethylationEPIC BeadChip array. *Clin Epigenetics*. 2018 Oct 16;10(1):123. doi: 10.1186/s13148-018-0556-2. PubMed PMID: 30326963; PubMed Central PMCID: PMC6192219.

156. McIntyre LA, Stewart DJ, Mei SHJ, Courtman D, Watpool I, Granton J, Marshall J, Dos Santos C, **Walley KR**, Winston BW, Schlosser K, Fergusson DA; Canadian Critical Care Trials Group; Canadian Critical Care Translational Biology Group. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. *Am J Respir Crit Care Med*. 2018 Feb 1;197(3):337-347. doi: 10.1164/rccm.201705-1006OC. PubMed PMID: 28960096.
157. McKinney J, Isserow S, **Krahn A**. Cardiac Arrest during Competitive Sports. *N Engl J Med*. 2018 Apr 12;378(15):1462-3. doi: 10.1056/NEJMc1802593. PubMed PMID: 29648425.
158. Mendell J, Bates J, Banner-Lukaris D, Horvat D, Kang B, Singer J, Ignaszewski A, **Lear SA**. What Do Patients Talk About? A Qualitative Analysis of Online Chat Sessions with Health Care Specialists During a "Virtual" Cardiac Rehabilitation Program. *Telemed J E Health*. 2019 Jan;25(1):71-78. doi: 10.1089/tmj.2017.0206. Epub 2018 May 9. PubMed PMID: 29742035.
159. Mente A, O'Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, **Lear S**, Ah STL, Wei L, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Mony P, Szuba A, Iqbal R, Yusuf R, Mohammadifard N, Khatib R, Yusoff K, Ismail N, Gulec S, Rosengren A, Yusufali A, Kruger L, Tsolekile LP, Chifamba J, Dans A, Alhabib KF, Yeates K, Teo K, Yusuf S. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. *Lancet*. 2018 Aug 11;392(10146):496-506. doi: 10.1016/S0140-6736(18)31376-X. Epub 2018 Aug 9. PubMed PMID: 30129465.
160. Miliku K, Robertson B, Sharma AK, Subbarao P, Becker AB, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR; **CHILD Study Investigators**, Bode L, Azad MB. Human milk oligosaccharide profiles and food sensitization among infants in the CHILD Study. *Allergy*. 2018 Oct;73(10):2070-2073. doi: 10.1111/all.13476. Epub 2018 Jul 2. PubMed PMID: 29775217. **D Daley, P Paré, A Sandford, and S Tebbutt are CHILD Study Investigators.**
161. Miller ER, Putman RK, Diaz AA, Xu H, San José Estépar R, Araki T, Nishino M, Poli de Frías S, Hida T, Ross J, **Coxson H**, Dupuis J, O'Connor GT, Silverman EK, Rosas IO, Hatabu H, Washko G, Hunninghake GM; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) and COPD Gene investigators. Increased Airway Wall Thickness in Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. *Ann Am Thorac Soc*. 2018 Dec 13. doi: 10.1513/AnnalsATS.201806-424OC. [Epub ahead of print] PubMed PMID: 30543456.
162. Milne KM, Chan C, Fisher JH, de Boer K, **Ryerson CJ**. Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. *ERJ Open Res*. 2018 Dec 21;4(4). pii: 00156-2018. doi: 10.1183/23120541.00156-2018. eCollection 2018 Oct. PubMed PMID: 30588478; PubMed Central PMCID: PMC6302207.
163. Milne S, **Sin DD**. What triggers acute exacerbations of COPD? Why not ask the patient! *Respirology*. 2019 Jan;24(1):7-8. doi: 10.1111/resp.13384. Epub 2018 Aug 14. PubMed PMID: 30106196.
164. Mitchell RA, Schaeffer MR, Ramsook AH, Wilkie SS, **Guenette JA**. Sex differences in respiratory muscle activation patterns during high-intensity exercise in healthy humans. *Respir Physiol Neurobiol*. 2018 Jan;247:57-60. doi: 10.1016/j.resp.2017.09.002. Epub 2017 Sep 7. PubMed PMID: 28890403.
165. Mohamud Y, **Luo H**. The Intertwined Life Cycles of Enterovirus and Autophagy. *Virulence*. 2018 Nov 26. doi: 10.1080/21505594.2018.1551010. [Epub ahead of print] PubMed PMID: 30475087.
166. Mohamud Y, Qu J, Xue YC, Liu H, Deng H, **Luo H**. CALCOCO2/NDP52 and SQSTM1/p62 differentially regulate coxsackievirus B3 propagation. *Cell Death Differ*. 2018 Aug 28. doi: 10.1038/s41418-018-0185-5. [Epub ahead of print] PubMed PMID: 30154446.
167. Mohamud Y, Shi J, Qu J, Poon T, Xue YC, Deng H, Zhang J, **Luo H**. Enteroviral Infection Inhibits Autophagic Flux via Disruption of the SNARE Complex to Enhance Viral Replication. *Cell Rep*. 2018 Mar 20;22(12):3292-3303. doi: 10.1016/j.celrep.2018.02.090. PubMed PMID: 29562184.
168. Molgat-Seon Y, Dominelli PB, Ramsook AH, Schaeffer MR, Molgat Sereacki S, Foster GE, Romer LM, Road JD, **Guenette JA**, Sheel AW. The effects of age and sex on mechanical ventilatory constraint and dyspnea during exercise in healthy humans. *J Appl Physiol (1985)*. 2018 Apr 1;124(4):1092-1106. doi: 10.1152/jappphysiol.00608.2017. Epub 2017 Dec 14. PubMed PMID: 29357513; PubMed Central PMCID: PMC5972460.
169. Molgat-Seon Y, Dominelli PB, Ramsook AH, Schaeffer MR, Romer LM, Road JD, **Guenette JA**, Sheel AW. Effects of Age and Sex on Inspiratory Muscle Activation Patterns during Exercise. *Med Sci Sports Exerc*. 2018 Sep;50(9):1882-1891. doi: 10.1249/MSS.0000000000001648. PubMed PMID: 29683923.

170. Mondésert B, Bashir J, Philippon F, Dubuc M, Amit G, Exner D, Joza J, Birnie DH, Lane C, Tsang B, Korley V, Spears D, Ling A, Djuric A, Crystal E, Hruczkowski T, Roux JF, Carroll S, Essebag V, **Krahn AD**, Healey JS. Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. *Am Heart J*. 2019 Jan;207:1-9. doi: 10.1016/j.ahj.2018.09.008. Epub 2018 Oct 9. PubMed PMID: 30399474.
171. Mookherjee N, Piyadasa H, Ryu MH, Rider CF, Ezzati P, Spicer V, **Carlsten C**. Inhaled diesel exhaust alters the allergen-induced bronchial secretome in humans. *Eur Respir J*. 2018 Jan 25;51(1). pii: 1701385. doi: 10.1183/13993003.01385-2017. Print 2018 Jan. PubMed PMID: 29371381.
172. Moon JY, Leitao Filho FS, Shahangian K, Takiguchi H, **Sin DD**. Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD). *Expert Rev Proteomics*. 2018 Nov;15(11):923-935. doi: 10.1080/14789450.2018.1539670. Epub 2018 Oct 29. PubMed PMID: 30362838.
173. Murphy A, Palafox B, O'Donnell O, Stuckler D, Perel P, AlHabib KF, Avezum A, Bai X, Chifamba J, Chow CK, Corsi DJ, Dagenais GR, Dans AL, Diaz R, Erbakan AN, Ismail N, Iqbal R, Kelishadi R, Khatib R, Lanan F, **Lear SA**, Li W, Liu J, Lopez-Jaramillo P, Mohan V, Monsef N, Mony PK, Puoane T, Rangarajan S, Rosengren A, Schutte AE, Sintaha M, Teo KK, Wielgosz A, Yeates K, Yin L, Yusoff K, Zatońska K, Yusuf S, McKee M. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. *Lancet Glob Health*. 2018 Mar;6(3):e292-e301. doi: 10.1016/S2214-109X(18)30031-7. PubMed PMID: 29433667; PubMed Central PMCID: PMC5905400.
174. Nakada TA, Wacharasint P, **Russell JA**, **Boyd JH**, Nakada E, Thair SA, Shimada T, **Walley KR**. The IL20 Genetic Polymorphism Is Associated with Altered Clinical Outcome in Septic Shock. *J Innate Immun*. 2018;10(3):181-188. doi: 10.1159/000486104. Epub 2018 Jan 16. PubMed PMID: 29334679.
175. Nayak JV, Rathor A, Grayson JW, Bravo DT, Velasquez N, Noel J, Beswick DM, Riley KO, Patel ZM, Cho DY, Dodd RL, **Thamboo A**, Choby GW, Walgama E, Harsh GR, Hwang PH, Clemons L, Lowman D, Richman JS, Woodworth BA. Porcine small intestine submucosal grafts improve remucosalization and progenitor cell recruitment to sites of upper airway tissue remodeling. *Int Forum Allergy Rhinol*. 2018 Oct;8(10):1162-1168. doi: 10.1002/alr.22156. Epub 2018 Jun 1. PubMed PMID: 29856526.
176. Nedeljkovic I, Carnero-Montoro E, Lahousse L, van der Plaats DA, de Jong K, Vonk JM, van Diemen CC, Faiz A, van den Berge M, **Obeidat M**, Bossé Y, Nickle DC, Consortium B, Uitterlinden AG, van Meurs JJB, Stricker BCH, Brusselle GG, Postma DS, Boezen HM, van Duijn CM, Amin N. Understanding the role of the chromosome 15q25.1 in COPD through epigenetics and transcriptomics. *Eur J Hum Genet*. 2018 May;26(5):709-722. doi: 10.1038/s41431-017-0089-8. Epub 2018 Feb 8. PubMed PMID: 29422661; PubMed Central PMCID: PMC5945654.
177. Nedeljkovic I, Lahousse L, Carnero-Montoro E, Faiz A, Vonk JM, de Jong K, van der Plaats DA, van Diemen CC, van den Berge M, **Obeidat M**, Bossé Y, Nickle DC, Consortium BIOS, Uitterlinden AG, van Meurs JJB, Stricker BHC, Brusselle GG, Postma DS, Boezen HM, van Duijn CM, Amin N. COPD GWAS variant at 19q13.2 in relation with DNA methylation and gene expression. *Hum Mol Genet*. 2018 Jan 15;27(2):396-405. doi: 10.1093/hmg/ddx390. PubMed PMID: 29092026; PubMed Central PMCID: PMC5886099.
178. Nesbitt JR, Steves EY, Schonhofer CR, Cait A, Manku SS, Yeung JHF, Bennet AJ, **McNagny KM**, Choy JC, Hughes MR, Moore MM. The *Aspergillus fumigatus* Sialidase (Kdnase) Contributes to Cell Wall Integrity and Virulence in Amphotericin B-Treated Mice. *Front Microbiol*. 2018 Jan 18;8:2706. doi: 10.3389/fmicb.2017.02706. eCollection 2017. PubMed PMID: 29403452; PubMed Central PMCID: PMC5778107.
179. **Obeidat M**, Dvorkin-Gheva A, Li X, Bossé Y, Brandsma CA, Nickle DC, Hansbro PM, Faner R, Agusti A, **Paré PD**, Stampfli MR, **Sin DD**. The Overlap of Lung Tissue Transcriptome of Smoke Exposed Mice with Human Smoking and COPD. *Sci Rep*. 2018 Aug 8;8(1):11881. doi: 10.1038/s41598-018-30313-z. PubMed PMID: 30089872; PubMed Central PMCID: PMC6082828.
180. **Obeidat M**, Zhou G, Li X, Hansel NN, Rafaels N, Mathias R, Ruczinski I, Beaty TH, Barnes KC, **Paré PD**, **Sin DD**. The genetics of smoking in individuals with chronic obstructive pulmonary disease. *Respir Res*. 2018 Apr 10;19(1):59. doi: 10.1186/s12931-018-0762-7. PubMed PMID: 29631575; PubMed Central PMCID: PMC5892035.
181. Ohana M, Sellers SL, Mooney J, Kueh SH, Grover R, Arepalli CD, Selvakumar K, Kim U, Blanke P, **Leipsic JA**. Prevalence and impact of scan-related anxiety during coronary CT angiography: A prospective cohort study of 366 patients. *J Cardiovasc Comput Tomogr*. 2018 Sep - Oct;12(5):364-371. doi: 10.1016/j.jcct.2018.04.013. Epub 2018 May 4. PubMed PMID: 29752224.

182. Ong S, Levy RD, Yee J, Partovi N, Churg A, Roméo P, Chalaoui J, Nador R, Wright A, Manganas H, **Ryerson CJ**. Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report. *BMC Pulm Med*. 2018 Oct 16;18(1):162. doi: 10.1186/s12890-018-0727-0. PubMed PMID: 30326889; PubMed Central PMCID: PMC6191892.
183. Opolski MP, Gransar H, Lu Y, Achenbach S, Al-Mallah MH, Andreini D, Bax JJ, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJ, Cury RC, DeLago A, Feuchtner GM, Hadamitzky M, Hausleiter J, Kaufmann PA, Kim YJ, **Leipsic JA**, Maffei EC, Marques H, Pontone G, Raff G, Rubinshtein R, Shaw LJ, Villines TC, Gomez M, Jones EC, Peña JM, Min JK, Lin FY. Prognostic value of chronic total occlusions detected on coronary computed tomographic angiography. *Heart*. 2019 Feb;105(3):196-203. doi: 10.1136/heartjnl-2017-312907. Epub 2018 Jul 30. PubMed PMID: 30061160.
184. Ospina MB, Michas M, Deuchar L, Leigh R, Bhutani M, Rowe BH, Marciniuk D, Goodridge D, Dechman G, Bourbeau J, Balter M, **Camp P**, Hernandez P, Goldstein RS, Stickland MK. Development of a patient-centred, evidence-based and consensus-based discharge care bundle for patients with acute exacerbation of chronic obstructive pulmonary disease. *BMJ Open Respir Res*. 2018 Jan 30;5(1):e000265. doi: 10.1136/bmjresp-2017-000265. eCollection 2018. PubMed PMID: 29468074; PubMed Central PMCID: PMC5812389.
185. Paine NJ, Bacon SL, Bourbeau J, **Tan WC**, Lavoie KL; CanCOLD Study Investigators, Aaron SD, Chapman KR, FitzGerald JM, Hernandez P, Marciniuk DD, Maltais F, O'Donnell DE, Sin D, Walker BL; Canadian Respiratory Research Network and the CanCOLD Collaborative Research Group. Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. *Respir Med*. 2019 Jan;146:1-9. doi: 10.1016/j.rmed.2018.11.006. Epub 2018 Nov 15. PubMed PMID: 30665505.
186. Park HY, Lee SY, Kang D, Cho J, Lee H, Lim SY, Yoon HI, Ra SW, Kim KU, Oh YM, **Sin DD**, Lee SD, Park YB. Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort. *Respir Res*. 2018 Mar 2;19(1):36. doi: 10.1186/s12931-018-0737-8. PubMed PMID: 29499758; PubMed Central PMCID: PMC5833074.
187. Parkash R, Thibault B, Philippon F, Mangat I, Coutu B, Bennett M, Crystal E, Healey J, Verma A, Sandhu R, Cameron D, Ayala-Paredes F, Sterns L, Essebag V, Sturmer M, Nery P, Wells G, **Krahn A**. Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. *Heart Rhythm*. 2018 Apr;15(4):524-529. doi: 10.1016/j.hrthm.2017.11.033. Epub 2017 Dec 2. PubMed PMID: 29198903.
188. Parkash R, Thibault B, Philippon F, Yee R, Stephenson E, Healey J, **Krahn A**, Exner D, Simpson C, Crystal E, Nery P, Essebag V, Sterns L, Tang A, Wells G. Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. *Can J Cardiol*. 2018 Jun;34(6):808-811. doi: 10.1016/j.cjca.2018.02.009. Epub 2018 Feb 19. PubMed PMID: 29801745.
189. Patel VS, Choby GW, **Thamboo A**, Blevins NH, Hwang PH. Nasoseptal flap closure of the eustachian tube for recalcitrant cerebrospinal fluid rhinorrhea. *Laryngoscope*. 2018 Jul;128(7):1523-1526. doi: 10.1002/lary.26988. Epub 2017 Nov 20. PubMed PMID: 29152752.
190. Payne BA, Ryan H, Bone J, Magee LA, Aarvold AB, Mark Ansermino J, Bhutta ZA, Bowen M, Guilherme Cecatti J, Chazotte C, Crozier T, de Pont AJM, Demirkiran O, Duan T, Kallen M, Ganzevoort W, Geary M, Goffman D, Hutcheon JA, Joseph KS, Lapinsky SE, Lataifeh I, Li J, Liskonova S, Hamel EM, McAuliffe FM, O'Herlihy C, Mol BWJ, Seaward PGR, Tadros R, Togal T, Qureshi R, Vivian Ukah U, Vasquez D, Wallace E, Yong P, Zhou V, **Walley KR**, von Dadelszen P; CIPHER Group. Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model. *Crit Care*. 2018 Oct 30;22(1):278. doi: 10.1186/s13054-018-2215-6. PubMed PMID: 30373675; PubMed Central PMCID: PMC6206915.
191. Pickkers P, **Russell JA**. Treatment with a polymyxin B filter to capture endotoxin in sepsis patients: is there a signal for therapeutic efficacy? *Intensive Care Med*. 2019 Feb;45(2):282-283. doi: 10.1007/s00134-018-5481-5. Epub 2018 Dec 3. PubMed PMID: 30511248.
192. Piyadasa H, Hemshekhar M, **Carlsten C**, Mookherjee N. Inhaled Diesel Exhaust Decreases the Antimicrobial Peptides α -Defensin and S100A7 in Human Bronchial Secretions. *Am J Respir Crit Care Med*. 2018 May 15;197(10):1358-1361. doi: 10.1164/rccm.201708-1714LE. PubMed PMID: 29244524.
193. Post S, Heijink IH, Hesse L, Koo HK, Shaheen F, Fouadi M, Kuchibhotla VNS, Lambrecht BN, Van Oosterhout AJM, **Hackett TL**, Nawijn MC. Characterization of a lung epithelium specific E-cadherin knock-out model: Implications for obstructive lung pathology. *Sci Rep*. 2018 Sep 5;8(1):13275. doi: 10.1038/s41598-018-31500-8. PubMed PMID: 30185803; PubMed Central PMCID: PMC6125431.

194. Poureslami I PhD, Shum J MSc, Lester RT MD, Tavakoli H MD, MSc, **Dorscheid DR MD, PhD**, FitzGerald JM MD. A pilot randomized controlled trial on the impact of text messaging check-ins and a web-based asthma action plan versus a written action plan on asthma exacerbations. *J Asthma*. 2018 Oct 16:1-13. doi: 10.1080/02770903.2018.1500583. [Epub ahead of print] PubMed PMID: 30003851.
195. Qi R, Chen LYC, Park S, Irvine R, **Seidman MA**, Kelsall JT, Collins D, Yin V, Slack GW, Mattman A, Lam E, Carruthers MN. Utility of Serum IgG4 Levels in a Multiethnic Population. *Am J Med Sci*. 2018 Jan;355(1):61-66. doi: 10.1016/j.amjms.2017.08.014. Epub 2017 Aug 24. PubMed PMID: 29289265.
196. Qiao D, Ameli A, Prokopenko D, Chen H, Kho AT, Parker MM, Morrow J, Hobbs BD, Liu Y, Beaty TH, Crapo JD, Barnes KC, Nickerson DA, Bamshad M, Hersh CP, Lomas DA, Agusti A, Make BJ, Calverley PMA, Donner CF, Wouters EF, Vestbo J, **Paré PD**, Levy RD, Rennard SI, Tal-Singer R, Spitz MR, Sharma A, Ruczinski I, Lange C, Silverman EK, Cho MH. Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. *Hum Mol Genet*. 2018 Nov 1;27(21):3801-3812. doi: 10.1093/hmg/ddy269. PubMed PMID: 30060175; PubMed Central PMCID: PMC6196654.
197. **Quon BS**, Sykes J, Stanojevic S, Marshall BC, Petren K, Ostrenga J, Fink A, Elbert A, Faro A, Goss CH, Stephenson AL. Clinical characteristics of cystic fibrosis patients prior to lung transplantation: An international comparison between Canada and the United States. *Clin Transplant*. 2018 Mar;32(3):e13188. doi: 10.1111/ctr.13188. Epub 2018 Feb 11. PubMed PMID: 29292522; PubMed Central PMCID: PMC6120341.
198. Rabinovitch N, Jones MJ, Faino A, Strand M, Morin AM, Maclsaac J, Reynolds PR, Singh A, Kobor MS, Gelfand EW, **Carlsten C**. Cysteinyl Leukotriene Receptor 1 and Health Effects of Particulate Exposure in Asthma. *Ann Am Thorac Soc*. 2018 Apr;15(Supplement_2):S129. doi: 10.1513/AnnalsATS.201706-469MG. PubMed PMID: 29676619; PubMed Central PMCID: PMC5955031.
199. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, **Ryerson CJ**, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. PubMed PMID: 30168753.
200. Ramsook AH, Mitchell RA, **Guenette JA**. Reply to: Assessment of 'neural respiratory drive' from the parasternal intercostal muscles. *Respir Physiol Neurobiol*. 2019 Jan;259:173-175. doi: 10.1016/j.resp.2018.08.003. Epub 2018 Aug 7. PubMed PMID: 30096376.
201. Raymakers AJN, Sadatsafavi M, **Sin DD**, De Vera MA, Lynd LD. Response. *Chest*. 2018 Feb;153(2):578-579. doi: 10.1016/j.chest.2017.12.006. PubMed PMID: 29406228.
202. Rayment JH, **Quon BS**. Back to the source - Modern insights into pulmonary exacerbations and lung function decline from CF registry data. *J Cyst Fibros*. 2018 Jul;17(4):425-427. doi: 10.1016/j.jcf.2018.05.001. Epub 2018 May 30. PubMed PMID: 29859835.
203. Razek O, Cermakova L, Armani H, Lee T, **Francis GA**, Mancini GBJ, Frohlich J, **Brunham LR**. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. *Can J Cardiol*. 2018 Aug;34(8):1004-1009. doi: 10.1016/j.cjca.2018.04.014. Epub 2018 Apr 20. PubMed PMID: 30056842.
204. Reed RM, Cabral HJ, Dransfield MT, Eberlein M, Merlo CA, Mulligan MJ, Netzer G, Sanchez PG, Scharf SM, **Sin DD**, Celli BR. Survival of Lung Transplant Candidates With COPD: BODE Score Reconsidered. *Chest*. 2018 Mar;153(3):697-701. doi: 10.1016/j.chest.2017.10.008. Epub 2017 Oct 17. PubMed PMID: 29054348; PubMed Central PMCID: PMC5989634.
205. Rider CF, **Carlsten C**. Air pollution and resistance to inhaled glucocorticoids: Evidence, mechanisms and gaps to fill. *Pharmacol Ther*. 2019 Feb;194:1-21. doi: 10.1016/j.pharmthera.2018.08.005. Epub 2018 Aug 20. Review. PubMed PMID: 30138638.
206. Rider CF, Yamamoto M, Günther OP, Singh A, Hirota JA, **Tebbutt SJ**, **Carlsten C**. Effects of Controlled Diesel Exhaust and Allergen Exposure on microRNA and Gene Expression in Humans. Modulation of Lung Inflammatory Markers Associated with Asthma. *Ann Am Thorac Soc*. 2018 Apr;15(Supplement_2):S130-S131. doi: 10.1513/AnnalsATS.201706-479MG. PubMed PMID: 29676639.

207. Roberts JM, Dai DLY, Hollander Z, **Ng RT, Tebbutt SJ**, Wilcox PG, **Sin DD, Quon BS**. Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations. *J Cyst Fibros*. 2018 May;17(3):333-340. doi: 10.1016/j.jcf.2017.10.013. Epub 2017 Nov 22. PubMed PMID: 29174082.
208. Robinson RK, Birrell MA, Adcock JJ, Wortley MA, Dubuis ED, Chen S, McGilvery CM, Hu S, Shaffer MSP, Bonvini SJ, Maher SA, Mudway IS, Porter AE, **Carlsten C**, Tetley TD, Belvisi MG. Mechanistic link between diesel exhaust particles and respiratory reflexes. *J Allergy Clin Immunol*. 2018 Mar;141(3):1074-1084.e9. doi: 10.1016/j.jaci.2017.04.038. Epub 2017 May 19. PubMed PMID: 28532657; PubMed Central PMCID: PMC5840514.
209. Roston TM, Dewar L, Franciosi S, Hathaway J, Bartels K, Cunningham T, Gibbs KA, Sheps S, **Laksman ZWM**, Sanatani S, **Krahn AD**. The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. *J Community Genet*. 2018 Jul;9(3):257-262. doi: 10.1007/s12687-017-0348-y. Epub 2017 Nov 23. PubMed PMID: 29170972; PubMed Central PMCID: PMC6002300.
210. Roston TM, Jones K, Hawkins NM, Bos JM, Schwartz PJ, Perry F, Ackerman MJ, **Laksman ZWM**, Kaul P, Lieve KVV, Atallah J, **Krahn AD**, Sanatani S. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. *Heart Rhythm*. 2018 Dec;15(12):1791-1799. doi: 10.1016/j.hrthm.2018.06.046. Epub 2018 Jul 3. PubMed PMID: 30063211.
211. Ruel I, Aljenedil S, Sadri I, de Varennes É, Hegele RA, Couture P, Bergeron J, Wanneh E, Baass A, Dufour R, Gaudet D, Brisson D, **Brunham LR, Francis GA**, Cermakova L, Brophy JM, Ryomoto A, Mancini GBJ, Genest J. Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. *Clin Chem*. 2018 Feb;64(2):355-362. doi: 10.1373/clinchem.2017.279422. Epub 2017 Oct 16. PubMed PMID: 29038147.
212. Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Bélanger A, Bergeron J, Bewick D, Brophy JM, **Brunham LR**, Couture P, Dufour R, **Francis GA**, Frohlich J, Gagné C, Gaudet D, Grégoire JC, Gupta M, Hegele RA, Mancini GBJ, McCrindle BW, Pang J, Raggi P, Tu JV, Watts GF, Genest J. Simplified Canadian Definition for Familial Hypercholesterolemia. *Can J Cardiol*. 2018 Sep;34(9):1210-1214. doi: 10.1016/j.cjca.2018.05.015. Epub 2018 May 19. PubMed PMID: 30093300.
213. Rush B, Tyler PD, Stone DJ, Geisler BP, **Walley KR**, Celi LA. Outcomes of Ventilated Patients With Sepsis Who Undergo Interhospital Transfer: A Nationwide Linked Analysis. *Crit Care Med*. 2018 Jan;46(1):e81-e86. doi: 10.1097/CCM.0000000000002777. PubMed PMID: 29068858; PubMed Central PMCID: PMC5734994.
214. Rush B, **Walley KR**. The Emerging Role of Palliative Care in the Management of Canadians With Heart Failure. *Can J Cardiol*. 2018 Sep;34(9):1114-1115. doi: 10.1016/j.cjca.2018.06.018. Epub 2018 Jul 11. PubMed PMID: 30093302.
215. Rush B, Wiskar K, Celi LA, **Walley KR, Russell JA**, McDermid RC, **Boyd JH**. Association of Household Income Level and In-Hospital Mortality in Patients With Sepsis: A Nationwide Retrospective Cohort Analysis. *J Intensive Care Med*. 2018 Oct;33(10):551-556. doi: 10.1177/0885066617703338. Epub 2017 Apr 7. PubMed PMID: 28385107; PubMed Central PMCID: PMC5680141.
216. Rush B, Wiskar K, Fruhstorfer C, Celi LA, **Walley KR**. The Impact of Chronic Ozone and Particulate Air Pollution on Mortality in Patients With Sepsis Across the United States. *J Intensive Care Med*. 2018 Oct 7:885066618804497. doi: 10.1177/0885066618804497. [Epub ahead of print] PubMed PMID: 30295138.
217. **Russell JA**, Lee T, Singer J, De Backer D, Annane D. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials. *J Crit Care*. 2018 Oct;47:333-337. doi: 10.1016/j.jcrc.2018.05.003. Epub 2018 May 12. PubMed PMID: 29958734.
218. **Russell JA**, Rush B, **Boyd J**. Pathophysiology of Septic Shock. *Crit Care Clin*. 2018 Jan;34(1):43-61. doi: 10.1016/j.ccc.2017.08.005. Review. PubMed PMID: 29149941.
219. **Russell JA**, Spronk P, **Walley KR**. Using multiple 'omics strategies for novel therapies in sepsis. *Intensive Care Med*. 2018 Apr;44(4):509-511. doi: 10.1007/s00134-018-5122-z. Epub 2018 Mar 15. PubMed PMID: 29546534.
220. **Russell JA**, Wellman H, **Walley KR**. Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital. *J Intensive Care*. 2018 Nov 16;6:73. doi: 10.1186/s40560-018-0344-2. eCollection 2018. PubMed PMID: 30473792; PubMed Central PMCID: PMC6240281.
221. **Russell JA**. In Reply. *Anesthesiology*. 2018 Jan;128(1):230-231. doi: 10.1097/ALN.0000000000001957. PubMed PMID: 29232237.

222. **Russell JA.** When and how to use predictive biomarkers for corticosteroid treatment of septic shock. *Crit Care.* 2018 Nov 21;22(1):318. doi: 10.1186/s13054-018-2254-z. PubMed PMID: 30463607; PubMed Central PMCID: PMC6249723.
223. Russo V, Klein T, Lim DJ, Solis N, Machado Y, Hiroyasu S, Nabai L, Shen Y, Zeglinski MR, Zhao H, Oram CP, Lennox PA, Van Laeken N, Carr NJ, Crawford RI, Franzke CW, Overall CM, **Granville DJ.** Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction. *Sci Rep.* 2018 Jun 26;8(1):9690. doi: 10.1038/s41598-018-28070-0. PubMed PMID: 29946113; PubMed Central PMCID: PMC6018769.
224. **Ryerson CJ,** Denton CP. The Fine Line between Success and Failure in Scleroderma Lung Fibrosis Trials. *Am J Respir Crit Care Med.* 2018 Mar 1;197(5):553-554. doi: 10.1164/rccm.201711-2268ED. PubMed PMID: 29186664.
225. **Ryerson CJ,** Kolb M. The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy? *Eur Respir J.* 2018 Jan 18;51(1). pii: 1702420. doi: 10.1183/13993003.02420-2017. Print 2018 Jan. PubMed PMID: 29348187.
226. **Ryerson CJ,** Walsh SLF, Collard HR; all authors. Reply to Moodley: A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. *Am J Respir Crit Care Med.* 2018 May 15;197(10):1366-1367. doi: 10.1164/rccm.201712-2515LE. PubMed PMID: 29342368.
227. **Ryerson CJ.** Lumpers versus splitters: What to do with suspected idiopathic pulmonary fibrosis? *Respirology.* 2018 Nov 15. doi: 10.1111/resp.13442. [Epub ahead of print] PubMed PMID: 30440108.
228. Saadalla AM, Osman A, Gurish MF, Dennis KL, Blatner NR, Pezeshki A, **McNagny KM,** Cheroutre H, Gounari F, Khazaie K. Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner. *Proc Natl Acad Sci U S A.* 2018 Feb 13;115(7):1588-1592. doi: 10.1073/pnas.1716804115. Epub 2018 Feb 2. PubMed PMID: 29429965; PubMed Central PMCID: PMC5816178.
229. Saavedra MT, **Quon BS,** Faino A, Caceres SM, Poch KR, Sanders LA, Malcolm KC, Nichols DP, Sagel SD, Taylor-Cousar JL, Leach SM, Strand M, Nick JA. Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study. *Ann Am Thorac Soc.* 2018 May;15(5):589-598. doi: 10.1513/AnnalsATS.201707-527OC. PubMed PMID: 29425066.
230. Sadatsafavi M, Gustafson P, Zafari Z, **Sin DD.** Relative impact characteristic curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers. *Ann Epidemiol.* 2018 Oct;28(10):717-723.e3. doi: 10.1016/j.annepidem.2018.07.014. Epub 2018 Jul 30. PubMed PMID: 30107972.
231. Sakakibara BM, **Lear SA,** Barr SI, Benavente O, Goldsmith CH, Silverberg ND, Yao J, Eng JJ. A telehealth intervention to promote healthy lifestyles after stroke: The Stroke Coach protocol. *Int J Stroke.* 2018 Feb;13(2):217-222. doi: 10.1177/1747493017729266. Epub 2017 Sep 4. PubMed PMID: 28869405; PubMed Central PMCID: PMC5770204.
232. Sauler M, Lamontagne M, Finnemore E, Herazo-Maya JD, Tedrow J, Zhang X, Morneau JE, Scirba F, Timens W, **Paré PD,** Lee PJ, Kaminski N, Bossé Y, Gomez JL. The DNA repair transcriptome in severe COPD. *Eur Respir J.* 2018 Oct 4;52(4). pii: 1701994. doi: 10.1183/13993003.01994-2017. Print 2018 Oct. PubMed PMID: 30190272.
233. Schaeffer MR, **Ryerson CJ,** Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, Mitchell RA, Sheel AW, Khalil N, **Camp PG, Guenette JA.** Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. *Eur Respir J.* 2018 Jan 18;51(1). pii: 1701726. doi: 10.1183/13993003.01726-2017. Print 2018 Jan. PubMed PMID: 29348183.
234. Scott A, Zahradnik TM, Squier K, Beck C, **Brunham LR.** Diagnostic accuracy of ultrasound and MRI for Achilles tendon xanthoma in people with familial hypercholesterolemia: A systematic review. *J Clin Lipidol.* 2019 Jan - Feb;13(1):40-48. doi: 10.1016/j.jacl.2018.10.013. Epub 2018 Nov 7. Review. PubMed PMID: 30503304.
235. Sehmi R, Lim HF, Mukherjee M, Huang C, Radford K, Newbold P, Boulet LP, **Dorscheid D,** Martin JG, Nair P. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. *J Allergy Clin Immunol.* 2018 Apr;141(4):1529-1532.e8. doi: 10.1016/j.jaci.2018.01.008. Epub 2018 Jan 31. PubMed PMID: 29382593.
236. **Seidman MA.** Consensus documents - past, present, and future. *Cardiovasc Pathol.* 2018 Sep - Oct;36:42-43. doi: 10.1016/j.carpath.2018.06.003. Epub 2018 Jun 22. PubMed PMID: 30014984.

237. Sellers SL, Fonte TA, Grover R, Mooney J, Weir-McCall J, Lau KP, Chavda A, McNabney C, Ahmadi A, Blanke P, Payne GW, Murphy DT, Ong K, Taylor CA, **Leipsic JA**. Hypertrophic Cardiomyopathy (HCM): New insights into Coronary artery remodelling and ischemia from FFR(CT). *J Cardiovasc Comput Tomogr*. 2018 Nov - Dec;12(6):467-471. doi: 10.1016/j.jcct.2018.08.002. Epub 2018 Aug 15. PubMed PMID: 30139668.
238. Sellers SL, Milad N, Chan R, Mielnik M, Jermilova U, Huang PL, de Crom R, Hirota JA, **Hogg JC**, Sandor GG, Van Breemen C, Esfandiarei M, **Seidman MA, Bernatchez P**. Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1-Independent Activation of Endothelial Function. *Am J Pathol*. 2018 Mar;188(3):574-585. doi: 10.1016/j.ajpath.2017.11.006. PubMed PMID: 29433732.
239. Sellers SL, Milad N, White Z, Pascoe C, Chan R, Payne GW, **Seow C**, Rossi F, **Seidman MA, Bernatchez P**. Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B. *J Lipid Res*. 2018 Feb;59(2):261-272. doi: 10.1194/jlr.M079459. Epub 2017 Nov 25. PubMed PMID: 29175948; PubMed Central PMCID: PMC5794421.
240. Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R, Mooney J, Nørgaard BL, Bax JJ, **Bernatchez PN**, Dweck MR, **Granville DJ**, Newby DE, Lauck S, Webb JG, Payne GW, Pibarot P, Blanke P, **Seidman MA, Leipsic JA**. Transcatheter Aortic Heart Valves: Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration. *JACC Cardiovasc Imaging*. 2019 Jan;12(1):135-145. doi: 10.1016/j.jcmg.2018.06.028. Epub 2018 Nov 15. PubMed PMID: 30448122.
241. **Seow CY**, Al-Jumaily AM. Mechanobiology in Medical Diagnostics and Therapy. *ASME J of Medical Diagnostics*. 2018 Mar;1(2):020201-1-020201-2. doi: 10.1115/1.4039559.
242. Shannon CP, Yang CX, **Tebbutt SJ**. A Bloody Primer: Analysis of RNA-Seq from Tissue Admixtures. *Methods Mol Biol*. 2018;1712:175-201. doi: 10.1007/978-1-4939-7514-3_12. PubMed PMID: 29224075.
243. Shen Y, Zeglinski MR, Turner CT, Raithatha SA, Wu Z, Russo V, Oram C, Hiroyasu S, Nabai L, Zhao H, Bozin T, Westendorf K, Kopko I, Huang R, Arns S, Tan J, Zeng H, Boey A, Liggins R, Jaquith J, Cameron DR, Papp A, **Granville DJ**. Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing. *Exp Mol Med*. 2018 May 30;50(5):68. doi: 10.1038/s12276-018-0095-0. PubMed PMID: 29849046; PubMed Central PMCID: PMC5976625.
244. Shi J, Zheng YZ, **Sin DD, DeMarco ML**. A Streamlined Method for Quantification of Apolipoprotein A1 in Human Plasma by LC-MS/MS. *Clin Chem*. 2018 Dec;64(12):1782-1784. doi: 10.1373/clinchem.2018.293530. PubMed PMID: 30487190.
245. Shin SH, Park HY, Kang D, Cho J, Kwon SO, Park JH, Lee JS, Oh YM, **Sin DD**, Kim WJ, Lee SD; KOLD Study Group. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. *Respir Res*. 2018 Jul 13;19(1):134. doi: 10.1186/s12931-018-0840-x. PubMed PMID: 30001715; PubMed Central PMCID: PMC6044087.
246. Shin SH, Park J, Cho J, **Sin DD**, Lee H, Park HY. Severity of Airflow Obstruction and Work Loss in a Nationwide Population of Working Age. *Sci Rep*. 2018 Jun 26;8(1):9674. doi: 10.1038/s41598-018-27999-6. PubMed PMID: 29946117; PubMed Central PMCID: PMC6018711.
247. Shrine N, Portelli MA, John C, Soler Artigas M, Bennett N, Hall R, Lewis J, Henry AP, Billington CK, Ahmad A, Packer RJ, Shaw D, Pogson ZEK, Fogarty A, McKeever TM, Singapuri A, Heaney LG, Mansur AH, Chaudhuri R, Thomson NC, Holloway JW, Lockett GA, Howarth PH, Djukanovic R, Hankinson J, Niven R, Simpson A, Chung KF, Sterk PJ, Blakey JD, Adcock IM, Hu S, Guo Y, **Obeidat M, Sin DD**, van den Berge M, Nickle DC, Bossé Y, Tobin MD, Hall IP, Brightling CE, Wain LV, Sayers I. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. *Lancet Respir Med*. 2019 Jan;7(1):20-34. doi: 10.1016/S2213-2600(18)30389-8. Epub 2018 Dec 11. PubMed PMID: 30552067; PubMed Central PMCID: PMC6314966.
248. Sima CA, Lau BC, Taylor CM, **van Eeden SF**, Reid WD, Sheel AW, Kirkham AR, **Camp PG**. Myocardial Infarction Injury in Patients with Chronic Lung Disease Entering Pulmonary Rehabilitation: Frequency and Association with Heart Rate Parameters. *PM R*. 2018 Sep;10(9):917-925. doi: 10.1016/j.pmrj.2018.03.005. Epub 2018 Mar 14. PubMed PMID: 29550408.
249. **Sin DD, Schellenberg RR**. A letter from 'O Canada'. *Respirology*. 2019 Feb;24(2):186-187. doi: 10.1111/resp.13425. Epub 2018 Oct 17. PubMed PMID: 30332712.
250. Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, Gauvreau GM, FitzGerald JM, Boulet LP, O'Byrne PM, **Tebbutt SJ**. Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response. *Am J Respir Crit Care Med*. 2018 Feb 15;197(4):450-462. doi: 10.1164/rccm.201701-0110OC. PubMed PMID: 29087730.

251. Skolnik K, **Quon BS**. Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations. *F1000Res*. 2018 May 14;7. pii: F1000 Faculty Rev-575. doi: 10.12688/f1000research.13926.1. eCollection 2018. Review. PubMed PMID: 29862015; PubMed Central PMCID: PMC5954331.
252. Smith BM, Jensen D, Brosseau M, Benedetti A, **Coxson HO**, Bourbeau J. Impact of pulmonary emphysema on exercise capacity and its physiological determinants in chronic obstructive pulmonary disease. *Sci Rep*. 2018 Oct 24;8(1):15745. doi: 10.1038/s41598-018-34014-5. PubMed PMID: 30356114; PubMed Central PMCID: PMC6200804.
253. Smith DM, Salters KA, Eyawo O, Franco-Villalobos C, Jabbari S, Wiseman SM, Press N, Montaner JSG, **Man SFP**, Hull M, Hogg RS. Mortality among people living with HIV/AIDS with non-small-cell lung cancer in the modern HAART Era. *AIDS Care*. 2018 Jul;30(7):936-942. doi: 10.1080/09540121.2018.1434120. Epub 2018 Feb 7. PubMed PMID: 29411625.
254. Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, **Ryerson CJ**. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. *Respiration*. 2018;96(4):314-322. doi: 10.1159/000489668. Epub 2018 Jul 19. PubMed PMID: 30025392.
255. Speevak MD, **DeMarco ML**, Wiebe NS, Chapman KR. An unusual case of alpha-1-antitrypsin deficiency: SZ/Z. *Clin Biochem*. 2019 Feb;64:49-52. doi: 10.1016/j.clinbiochem.2018.12.008. Epub 2018 Dec 21. PubMed PMID: 30579752.
256. Sun Y, **Sin DD**. Crisis of COPD in China: the future is now. *Lancet Respir Med*. 2018 Jun;6(6):404-405. doi: 10.1016/S2213-2600(18)30133-4. Epub 2018 Apr 9. PubMed PMID: 29650406.
257. Syn NL, Wong AL, Lee SC, Teoh HL, Yip JWL, Seet RC, Yeo WT, Kristanto W, Bee PC, Poon LM, Marban P, Wu TS, Winther MD, **Brunham LR**, Soong R, Tai BC, Goh BC. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. *BMC Med*. 2018 Jul 10;16(1):104. doi: 10.1186/s12916-018-1093-8. PubMed PMID: 29986700; PubMed Central PMCID: PMC6038204.
258. **Tan WC**, Bourbeau J, Aaron SD, Zhou G, Maltais F, Hernandez P, Fitzgerald JM, Marciniuk DD, Walker BL, **Sin DD**. Global Initiative for Chronic Obstructive Lung Disease 2017 Classification and Lung Function Decline in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2018 Mar 1;197(5):670-673. doi: 10.1164/rccm.201706-1154LE. PubMed PMID: 28858570.
259. **Tan WC**, **Sin DD**. What are the long-term effects of smoked marijuana on lung health? *CMAJ*. 2018 Oct 22;190(42):E1243-E1244. doi: 10.1503/cmaj.181307. PubMed PMID: 30348738; PubMed Central PMCID: PMC6199161.
260. **Tan WC**. Low body mass index and latent tuberculous infection: current evidence? *Int J Tuberc Lung Dis*. 2018 Apr 1;22(4):355. doi: 10.5588/ijtld.18.0070. PubMed PMID: 29562978.
261. Tanabe N, Vasilescu DM, Kirby M, **Coxson HO**, Verleden SE, Vanaudenaerde BM, Kinose D, Nakano Y, **Paré PD**, **Hogg JC**. Analysis of airway pathology in COPD using a combination of computed tomography, micro-computed tomography and histology. *Eur Respir J*. 2018 Feb 14;51(2). pii: 1701245. doi: 10.1183/13993003.01245-2017. Print 2018 Feb. PubMed PMID: 29444912.
262. Tangbumrungtham N, Patel VS, **Thamboo A**, Patel ZM, Nayak JV, Ma Y, Choby G, Hwang PH. The prevalence of Eustachian tube dysfunction symptoms in patients with chronic rhinosinusitis. *Int Forum Allergy Rhinol*. 2018 May;8(5):620-623. doi: 10.1002/alr.22056. Epub 2017 Dec 11. PubMed PMID: 29227048.
263. Teboul JL, Duranteau J, **Russell JA**. Intensive care medicine in 2050: vasopressors in sepsis. *Intensive Care Med*. 2018 Jul;44(7):1130-1132. doi: 10.1007/s00134-017-4909-7. Epub 2017 Aug 31. PubMed PMID: 28861671.
264. **Thamboo A**, Rathor A, Borchard NA, Nayak JV, Hwang PH, Patel ZM. Precision medicine: why surgeons deviate from "appropriateness criteria" in the management of chronic rhinosinusitis and effects on outcomes. *Int Forum Allergy Rhinol*. 2018 Dec;8(12):1389-1394. doi: 10.1002/alr.22184. Epub 2018 Jul 12. PubMed PMID: 29999595.
265. Toor A, Culibrk L, Singhera GK, Moon KM, Prudova A, Foster LJ, Moore MM, **Dorscheid DR**, **Tebbutt SJ**. Transcriptomic and proteomic host response to *Aspergillus fumigatus* conidia in an air-liquid interface model of human bronchial epithelium. *PLoS One*. 2018 Dec 27;13(12):e0209652. doi: 10.1371/journal.pone.0209652. eCollection 2018. PubMed PMID: 30589860; PubMed Central PMCID: PMC6307744.

266. Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, Becker AB, Mandhane PJ, Turvey SE, Sears MR; **Canadian Healthy Infant Longitudinal Development Study investigators**. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. *J Allergy Clin Immunol*. 2018 Feb;141(2):601-607.e8. doi: 10.1016/j.jaci.2017.08.024. Epub 2017 Nov 15. PubMed PMID: 29153857. **D Daley, P Paré, A Sandford, and S Tebbutt are CHILd Study Investigators.**
267. Trinder M, Genga KR, Kong HJ, Blauw LL, Lo C, Li X, Cirstea M, Wang Y, Rensen PCN, **Russell JA, Walley KR, Boyd JH, Brunham LR**. Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. *Am J Respir Crit Care Med*. 2018 Oct 15. doi: 10.1164/rccm.201806-1157OC. [Epub ahead of print] PubMed PMID: 30321485.
268. Turner CT, Zeglinski MR, Richardson KC, Zhao H, Shen Y, Papp A, Bird PI, **Granville DJ**. Granzyme K Expressed by Classically Activated Macrophages Contributes to Inflammation and Impaired Remodeling. *J Invest Dermatol*. 2018 Nov 3. pii: S0022-202X(18)32778-7. doi: 10.1016/j.jid.2018.09.031. [Epub ahead of print] PubMed PMID: 30395844.
269. van der Gugten G, **DeMarco ML**, Chen LYC, Chin A, Carruthers M, Holmes DT, Mattman A. Resolution of Spurious Immunonephelometric IgG Subclass Measurement Discrepancies by LC-MS/MS. *Clin Chem*. 2018 Apr;64(4):735-742. doi: 10.1373/clinchem.2017.282319. Epub 2018 Jan 19. PubMed PMID: 29352044.
270. van Rosendael AR, Maliakal G, Kolli KK, Beecy A, Al'Aref SJ, Dwivedi A, Singh G, Panday M, Kumar A, Ma X, Achenbach S, Al-Mallah MH, Andreini D, Bax JJ, Berman DS, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJW, Cury RC, DeLago A, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann PA, Kim YJ, **Leipsic JA**, Maffei E, Marques H, Pontone G, Raff GL, Rubinshtein R, Shaw LJ, Villines TC, Gransar H, Lu Y, Jones EC, Peña JM, Lin FY, Min JK. Maximization of the usage of coronary CTA derived plaque information using a machine learning based algorithm to improve risk stratification; insights from the CONFIRM registry. *J Cardiovasc Comput Tomogr*. 2018 May - Jun;12(3):204-209. doi: 10.1016/j.jcct.2018.04.011. Epub 2018 Apr 30. PubMed PMID: 29753765.
271. Vancheri C, Kreuter M, Richeldi L, **Ryerson CJ**, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. *Am J Respir Crit Care Med*. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC. PubMed PMID: 28889759.
272. Vanderstocken G, Dvorkin-Gheva A, Shen P, Brandsma CA, **Obeidat M**, Bossé Y, Hassell JA, Stampfli MR. Identification of Drug Candidates to Suppress Cigarette Smoke-induced Inflammation via Connectivity Map Analyses. *Am J Respir Cell Mol Biol*. 2018 Jun;58(6):727-735. doi: 10.1165/rcmb.2017-0202OC. PubMed PMID: 29256623.
273. Vieillard-Baron A, **Boyd J**. Non-antiarrhythmic interventions in new onset and paroxysmal sepsis-related atrial fibrillation. *Intensive Care Med*. 2018 Jan;44(1):94-97. doi: 10.1007/s00134-017-4986-7. Epub 2017 Nov 7. PubMed PMID: 29116333.
274. von Dadelszen P, Magee LA, Benton SJ, Hu Y, Ansermino JM, Carleton B, Carter C, Douglas MJ, Janssen PA, Lee SK, Leung PCK, Li J, MacNab Y, Payne BA, Peng G, Rodger M, Skoll MA, Synnes A, **Walley KR, Russell JA**. Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. *Pregnancy Hypertens*. 2018 Jul;13:121-126. doi: 10.1016/j.preghy.2018.05.009. Epub 2018 May 28. PubMed PMID: 30177038.
275. **Walley KR**. Mitigating Microvascular Leak during Fluid Resuscitation of Hemorrhagic Shock. *Anesthesiology*. 2018 Feb;128(2):252-253. doi: 10.1097/ALN.0000000000002008. PubMed PMID: 29232207.
276. **Walley KR**. Sepsis-induced myocardial dysfunction. *Curr Opin Crit Care*. 2018 Aug;24(4):292-299. doi: 10.1097/MCC.0000000000000507. PubMed PMID: 29846206.
277. Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, Make BJ, Crapo JD, DeMeo DL, Silverman EK; **COPDGene Investigators**. Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. *Am J Respir Crit Care Med*. 2018 Dec 1;198(11):1397-1405. doi: 10.1164/rccm.201804-0663OC. PubMed PMID: 29874098; PubMed Central PMCID: PMC6290948. **H Coxson is a COPDGene Investigator.**
278. Wang C, Bangdiwala SI, Rangarajan S, **Lear SA**, AlHabib KF, Mohan V, Teo K, Poirier P, Tse LA, Liu Z, Rosengren A, Kumar R, Lopez-Jaramillo P, Yusuf K, Monsef N, Krishnapillai V, Ismail N, Seron P, Dans AL, Kruger L, Yeates K, Leach L, Yusuf R, Orlandini A, Wolyniec M, Bahonar A, Mohan I, Khatib R, Temizhan A, Li W, Yusuf S. Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. *Eur Heart J*. 2018 Dec 5. doi: 10.1093/eurheartj/ehy695. [Epub ahead of print] PubMed PMID: 30517670.

279. Wang C, Fung G, Deng H, Jagdeo J, Mohamud Y, Xue YC, Jan E, Hirota JA, **Luo H**. NLRP3 deficiency exacerbates enterovirus infection in mice. *FASEB J*. 2019 Jan;33(1):942-952. doi: 10.1096/fj.201800301RRR. Epub 2018 Aug 6. PubMed PMID: 30080445.
280. Wang MG, Huang WW, Wang Y, Zhang YX, Zhang MM, Wu SQ, **Sandford AJ**, He JQ. Association between tobacco smoking and drug-resistant tuberculosis. *Infect Drug Resist*. 2018 Jun 12;11:873-887. doi: 10.2147/IDR.S164596. eCollection 2018. Review. PubMed PMID: 29928135; PubMed Central PMCID: PMC6003534.
281. Wang Y, Zhang MM, Huang WW, Wu SQ, Wang MG, Tang XY, **Sandford AJ**, He JQ. Polymorphisms in Toll-Like Receptor 10 and Tuberculosis Susceptibility: Evidence from Three Independent Series. *Front Immunol*. 2018 Feb 23;9:309. doi: 10.3389/fimmu.2018.00309. eCollection 2018. PubMed PMID: 29527210; PubMed Central PMCID: PMC5829065.
282. Weir-McCall JR, Blanke P, Sellers SL, Ahmadi AA, Andreini D, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Chun EJ, Conte E, Gottlieb I, Hadamitzky M, Kim YJ, Lee BK, Lee SE, Maffei E, Marques H, Pontone G, Raff GL, Shin S, Sung JM, Stone P, Samady H, Virmani R, Narula J, Berman DS, Shaw LJ, Bax JJ, Lin FY, Min JK, Chang HJ, **Leipsic JA**. Impact of Non-obstructive left main disease on the progression of coronary artery disease: A PARADIGM substudy. *J Cardiovasc Comput Tomogr*. 2018 May - Jun;12(3):231-237. doi: 10.1016/j.jcct.2018.05.011. Epub 2018 May 19. PubMed PMID: 29802032.
283. Welch JF, Archiza B, **Guenette JA**, West CR, Sheel AW. Effect of diaphragm fatigue on subsequent exercise tolerance in healthy men and women. *J Appl Physiol* (1985). 2018 Dec 1;125(6):1987-1996. doi: 10.1152/jappphysiol.00630.2018. Epub 2018 Oct 11. PubMed PMID: 30307818.
284. Welch JF, Archiza B, **Guenette JA**, West CR, Sheel AW. Sex differences in diaphragmatic fatigue: the cardiovascular response to inspiratory resistance. *J Physiol*. 2018 Sep;596(17):4017-4032. doi: 10.1113/JP275794. Epub 2018 Jun 12. PubMed PMID: 29756638; PubMed Central PMCID: PMC6117572.
285. Wilson R, McNabney C, Weir-McCall JR, Sellers S, Blanke P, **Leipsic JA**. Transcatheter Aortic and Mitral Valve Replacements. *Radiol Clin North Am*. 2019 Jan;57(1):165-178. doi: 10.1016/j.rcl.2018.08.001. Epub 2018 Oct 31. Review. PubMed PMID: 30454811.
286. Winstone T, Hague CJ, Churg A, Wright JL, **Schellenberg R, Ryerson C**. Biopsy-proven recurrent, acute, familial hypersensitivity pneumonitis: A case report and literature review. *Respir Med Case Rep*. 2018 May 17;24:173-175. doi: 10.1016/j.rmcr.2018.05.007. eCollection 2018. PubMed PMID: 29977789; PubMed Central PMCID: PMC6010641.
287. Winstone TA, Hague CJ, Soon J, Sulaiman N, Murphy D, **Leipsic J, Dunne JV, Wilcox PG, Ryerson CJ**. Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. *Respirology*. 2018 Oct;23(10):921-926. doi: 10.1111/resp.13309. Epub 2018 Apr 11. PubMed PMID: 29641847.
288. Wiskar KJ, Celi LA, McDermid RC, **Walley KR, Russell JA, Boyd JH, Rush B**. Patterns of Palliative Care Referral in Patients Admitted With Heart Failure Requiring Mechanical Ventilation. *Am J Hosp Palliat Care*. 2018 Apr;35(4):620-626. doi: 10.1177/1049909117727455. Epub 2017 Aug 22. PubMed PMID: 28826226.
289. Wister A, **Lear S**, Schuurman N, MacKey D, Mitchell B, Cosco T, Fyffe I. Development and validation of a multi-domain multimorbidity resilience index for an older population: results from the baseline Canadian Longitudinal Study on Aging. *BMC Geriatr*. 2018 Jul 27;18(1):170. doi: 10.1186/s12877-018-0851-y. PubMed PMID: 30053838; PubMed Central PMCID: PMC6062931.
290. Won KB, Lee SE, Lee BK, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Sung JM, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Chun EJ, Cademartiri F, Maffei E, Marques H, **Leipsic JA**, Shin S, Choi JH, Virmani R, Samady H, Chinnaiyan K, Raff GL, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Chang HJ. Longitudinal assessment of coronary plaque volume change related to glycemic status using serial coronary computed tomography angiography: A PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) substudy. *J Cardiovasc Comput Tomogr*. 2018 Dec 17. pii: S1934-5925(18)30181-3. doi: 10.1016/j.jcct.2018.12.002. [Epub ahead of print] PubMed PMID: 30580992.
291. Wu AC, Kiley JP, Noel PJ, Amur S, Burchard EG, Clancy JP, Galanter J, Inada M, Jones TK, Kropski JA, Loyd JE, Noguee LM, Raby BA, Rogers AJ, Schwartz DA, **Sin DD**, Spira A, Weiss ST, Young LR, Himes BE. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. *Am J Respir Crit Care Med*. 2018 Dec 15;198(12):e116-e136. doi: 10.1164/rccm.201810-1895ST. PubMed PMID: 30640517.

292. Wu W, Jin Y, **Carlsten C**. Inflammatory health effects of indoor and outdoor particulate matter. *J Allergy Clin Immunol*. 2018 Mar;141(3):833-844. doi: 10.1016/j.jaci.2017.12.981. Review. PubMed PMID: 29519450."
293. Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, Latourelle JC, Smith AV, Bartz TM, Feitosa MF, Gao W, Ahluwalia TS, Tang W, Oldmeadow C, Duan Q, de Jong K, Wojczynski MK, Wang XQ, Noordam R, Hartwig FP, Jackson VE, Wang T, **Obeidat M**, Hobbs BD, Huan T, Gui H, Parker MM, Hu D, Mogil LS, Kichaev G, Jin J, Graff M, Harris TB, Kalhan R, Heckbert SR, Paternoster L, Burkart KM, Liu Y, Holliday EG, Wilson JG, Vonk JM, Sanders JL, Barr RG, de Mutsert R, Menezes AMB, Adams HHH, van den Berge M, Joehanes R, Levin AM, Liberto J, Launer LJ, Morrison AC, Sitlani CM, Celedón JC, Kritchevsky SB, Scott RJ, Christensen K, Rotter JI, Bonten TN, Wehrmeister FC, Bossé Y, Xiao S, Oh S, Franceschini N, Brody JA, Kaplan RC, Lohman K, McEvoy M, Province MA, Rosendaal FR, Taylor KD, Nickle DC, Williams LK, Burchard EG, Wheeler HE, **Sin DD**, Gudnason V, North KE, Fornage M, Psaty BM, Myers RH, O'Connor G, Hansen T, Laurie CC, Cassano PA, Sung J, Kim WJ, Attia JR, Lange L, Boezen HM, Thyagarajan B, Rich SS, Mook-Kanamori DO, Horta BL, Uitterlinden AG, Im HK, Cho MH, Brusselle GG, Gharib SA, Dupuis J, Manichaikul A, London SJ. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. *Nat Commun*. 2018 Jul 30;9(1):2976. doi: 10.1038/s41467-018-05369-0. PubMed PMID: 30061609; PubMed Central PMCID: PMC6065313.
294. Xu S, Tsai A, Sze MA, Vucic EA, Shaipanich T, Harris M, Guillemi S, Yang J, Sinha S, Nislow C, Montaner J, Lam W, Lam S, **Sin DD, Paul Man SF, Leung JM**. Decreased microbiome diversity in the HIV small airway epithelium. *Respir Res*. 2018 Jul 27;19(1):140. doi: 10.1186/s12931-018-0835-7. PubMed PMID: 30053882; PubMed Central PMCID: PMC6062954.
295. Xu S, Vucic EA, Shaipanich T, Lam S, Lam W, Montaner JS, **Sin DD, Paul Man SF, Leung JM**. Decreased telomere length in the small airway epithelium suggests accelerated aging in the lungs of persons living with human immunodeficiency virus (HIV). *Respir Res*. 2018 Jun 13;19(1):117. doi: 10.1186/s12931-018-0821-0. PubMed PMID: 29895291; PubMed Central PMCID: PMC5998581.
296. Xue YC, Feuer R, Cashman N, **Luo H**. Enteroviral Infection: The Forgotten Link to Amyotrophic Lateral Sclerosis? *Front Mol Neurosci*. 2018 Mar 12;11:63. doi: 10.3389/fnmol.2018.00063. eCollection 2018. Review. PubMed PMID: 29593492; PubMed Central PMCID: PMC5857577.
297. Xue YC, Ruller CM, Fung G, Mohamud Y, Deng H, Liu H, Zhang J, Feuer R, **Luo H**. Enteroviral Infection Leads to Transactive Response DNA-Binding Protein 43 Pathology in Vivo. *Am J Pathol*. 2018 Dec;188(12):2853-2862. doi: 10.1016/j.ajpath.2018.08.013. Epub 2018 Sep 28. PubMed PMID: 30273599.
298. Yamasaki K, **Eeden SFV**. Lung Macrophage Phenotypes and Functional Responses: Role in the Pathogenesis of COPD. *Int J Mol Sci*. 2018 Feb 15;19(2). pii: E582. doi: 10.3390/ijms19020582. PMID: 29462886.
299. Yang S, Wang J, **Ng RT**. Inferring RNA sequence preferences for poorly studied RNA-binding proteins based on co-evolution. *BMC Bioinformatics*. 2018 Mar 12;19(1):96. doi: 10.1186/s12859-018-2091-8. PubMed PMID: 29529991; PubMed Central PMCID: PMC5848454.
300. Yang SJ, Allahverdian S, Saunders ADR, Liu E, **Dorscheid DR**. IL-13 signaling through IL-13 receptor $\alpha 2$ mediates airway epithelial wound repair. *FASEB J*. 2019 Mar;33(3):3746-3757. doi: 10.1096/fj.201801285R. Epub 2018 Nov 27. PubMed PMID: 30481486.
301. Yoon HI, **Sin DD**. COPD in China: From Crisis to Hope.... *Chest*. 2018 Sep;154(3):474-475. doi: 10.1016/j.chest.2018.07.012. PubMed PMID: 30195339.
302. Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, Hersh CP; **COPD Gene and ECLIPSE Investigators**. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2018 Jun;141(6):2037-2047. e10. doi: 10.1016/j.jaci.2018.04.010. Epub 2018 Apr 28. PubMed PMID: 29709670; PubMed Central PMCID: PMC5994197. **H Coxson is a COPD Gene Investigator**.
303. Zeng X, Vonk JM, van der Plaats DA, Faiz A, **Paré PD**, Joubert P, Nickle D, Brandsma CA, Kromhout H, Vermeulen R, Xu X, Huo X, de Jong K, Boezen HM. Genome-wide interaction study of gene-by-occupational exposures on respiratory symptoms. *Environ Int*. 2019 Jan;122:263-269. doi: 10.1016/j.envint.2018.11.017. Epub 2018 Nov 16. PubMed PMID: 30449631.
304. Zhang M, Tang X, Wang Y, Wu S, Wang M, Liu Q, **Sandford AJ**, He JQ. Variants of TLR1 associated with tuberculosis susceptibility in the Chinese Tibetan population but not in Han Chinese. *Infect Genet Evol*. 2018 Jul;61:53-59. doi: 10.1016/j.meegid.2018.02.021. Epub 2018 Feb 15. PubMed PMID: 29454979.
305. Zhao G, Qiu Y, Zhang HM, **Yang D**. Intercalated discs: cellular adhesion and signaling in heart health and diseases. *Heart Fail Rev*. 2019 Jan;24(1):115-132. doi: 10.1007/s10741-018-9743-7. Review. PubMed PMID: 30288656.

Appendix C: 2018 HLI Friday Seminar Series

Month	Day	Speaker	Host	Title of Lecture
January	8	Michael Wechsler	Don Sin	EGPA and other eosinophilic lung diseases
	19	Rubin Tudor	Jim Hogg	Fatty acid oxidation and the metabolic landscape in pulmonary vascular disease
	26	Decheng Yang	HLI	MicroRNAs in coxsackieviral pathogenesis of myocarditis
February	2	Fabio Rossi	Pascal Bernatchez	Novel insights in the role of stromal cells in cardiac pathology
	9	Benjamin Raby	Don Sin	Integrative genomics for mapping disease genes in asthma: discovery and functional dissection
	16	Philippe Pibarot	Jonathon Leipsic	New insights into the pathogenesis of calcific aortic stenosis and future perspectives for pharmacological treatment
	23	Sam Wadsworth	Tillie Hackett	How 3D Bioprinting can shape the future of medicine
March	2	Teija Beck	HLI	How St. Paul's Foundation can help support your research
	9	Thomas Geiser	Chris Ryerson	Novel aspects and possible therapeutic approaches in lung fibrosis
	16	Jeffrey Reed Galvin	Jim Hogg	Idiopathic Pulmonary Fibrosis (IPF): diffuse lung injury modified by lung mechanics
	23	Cormac McCarthy	Bradley Quon	Rare lung diseases: a molecular pathogenesis-based approach to therapies
	30	Good Friday - No Lecture		
April	6	Peter Zandstra	Keith Walley	Engineering cell fate and function
	20	Anne Sperling	Del Dorscheid	Type 2 immune mechanisms in allergic lung disease
	27	Byron Caughey	Mari DeMarco	Prions and the transmissibility of protein misfolding diseases
May	4	Christopher Rembold	Chun Seow	Regulation of vascular smooth muscle force
	11	Matthew Miller	Honglin Luo	Lessons from nature: how pandemics are helping us build better influenza virus vaccines and therapeutics
	18	American Throacic Society Conference - No Lecture		

June	1	Mireille Ouimet	Gordon Francis	Autophagy as a regulator of immunometabolism and atherosclerosis
	22	Tom Lagace	Gordon Francis	Targeting PCSK9 for advanced LDL-cholesterol lowering
July - August	Summer Hiatus			
September	14	Megan Levings	Jim Hogg	Measuring and engineering immune tolerance
	21	Kelly McNagny	HLI	Immune regulation of inflammatory disease, fibrosis and tissue repair
	28	Jonathan Rayment	Bradley Quon	Something old and something new: novel measures of respiratory function in paediatric cystic fibrosis
October	12	Craig Wheelock	Chris Carlsten	Molecular phenotyping of obstructive lung disease
	19	Eric Jan	Honglin Luo	From insects to humans: insights into viral strategies that hijack host functions
	26	Sepideh Pakpour	Don Sin	Human microbiome-based diagnostics and therapeutics at the frontier of personalized medicine
November	2	Janet Scott	HLI	Is this personal information?
	16	Pratik Sinha	Keith Walley	Tackling heterogeneity in ARDS
	23	Angela Devlin	Pascal Bernatchez	Preventing cardiometabolic disease in children
	30	David Granville	Gordon Francis	The long and winding road: translating basic science discoveries towards clinical application and commercialization
December	7	PHC	HLI	The PHC strategic plan discussion
	14	Colin Ross	Maen Obeidat	Using genetics to help improve the safety and effectiveness of medications

Appendix D: 2018 HLI Research in Progress Seminars

Month	Day	Speaker	Title of Lecture
January	8	Aida Eslami	Genome wide meta-analysis of parent of origin effects of asthma and related phenotypes
	15	Sabina Guler	Frailty and sarcopenia in fibrotic interstitial lung disease
	22	Chhavi Tripathi	Harmonization of SNP identifiers
	29	Anna Siedlecki	Using serum biomarkers to evaluate causes of TH2 inflammation during pulmonary exacerbation in cystic fibrosis patients
February	5	Josh Dubland	Low expression of lysosomal acid lipase in smooth muscle cells relative to macrophages provides new insights into foam cell lipid accumulation
	12	Family Day – No Lecture	
	19	Kang Dong	Characterizing CFTR activity in peripheral blood monocytes and nasal epithelial cells from CF patients
	26	Reid Mitchell	Physiological determinants of freely chosen cadence in highly trained cyclists
March	5	Young Woong Kim	Investigating systemic immune responses in the pathophysiology of allergic rhinitis using peripheral blood
	12	Feng Xu	Hot spot for terminal bronchiolar destructions in COPD
	19	Kyle Boyle	The effects of diaphragm fatigue on the multidimensional components of dyspnea
	26	Tadanaga Shimada	Very low density lipoprotein receptor sequesters LPS into adipose tissue during sepsis
April	2	Easter Monday - No Lecture	
	9	Seo Am Hur	Physical activity in fibrotic interstitial lung disease
	16	Kimia Shahangian	Investigations into the H1N1 pandemic: the role of IL-4Ra as a mediator of morbidity and mortality
	23	Ling Luo	What controls shortening velocity in airway smooth muscle?
	30	Effe Christidi	Modeling doxorubicin induced cardiotoxicity using induced pluripotent stem cell derived cardiomyocytes
May	7	David Jaw	Myeloperoxidase inhibition prevent plaque rupture in mice
	14	Mark Trinder	Cholesteryl ester transfer protein genotype influences high-density lipoprotein levels and survival during sepsis
	21	Victoria Day and American Thoracic Society Conference - No Lecture	
	28	Haojun Huang	CRISPR/Cas9 genome-editing in human induced pluripotent stem cells to study the functional impacts of RARG variant in doxorubicin-induced cardiotoxicity

June	4	Phil Hansbro	Understanding pathogenesis to develop new treatments for respiratory diseases
July - August	Summer Hiatus		
September	10	Lauren Forgrave	Characterization of TDP deposits in frontotemporal degeneration
	17	Huitao Liu	Development of coxsackievirus B3 as an oncolytic virus for lung cancer treatment
	24	Fall Quarterly Meeting - No Lecture	
October	1	Nancy Yang	Anti-inflammatory action of long-acting beta agonists on bronchial epithelium
	8	Thanksgiving - No Lecture	
	15	Yannick Molgat-Seon	CT-derived measures of pectoralis muscle area and their association with pulmonary function, dyspnea, and functional capacity in patients with interstitial lung disease
	22	Amy Nguyen	Quantification of amyloid- β 1-40, 1-42 and familial variants using high performance liquid chromatography mass spectrometry: pre-analytical and analytical considerations
	29	Taylor Pobran	TDP-43 enrichment using RNA aptamers
November	5	Airway Conference - No Lecture	
	12	Remembrance Day - No Lecture	
	19	Fernando Studart	Investigating the sputum microbiome in COPD exacerbations and its association with 1-year mortality
December	3	Daniela Castillo-Saldana	Quantitative computed tomography in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a densitometric assessment of disease severity



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

The Centre for Heart Lung Innovation
St. Paul's Hospital
Room 166 – 1081 Burrard Street
Vancouver, British Columbia, V6Z 1Y6
Tel: 604.806.8346 / Fax: 604.806.9274
info@hli.ubc.ca / www.hli.ubc.ca

Follow us on



THE UNIVERSITY
OF BRITISH COLUMBIA



PROVIDENCE HEALTH CARE
Research Institute